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This thesis addresses risk factors and proposed mechanisms to explain relapse to 
depression. Volume 1 comprises three parts:  
  Part 1 is a literature review consisting of meta-reviews of systematic and non-
systematic reviews of studies reporting on risk factors for relapse to depression, and a 
systematic-review of neuroimaging and experimental studies investigating risk factors for 
relapse and potential mechanisms of action of these risk factors. The reviews found that 
only residual symptoms of depression at the end of treatment and childhood maltreatment 
were sufficiently evidenced as predictors of relapse and neither have great clinical utility. A 
number of psychological and neuropsychological factors were suggested to play a role in 
conferring risk for relapse. Considering the inter-relationships between these factors the 
reviews were used to propose a conceptual framework which may be used to help guide 
future research into relapse to depression in adults.  
  Part 2 is an empirical paper in which data were analysed from service users of a 
primary care mental health service to identify risk factors for relapse and for the presence 
of residual symptoms, and survival analysis methods were used to determine when 
relapses occur most often and what factors impact survival. In addition, a prospective 
cohort study was formed to investigate the relationship between cognitive control and 
depressive symptoms. The findings confirmed that cognitive control can be used to predict 
residual symptoms of depression post-treatment and therefore potentially to predict 
relapse.  
  Part 3 is a critical appraisal focussing on the theoretical reasons as to why studying 
relapse in a manner as used in the prospective study is so important and discusses the 
logistical difficulties conducting such research in the current context of NHS services and of 
the D.Clin.Psy research project. Methodological decisions made that impacted upon the 
research process are discussed and reflective conclusions are offered.  4 
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PART 1: LITERATURE REVIEW 
 
Identifying Risk Factors for Relapse to Depression and Considering 
How They Operate: A Three-Stage Systematic Review of the Literature   12 
 
Abstract 
Aims: To determine what factors confer risk for relapse to depression after acute-phase 
treatment in adults and to consider the mechanisms by which they might operate.  
Methods: Three separate reviews were conducted: Study 1 included only systematic 
reviews; Study 2 included non-systematic reviews; and Study 3 included neuroimaging and 
experimental studies. Quality ratings in Study 1 were based on the AMSTAR, along with 
items from PRISMA and the Cochrane Reviewer’s Handbook; study quality was not 
assessed in Study 2; and criteria developed by Kmet, Lee and Cook (2004) were used for 
Study 3. Each of the three studies involved a narrative synthesis with the formation of a 
matrix to consider each risk factor identified as associated with relapse/recurrence from 
the perspective of each reviewed study, and a conceptual framework was then built on the 
basis of findings from all three studies. Results: Seven articles were reviewed in Study 1, 21 
in Study 2, and 15 in Study 3. Only the presence of residual symptoms of depression after 
treatment and childhood maltreatment were well supported with strong evidence from 
high quality systematic reviews as risk factors for relapse to depression.  A number of 
factors that to date had not been systematically reviewed were identified as conferring risk 
for relapse, but these were not supported in the literature with the same degree of strong 
evidence. Conclusions: The consensus view that only residual depressive symptoms and a 
history of multiple previous episodes confer risk for relapse to depression (Campbell, 2009) 
needs amending. There were no factors supported by high quality reviews able to provide 
strong evidence that have utility in guiding the treating clinician in reducing their patient’s 
risk of relapse/recurrence to depression. A number of affective and information processing 
biases were suggested to play a role relapse. Considering the inter-relationships between 
these factors a conceptual framework was built which may help guide future research into 
relapse/recurrence to depression in adults. (For a full abstract in the format outlined by 
PRISMA see Appendix I). Introduction 
Depression is considered to be the single most burdensome disease world-wide in terms of 
years of life lost to disability (Murray & Lopez, 1996; Prince et al., 2007). This is due to the 
fact that depression is highly prevalent, results in significant functional impairment, 
increases the risk of suicide and of comorbid physical health problems, and as many as 80% 
of sufferers will have more than one episode (Judd, 1997; Kessler & Wang, 2009; Mueller et 
al., 1999; Murray & Lopez, 1996; Roiser, Elliot & Sahakian, 2012). Indeed it has been 
reported that the mean number of episodes of depression per sufferer is approximately 
four, with a mean duration of approximately 20 weeks per episode (Judd, 1997). While 
depression can occur as an acute condition (Angst, Kupfer & Rosenbaum, 1996) it is widely 
considered by most commentators to follow a ‘relapsing-remitting’ course (e.g. Burcusa & 
Iacono, 2007), with disabling sub-syndromal symptoms periodically occurring in between 
discrete episodes (Angst et al., 1996). Depression and the relapse or recurrence of it 
therefore result in a heavy burden on health services,  with this now a major public health 
concern both within the UK (e.g. Public Health England, 2013) and internationally (e.g. 
Prince et al., 2007; World Health Organization [WHO], 2009).  
  The consensus view of relapse/recurrence (used interchangeably throughout this 
article) to depression as defined by Campbell’s Dictionary of Psychiatry (2009) is that only 
two factors are reliably known to influence risk for relapse: having residual sub-threshold 
depressive symptoms at the end of acute phase treatment, and having had two or more 
depressive episodes prior to the index episode. It is also reported that with increasing 
episodes relapse becomes autonomous from stressful life events (Campbell, 2009). So, 
despite more than half a century of active research into treating depressive episodes, 
preventing relapses and recurrences, and understanding the risk factors for depression, we 
are still a long way from predicting who will relapse following treatment (Beckerman & 
Corbett, 2010; Hughes & Cohen, 2009; Roiser, et al., 2012). It is therefore unsurprising that 14 
 
there is no treatment currently able to provide more than a small-to-medium effect size for 
preventing depressive relapses (Clarke, Mayo-Wilson, Kenny, & Pilling, in press).  
Several experts in the field have suggested that part of the difficulty in finding more 
successful treatments for preventing depressive relapses is due to a lack of clarity about 
what it is that actually confers risk for relapse and how identified risk factors can be utilised 
in the consulting room (e.g. Burcusa & Iacono, 2007). In addition, many studies that have 
investigated relapse have been hampered by methodological problems or inconsistencies 
(Monroe & Harkness, 2011).  
  Early studies into these phenomena did not use consistent definitions of relapse 
and recurrence (Beshai, Dobson, Bockting, & Quigley, 2011). However, a majority of studies 
now follow the criteria suggested by Franck et al. (1991) who defined relapse as ‘a return to 
the depressive episode after remission but without reaching a full recovery (i.e. less than 
eight weeks symptom free)’, and recurrence as ‘the onset of a new depressive episode 
after having fully recovered from a previous one (i.e. being symptom free for eight or more 
weeks)’ (Frank et al., 1991). More recently though, it has been suggested that even these 
definitions may have biased research by failing to discriminate those patients with a first 
lifetime episode of depression from those with a history of multiple previous depressive 
episodes. As such, researchers following these criteria may have been combining results of 
those that may never suffer a relapse of depression with those that have already suffered 
relapses. Combining results together in such a way may have led to spurious conclusions 
about the course of depression and what confers risk for relapse or recurrence (Monroe & 
Harkness, 2011).  
  Most studies seeking to understand or identify risk factors for depressive relapse 
have involved prospective longitudinal follow-up of patients after they have presented with 
a depressive episode at a treatment centre and have either remitted or fully recovered. 
However, some studies have included only those with unipolar depression whilst others 15 
 
have included those with recurrent episodes of depression in the context of bipolar 
disorders. This is particularly relevant to studies of clinical samples as bipolar disorders are 
more common in these populations than in the general population as a whole. Further 
difficulty has arisen when assessing the findings of randomised controlled trials as many 
have required participants to be free from comorbid ‘Axis 1’ and/or ‘Axis II’ disorders, and 
given that 45% of people with any mental disorder have more than one separate mental 
health diagnosis (Kessler, Chiu, Demler & Walters, 2007), findings from such studies may 
not be applicable to a large number of patients seen in health services (Kessler et al., 1996). 
Many large observational studies have used hospital readmission rates to determine when 
a study participant has suffered a relapse/recurrence. However, such methods may 
introduce significant selection bias as this might only represent the most severe of cases or 
those with greatest access to healthcare, missing large numbers of others that are either 
not receiving care at all, or not as an inpatient (Hatch et al., 2011; Hatch & Thornicroft, 
2012). Further, such naturalistic studies have often failed to account for differences in 
maintenance treatments and their effects on the rate of recurrence (Burcusa & Iacono, 
2007), and many of the trials and observational studies investigating relapse/recurrence 
have suffered from high attrition rates suggesting yet further bias in the interpretation of 
their results (Burcusa & Iacono, 2007).  
  In addition to the above there has been debate about whether or not recurrence 
represents a phenomenon which can be understood and eventually prevented, or whether 
it represents a sub-type of depression naturally leading to multiple episodes occurring over 
the life-course (Burcusa & Iacono, 2007). The concept of depression as a diagnosis has been 
repeatedly questioned and many researchers have attempted to differentiate subtypes of 
depression with various nosologies, including recurrent depression and many others (e.g. 
anxious depression, atypical depression, endogenous depression, melancholic depression, 
and reactive depression).  However, separating cases into these proposed subtypes has led 16 
 
to few advances in treating depression, either in resolving the acute episode or in 
preventing relapse/recurrence (Monroe & Harkness, 2005; 2011). The heterogeneity within 
the diagnostic category of depression suggests a number of different causal pathways and 
prognoses (National Institute for Clinical Excellence [NICE], 2004). The use of a single 
diagnostic label for the heterogeneous experiences that can occur within this diagnosis 
may have limited the ability of researchers and clinicians in finding more successful 
solutions to treating and preventing relapse (NICE, 2004).  
  It may be the case that the difficulty in coming to conclusions about what does and 
does not confer risk for depressive relapse is due in part to the restrictions of using disease 
classification systems that group disorders based on clusters of symptoms rather than 
either behavioural/functional experiences or underlying biology. Such systems do not lend 
themselves to greater understanding of the mechanisms behind the separate experiences 
within the cluster of symptoms (Cuthbert & Insel, 2010; Insel et al., 2010; NICE, 2004). 
However, given the above outlined methodological difficulties in this literature, it is not 
surprising that researchers have thus far struggled to determine exactly what explains 
relapse/recurrence to depression and how this knowledge can be utilised. Despite this, 
there is a large body of literature to draw upon and means of rigorously and systematically 
summarising and synthesising the data available may yet deliver a basis for understanding 
relapse/recurrence and a conceptual framework to be tested in new research in this field.  
  The present study therefore aimed to summarise and synthesise findings of studies 
that have reported either on risk factors for depressive relapse/recurrence or those that 
have sought to explain the mechanisms underlying the action of these risk factors. This was 
with a view to developing a conceptual framework that may help us better understand the 
phenomena of depressive relapse and recurrence, and consider how the body of evidence 
can be built in future studies whether or not newer nosological systems for mental 




The National Health and Medical Research Council of Australia (NHMRC) suggest that in 
developing clinical guidelines the best evidence for the prognosis or aetiology of disorders 
comes from systematic reviews of prospective cohort studies, with the next greatest level 
of evidence coming from systematic reviews of retrospective cohort studies or randomised 
controlled trials (RCTs), and then from pseudo-randomised trials, non-randomised trials, 
and case-control studies (Coleman et al., 2009). The aim of the present study was therefore 
to conduct a meta-review of systematic reviews of prospective cohort studies, RCTs, 
retrospective cohort studies, pseudo-randomised trials, non-randomised trials, or case-
control studies that reported on risk factors for relapse/recurrence to depression in adults.  
The findings from this meta-review would then be considered in light of the consensus view 
on relapse to depression (e.g. Campbell, 2009), to determine whether or not this may be 
amended or expanded based upon the findings of those studies considered to have the 
greatest level of evidence for the aetiology and prognosis of depressive relapse/recurrence.  
Methods 
A meta-review of systematic reviews was conducted in accordance with the preferred 
reporting method for systematic reviews (PRISMA) guidelines wherever possible (Moher, 
Liberati, Tetzlaff & Altman, 2009). However, no protocol was registered for this review.   
Search Strategy 
Studies were identified by using a combination of keyword and subject heading searches 
on the following bibliographic databases: Cochrane Database of Reviews (searched on 16
th 
November 2013), Embase 1947 to 2013 Week 47, Ovid MEDLINE 1946 to November Week 
3 2013, Prospero (searched on 16
th November 2013), PsycEXTRA 1908 to November 16, 18 
 
2013, and PsycINFO 1806 to November Week 3 2013. Each database was searched 
individually and results were combined before removing duplicates. Search terms included 
variations of phrases such as “depression” or “major depression” or “major depressive 
episode” or “MDD” or “unipolar depression” or “depressive episode”, and “relapse” or 
“recurrence”, and in the relevant databases the searches were run to include terms such as 
“review”, “systematic review” or “meta analysis”. An example of the search conducted for 
articles in PsycINFO is listed in Table 1. A full list of all the searches conducted and results 
thereof can be found in Appendix II.  
Study Selection 
All search results were reviewed by a single reviewer reading through study titles to 
remove any clearly non-relevant articles based on the inclusion and exclusion criteria listed 
below. The remaining study abstracts were read and judged as either relevant to this 
review, possibly relevant, or definitely not relevant, based on inclusion and exclusion 
criteria. All studies deemed to be either relevant or possibly relevant were read in full and 
independently judged against inclusion and exclusion criteria by two reviewers. Disputes 
were resolved by consensus and by consultation with a third reviewer where necessary. 
Hand searching of the references from all the included studies was conducted to identify 
studies missed in the bibliographic database searches. Any possibly relevant or relevant 


























Inclusion Criteria: Studies were included if: 1) they were systematic reviews (with 
or without any quantitative synthesis) of RCTs, quasi-randomised controlled trials, non-
randomised controlled trials, prospective cohort studies, retrospective cohort studies, or 
case-control studies; 2) they provided data on at least one explanatory factor for 
relapse/recurrence to depression; 3) studies reviewed in the article under consideration 
had some longitudinal measurement of depressive symptoms and either a clinical interview 
to determine status of onset, remission, recovery, relapse, and/or recurrence, or used well 
validated interviewer-rated or self-report measure(s) of depressive symptoms; 4) they 
reviewed studies of adults aged 18 years or older; and 5) were journal articles published in 
the English language. 
Exclusion Criteria: Studies were excluded if: 1) they were not systematic reviews; 
2) they provided no data on explanatory factors associated with relapse/recurrence to 
PsycINFO 1806 to November Week 3 2013  N 
1. exp major depression/ or exp "depression (emotion)"/  111027 
2. recurrent depression/  617 
3. exp Relapse Prevention/ or exp "Relapse (Disorders)"/  6945 
4. 1 or 2  111027 
5. ((relapse or recurrence) adj5 depressi*).mp.  1939 
6. 3 and 4  1133 
7. 6 or 5  2229 
8. 7  2229 
9. limit 8 to (human and english language and journal article)  1598 
10. bipolar disorder/ or affective psychosis/ or mania/  21943 
11. exp Schizoaffective Disorder/  2568 
12. 10 or 11  24023 
13. 9 not 12  1382 
14. exp Child Psychopathology/  1426 
15. 13 not 14  1381 
Substance abuse.mp  27069 
exp Drug Abuse/  85848 
exp Alcohol Abuse/  38362 
16 or 17 or 18   85848 
15 not 19  1320 20 
 
depression; 3) they reviewed studies of populations with bipolar disorder, psychotic 
depression, seasonal affective disorder, depression secondary to organic brain disorders, or 
if they focussed on relapse to other conditions (such as drug or alcohol misuse disorders) 
comorbid to depression; 4) they were reviews of studies exclusively of children or 
adolescents (i.e. those younger than 18 years old), including studies of the impact of 
parental depression on children, or of studies of older adults only and/or factors relevant 
only to a geriatric population; 5) they were non-journal articles; and 6) if they were not 
published in the English language.  
Data Extraction  
Data on the search strategy, databases searched, terms used for searching, inclusion and 
exclusion criteria, as well as methods of quantitative synthesis (where applicable) were 
extracted from each included study by a single reviewer. In addition, data on the studies 
included in the review and the main results of relevance to associations between identified 
factors and relapse/recurrence to depression, were also extracted from each included 
study by a single reviewer. The latter information was used to build a matrix such that 
every proposed factor could be considered from the perspective of each included study. 
The strength of association between the factor and relapse/recurrence as reported in each 
study by the study authors was entered into each cell of the matrix. 
Rating Study Quality 
Quality ratings for all included studies were established independently by two reviewers, 
with disputes resolved by consensus or by consultation with a third reviewer where 
necessary. The ‘a measurement tool to assess the methodological quality of systematic 
reviews’ (AMSTAR) rating system (Shea et al., 2007) was used to judge the quality of the 
included studies, with further consideration given to factors listed in the PRISMA statement 
(Moher et al., 2009) and factors identified in the Cochrane Reviewer’s Handbook (Higgins & 21 
 
Green, 2008) regarding preferred reporting standards and assessment of bias in included 
studies. The AMSTAR consists of 11 items listed as questions, for example: ‘Was there 
duplicate study selection and data extraction?’. For each item one of four responses must 
be given ‘Yes’, ‘No’, ‘N/A’, or ‘Cannot Answer’. The authors of the AMSTAR do not suggest a 
summary score or categorical statement about the quality of the reviewed studies.  
The AMSTAR is the best available method for judging the quality of systematic 
reviews of the types included in the present study (Shea et al., 2007). However, in order to 
bring a common structure to the interpretation of the AMSTAR quality ratings the 
categories suggested by Guyatt and colleagues in the GRADE rating system (Guyatt et al., 
2008) (favoured by the National Institute for Clinical Excellence as a means of judging 
quality of RCTs in systematic reviews) were used. Each study was labelled as fitting into one 
of the following four categories: High quality – suggesting that further research is very 
unlikely to change the level of confidence in the estimate of the effect; Moderate quality – 
suggesting that further research is likely to have an important impact on the level of 
confidence in the estimate of the effect; Low quality – suggesting that further research is 
very likely to impact upon confidence in the estimate of effect; and Very low quality – 
suggesting that any estimate of effect is particularly uncertain (Guyatt et al., 2008). Studies 
were judged as being of very low quality if very few or none of the AMSTAR items were 
answered ‘yes’ and as low quality if more of the AMSTAR items were answered ‘no’ than 
were answered ‘yes’. Studies were judged as of moderate quality if marginally more 
AMSTAR items were answered ‘yes’ than ‘no’ or if many more were answered ‘yes’ than 
‘no’ but the study was not awarded a ‘yes’ answer to the questions relating to study 
selection or quality ratings. In addition, if the reviews did not give at least cursory reasons 
as to why studies were excluded from the review (PRISMA – Moher et al., 2009), if they 
included RCTs that did not blind investigators to participant allocation, and/or if they did 
not deal appropriately with the likely sources of bias in their methods and/or the 22 
 
interpretation of their results (Cochrane Reviewer’s Handbook – Higgins & Green, 2008), 
they were rated as of moderate quality. If these latter criteria were met and studies had 
many more ‘yes’ answers from the AMSTAR items than ‘no’ answers then they were rated 
as high quality.    
Results 
Six studies were identified as meeting inclusion criteria from the bibliographic database 
searches and one study was added after consulting experts in the field for unpublished 
reports, giving a total of seven studies included in the present review (see Figure 1).23 
 
Figure 1. 
Flow diagram of study selection.  
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Characteristics of Included Studies 
Of the seven systematic reviews included in the present study, three reviewed cohort 
studies, two reviewed RCTs of non-pharmacological relapse prevention therapies, one 
reviewed both RCTs and quasi-randomised controlled trials (of any psychological relapse 
prevention treatment), and one reviewed both cohort studies and clinical trials (of either 
pharmacological or non-pharmacological relapse prevention treatments). All included 
articles reviewed studies of adults aged 18 or over, whilst two articles also included studies 
of children or adolescents; for the latter two, details pertaining only to adults 18 or over 
were used for the present review. Full details of the methods adopted by each included 
review can be found in Appendix III. Details regarding the reviewed studies in each review, 
the participants, interventions, comparators, and outcomes, along with the main results of 
each review in relation to factors associated/not associated with relapse are outlined in 
Table 2. 
Study Quality 
Quality judgements were made at the level of the review not of the studies included in 
each review. Only three of the included reviews reported on the quality of the studies 
reviewed therein: Clarke et al. (in press) reported that the majority of the 24 studies they 
reviewed were of ‘low quality’; Feng et al. (2012) reported that the 32 studies they 
reviewed were all of ‘good quality’; and Kok et al. (2013) reported that the four studies 
they reviewed were of ‘low-to-moderate quality’.  
Quality of reviewed studies: Of the seven included reviews three were judged to 
be of high quality (See Table 3) (Clarke et al, in press; Feng et al., 2012; Nanni, Uher & 
Danese, 2012), though all of these focussed only on narrow areas related to relapse to 
depression rather than considering multiple potential explanatory factors. The Clarke et al. 
(in press) review looked only at non-pharmacological relapse prevention treatments and 
aimed to consider the relative efficacy of each type of treatment in preventing relapse. The 25 
 
only factor of relevance to the present review was the presence or absence of sub-
threshold residual symptoms of depression after acute phase treatment, for which they 
reported some evidence of a positive association with relapse such that those with residual 
symptoms were more likely to relapse than those without residual symptoms. Feng et al. 
(2012) investigated the factors impacting on the efficacy of group based CBT as a relapse 
prevention treatment and focussed mainly on the treatment related factors impacting 
upon this. As with the Clarke et al. study (in press), they also investigated the impact of 
having residual symptoms on the efficacy of the treatment and found very strong evidence 
for a positive association between the presence of residual symptoms and relapse. There 
was some overlap between the studies reviewed by Clarke et al. (in press) and Feng et al. 
(2012) with seven studies included in both of these reviews.  
Feng et al. (2012) also looked at the impact of having multiple previous depressive 
episodes and found no association between this and the risk of relapse. Nanni and 
colleagues (2012) investigated the impact of various forms of childhood maltreatment and 
found very strong evidence of a positive association between suffering any form of 
childhood maltreatment and greater risk of relapse/recurrence to depression.  
Of the remaining four reviews one was rated as moderate quality (Kok et al., 2013). 
This too had a very narrow focus investigating the impact of comorbid physical health 
problems on relapse, and finding no evidence of an association between the two. The three 
reviews that aimed to consider multiple risk factors for relapse/recurrence were all rated as 
low quality (Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010; Hughes & Cohen, 2009) 
or very low quality (Beshai et al., 2011) and the results from these are therefore considered 
with caution. Beshai et al. (2011) reported inconclusive evidence related to residual 
symptoms despite including seven of the same studies as Feng et al. (2012) and 13 of those 
reviewed by Clarke et al. (in press). Otherwise there was little overlap in the studies 
included in each review. 26 
 
Table 2.             
Data extracted from included systematic reviews.     
Reviewed 
Studies 
Number of included 
studies and study 
design 
Study population  Intervention   Comparisons of 
relevance 
Main outcomes and 
how recorded 
Main results relevant to relapse/recurrence 
Beshai et 
al., 2011 














tted patients in 
different 
intervention 
groups of trials.  
Most studies used 
SCID-I or equivalent, 
others used self-
report e.g. BDI + 
interviewer rated 
e.g. HRSD 
Role of residual symptoms is inconclusive. Evidence that 
cognitive vulnerability corresponds to deficits in neural circuitry 
and abnormalities in certain brain regions implicated in 
emotional processing. Chronic interpersonal stress (as opposed 
to cognitive or personality factors) only variable significant for 
depressive relapse. Access to negative thinking may be 
important for recurrent depression.  
             
Clarke et al., 
in press 
24 RCTs. 19 included in 
meta-analysis combined 
N= 1463 
Adults with at 
least one past 
episode of MDD 
who had partially 















MBCT, CBT, and IPT are all efficacious as relapse prevention 
treatments. In included trials risk reduced by between 22% and 
25% compared to controls.  
             
Feng et al., 
2012 
32 RCTs. 19 included in 
meta-analysis, 
combined N=2152 
Adults 18+ with 
MDD 
Group CBT  Relapsers vs 
Non-relapsers 






Residual symptoms increased the risk of relapse. Past relapse 
episodes, experience of the therapist, type of control group, 
group size, group manual, therapy frequency, and take-home 
assignments showed no significant differences in effect.  
             
Hardeveld 
et al., 2010 
27 naturalistic cohort 
studies 








Two main predictors of recurrence: the number of previous 
episodes and residual symptoms after recovery. Gender, SES, 
and civil status, and age at first onset do not predict recurrence. 
The evidence is inconclusive for: neuroticism, lack of social 
support, severe life events, comorbid axis I and II disorder, the 
severity and duration of the previous episode, younger age of 
onset, family history of MDD and psychosocial impairment. 






studies (24 publications) 









HAM-D, BDI, SCID, 
and other clinical 
interviews based on 
DSM-III and DSM-IV, 
or ICD-10 
There was inconsistent evidence for episode duration and 
symptom severity as predictors. 27 
 
             
Kok et al., 
2013 
3 Prospective cohort 







(aged 8-13) with 







Illness in three 
of the four 
studies, 
children (aged 
8-13) with MDD 
without CSI in 
the other. 




No indication that comorbid somatic illness was associated with 
a greater risk for recurrence. 
Nanni et al., 
2012 
16 Epidemiological 
studies: 9 Population 
health surveys with 
prospective follow-up, 7 
clinical sample surveys 
with prospective follow-
up, combined N=23,544.  
10 Clinical Trials (2 
controlled observational 
studies; 6 RCTs; 2 non-
randomised controlled 
trial) combined N = 
3,098. 
Adults 18+ in 
Epidemiological 
studies (except 
one study 15+), 
Adolescents and 
adults of all 
ages in RCTs.  
In Clinical Trials 







HAM-D and Number 







Maltreated individuals were approximately twice as likely as 
those without a history of childhood maltreatment to develop 
recurrent or persistent depressive episodes. Confounding by 
age at onset was unlikely. From Clinical Trials: maltreated 
individuals were more likely than those without a history of 
childhood maltreatment to show poor treatment outcome. 
Abbreviations: BDI – Beck Depression Inventory; CBT; cognitive behaviour therapy; CI – confidence interval; CSI –chronic somatic illness; DSM-IV/DSM-III – Diagnostic and Statistical Manual of Mental Disorders 
4
th/3
rd Edition; HAM-D – Hamilton depression rating scale; HRSD - Hamilton rating scale for depression; ICD-10 – International Classification of Diseases 10
th Edition; IPT – interpersonal psychotherapy; MADRS – 
Montgomery-Asberg Depression Rating Scale; MBCT –Mindfulness based cognitive therapy; MDD – major depressive disorder; MDE – major depressive episode; RCT – randomised controlled trial; RDC – research 
diagnostic criteria; SCID – Structured Clinical Interview for DSM-IV. 28 
 
Matrix of factors associated/not associated with relapse 
The only factors to be endorsed as positively associated with relapse/recurrence for which 
there was strong evidence from high quality reviews were the presence of residual 
symptoms post-treatment and suffering childhood maltreatment. Only one of the reviews 
reporting these effects also reported that the studies reviewed therein were of good 
quality; the studies included in the other reviews to report on these factors were either 
considered to be ‘low quality’ or the quality of them was not reported on.  
There was no association found between having multiple previous episodes and 
risk of relapse in the only high quality review to examine this, and all the studies included in 
this review were reported to be of ‘good quality’ (Feng et al., 2012). One low quality review 
(Hughes & Cohen, 2009) found the same result whilst a second (Hardeveld et al., 2010) 
found the opposite; a positive association between multiple previous episodes and 
increased risk of relapse. However, only one of the studies included in the latter review was 
also included in the high quality review, so the respective results are for the most part 
based on different studies.  
Most other factors were found to have no association with relapse or the evidence 
for them was inconclusive. The low and very low quality reviews suggested some links 
between a number of other factors and relapse, though there was no strong evidence for 
these associations. Most studies commented on the impact of stress on the risk for relapse, 
though there was no agreement on the mechanism for this with some reviews suggesting 
that relapses occur autonomously from stress whilst others suggested stressful life events 
were important in triggering relapses, in particular stress in the interpersonal domain (see 
Table 4 for details). 29 
 
Table 3. 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Beshai et al., 
2011 
Yes  Can't answer  No  Can't answer  No  No  No  N/A  N/A  No  No  No  No  No  Very low 
Clarke et al., in 
press 
Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  High 
Feng et al., 
2012 
Yes  Yes  Yes  Yes  No  Yes  Yes  Yes  Yes  Yes  No  Yes  Yes  No  High 
Hardeveld et 
al., 2010 
Yes  Yes  Yes  Yes  No  No  No  N/A  N/A  No  No  Yes  N/A  No  low 
Hughes & 
Cohen, 2009 
Yes  No  Yes  Yes  No  Yes  No  N/A  N/A  No  Can't answer  Yes  N/A  No  low 
Kok et al., 
2013 
Yes  Yes  Yes  Can't answer  No  Yes  Yes  No  Can't answer  No  No  Yes  N/A  No  Moderate 
Nanni et al., 
2012 
Yes  Yes  Yes  Can't answer  No  Yes  No  Yes  Yes  Yes  Yes  Yes  No  Yes  High 
 
All items are from AMSTAR unless otherwise stated; 
*From PRISMA; 
# From Cochrane Reviewer’s Handbook. 
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Key:  +++ Strong evidence for positive association with relapse; ++ good evidence of positive association with relapse; + some evidence/suggestion of positive association with relapse 
         === Strong evidence for no association with relapse; = = good evidence of no association with relapse; = some evidence/suggestion of no association with relapse 
         ~ Inconclusive evidence regarding association with relapse.  
Table 4. 
Factors associated and not associated with relapse/recurrence to depression in adults and strength of associations as reported in each of the included 
systematic reviews.  
Study citation and 
quality rating 
Factors investigated for their association with relapse/recurrence       











Age at first 
onset 
Neuroticism  Demographics - Sex, Marital 
Status, Socio-economic 
status, Educational History 
Other 
Beshai et al., 2011 
Very low quality 
~          =    Interpersonal Stress ++; Cognitive Reactivity +; 
Cognitive Biases +; Rumination +; Negative Thought 
Content = = 
Clarke et al., in press 
High quality 
 
+               
Feng et al., 2012 
High quality 
+++  = = =            For Group CBT: Group size, type of manual, frequency 
of sessions, and whether using take-home 
assignments or not, all = = 
Hardeveld et al., 2010  
Low quality 
++  ++  +  =  ~  ~  = =  Low social support =; Psychosocial impairment post 
depression +; Severe life events ~; Comorbid Axis I ~ 
or Axis II ~; Family history of Affective Disorders = 
Hughes & Cohen, 2009  
Low quality 
 
  = =  = =  = =  =    = =   
Kok et al., 2013 
Moderate quality 
 
              Comorbid Physical Illness = = = 
Nanni et al., 2012 
High quality 
        =      Childhood Maltreatment +++ 31 
 
Discussion 
From the seven included systematic reviews there were only two factors that we can 
definitively conclude are positively associated with relapse/recurrence. These are the 
presence of sub-threshold residual symptoms of depression at the end of acute phase 
treatment, and having suffered some form of maltreatment during childhood. It is likely 
that there is no association between having multiple previous episodes and relapse, 
although one low quality review found good evidence for a positive association between 
the two. Certain groups of factors related to cognitive processing of information (rather 
than the content of cognitions) and interpersonal stress were suggested to be associated 
with greater risk for relapse but without good evidence to support this.  
  The results of this study differ from the consensus view of relapse to depression 
(e.g. Campbell, 2009), suggesting a need to reconsider the ‘conventional wisdom’ that risk 
of relapse is increased only by the presence of residual symptoms and in those with 
multiple previous episodes of depression (e.g. Campbell, 2009). However, neither of the 
two factors found to be positively associated with relapse here lend themselves to guiding 
the clinician seeing a depressed patient in their consulting room to deliver a treatment 
programme that will reduce the risk of future relapse; they therefore have limited utility. 
There were several factors suggested to be associated with relapse for which it is 
conceivable that a mechanism for their action may be able to help guide clinicians (e.g. 
cognitive reactivity and interpersonal stress – Beshai et al., 2011). However, there is little 
evidence to support their association(s) with relapse. Further, the reviews included in this 
study did not focus on these factors in any great detail so were not able to propose any 
such mechanisms. Therefore it may be that other non-systematic reviews, which focussed 
specifically on these factors, may give greater insight into the mechanisms behind relapse 





Given the paucity of systematic reviews investigating factors associated with relapse to 
depression and the limited utility of the factors found from such reviews, the present study 
aimed to perform a meta-review of non-systematic reviews reporting on factors associated 
with relapse/recurrence to depression in adults.  
Method 
Using the same searches and procedure for identification of studies conducted for Study 1 
but applying a different set of inclusion and exclusion criteria (detailed below), non-
systematic reviews reporting on factors associated with relapse to depression and/or the 
mechanism of action for such factors were identified and data were extracted for this 
review.  
Inclusion Criteria: Studies were included if: 1) they were non-systematic reviews; 2) 
they reported on at least one explanatory factor for relapse/recurrence to depression; 3) 
they reviewed studies of adults 18 years or older; and 4) they were journal articles 
published in the English language. 
Exclusion Criteria: Studies were excluded if: 1) they were not review articles or if 
they were systematic review articles; 2) they only reviewed articles covered in the 
systematic reviews included in Study 1; 3) they did not report on explanatory factors 
associated with relapse/recurrence to depression; 4) they reviewed studies of populations 
with bipolar disorder, psychotic depression, seasonal affective disorder, depression 
secondary to organic brain disorders, or if they focussed on relapse to other conditions 
(such as drug or alcohol misuse disorders) comorbid to depression; 5) they were reviews 
exclusively of studies of children or adolescents (i.e. those younger than 18 years old), 
including studies of the impact of parental depression on children, or of studies of older 33 
 
adults only and/or factors relevant only to a geriatric population; 6) they were non-journal 
articles; and 7) they were not published in the English language.  
Data extraction and quality ratings 
From each included study data relevant to the methods used to identify studies (where 
given), the main results of relevance to relapse/recurrence and any proposed mechanisms 
to explain relapse/recurrence to depression were extracted by a single reviewer. These 
data were then used to build a matrix as in Study 1. Given the low quality of these studies, 
any evidence relating to factors identified in the matrix in Study 1 was excluded from the 
present study matrix as the evidence for these came from higher quality reviews and is 
therefore considered more robust. Quality ratings were not made for these reviews, as 
being non-systematic there are no established criteria for judging their quality and as they 
do not report any specific methods for conducting the review it is reasonable to assume 
that against any existing quality rating criteria they would all be judged as of ‘very low 
quality’.  
Results 
Twenty one non-systematic reviews identified as meeting inclusion criteria from the 
bibliographic database searches were included in the present study (see Figure 2). The 
studies reviewed in each included non-systematic review were cross-checked with those 
reviewed in the systematic reviews in Study 1 to ensure that they were able to contribute 
knowledge beyond the findings of Study 1. Of the 702 studies included in all 28 reviews, 
only 22 were reviewed by reviews included in both Study 1 and Study 2. None of the 21 
non-systematic reviews included more than two articles also reviewed by Study 1 reviews.    34 
 
Figure 2. 
Flow diagram of study selection.  
 
 























Records identified from electronic 
database searching (n= 3719) 
Cochrane Database of Systematic Reviews 
= 23; Embase = 1150; Medline = 990; 
Prospero = 227; PsycEXTRA = 9; PsycINFO 
















































Additional records identified through other 
sources (n= 0) 
0 from correspondence with experts in the 
field  
0 From hand searching of references 






1,575 records excluded as irrelevant to 
review question  
243 relevant but excluded as not review 
articles 
Full-text articles assessed 
for eligibility 
(n= 82) 
Full-text articles excluded (n =61) 
44 excluded as did not report on any 
explanatory factors for 
relapse/recurrence 
8 excluded as not review articles (5 
editorials, 3 letters)  
6 excluded as they were systematic 
reviews included in study 1 
3 excluded as only included older adults 
Studies included in 
qualitative synthesis 
(n= 21) 35 
 
Characteristics of the included studies 
Given the narrative nature of most non-systematic reviews it is difficult to determine what 
exactly has been included in the review and therefore extracting data on the study type, 
population, interventions, comparisons, and outcomes of relevance to the present review 
was not always possible. Where multiple study designs were cited in a review this has been 
reflected in the study characteristics table (Table 5). However where a review cited mostly 
one type of study design but supplemented it with mention of one or two different types of 
study, the predominant design of the cited studies has been outlined in the table. All of the 
included studies reviewed clinical trials, cohort studies, experimental studies, or 
neuroimaging studies, with 11 of the 21 including more than one type of study. Several of 
the included studies also reviewed case-control studies, cross-sectional studies, quasi-
experimental studies, and/or animal laboratory studies.   
  Many of the included studies focussed or reported on factors suggested as related 
to relapse in Study 1, with seven studies reporting positive associations between cognitive 
biases and relapse, seven reporting on the relationship between stressful life events and 
relapse, and five studies reporting a positive association between ruminative thinking 
patterns and relapse. However, a number of factors not identified in Study 1 were also 
reported to be associated with relapse. In particular, eight studies reported associations 
between relapse and information processing biases, and six studies reported a positive 
association with relapse and either dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) axis, dysregulation of rapid eye movement (REM) phase sleep, or both.     
Matrix of factors associated/not associated with relapse and proposed 
mechanisms of action 
Details of the factors reported to be associated or not associated with relapse in each of 
the included studies along with any proposed mechanism of action can be found in Table 6. 
Overall, the reviewed studies propose associations between the presence of information 36 
 
processing biases, cognitive biases, and rumination and greater risk of relapse. Each study 
reporting on these factors considers slightly different mechanisms of action, though there 
are some common themes among them:  the suggestion that such biases are triggered in 
response to a change in mood (to become dysphoric); that there is a learned association 
between the depressed state and the biases, as they occur together; and the biases may 
trigger ruminative patterns of thinking by increasing awareness of negatively valenced 
information and decreasing awareness of positively valenced information, impacting upon 
the ability to recognise positive social cues and privileging depressogenic attributions. Such 
processes might then lead to further engagement in depressive thinking patterns, then 
might lead to greater depressive symptoms, and eventually to relapse/recurrence.  These 
processes are proposed to be accentuated by limbic and neocortical reactivity to changes in 
mood, in particular by dysregulation of the HPA axis which may act as a long-term diathesis 
for depression onset if occurring early in the life-course, and REM sleep dysregulation 
which interrupts the ability to process emotionally valenced information and to regulate 
affect.37 
 
Table 5.         
Data extracted from included non-systematic reviews.     
Reviewed 
Studies 
Study design of included 
studies 
Study population and 
Intervention 




Clinical trials  Adults with depression or 
formerly depressed. Treated 








Cohort studies  Adults  Relapsers vs non-
relapsers 
The longer patients stay well, the less likely they are to relapse. Factors increasing risk of 
relapse are: recent environmental stress, absence of social support from family members, a 
history of depressive episodes, persistent neuroendocrine dysregulation. No significant 





studies and clinical trials 
children, adolescents, 




groups of those with 
different treatment(s)  
Gender, SES, and marital status are not risk factors for recurrence. Age at onset, number of 
prior episodes, severity of the first or index episode, comorbid psychopathology especially 
other affective disorders, and family history of psychopathology, particularly depression or 
other affective disorders, all associated with increased risk of recurrence. Negative 
cognitions, high neuroticism, poor social support, and stressful life events may be risk factors 




clinical trials, and animal 
studies 
Adults with depression 
treated with ADM; animals 
used to test ADM 
Depressed vs healthy 




Alteration of metabolism and atrophy and/or death of specific neural populations, in brain 
structures involved in the control of mood and emotions; the hippocampus, the amygdala, 
and prefrontal cortex, resulting in a decrease in neuroplasticity, may be in the etiology of 
depression. The decreased risk of relapse with maintenance anti-depressant medication may 
be related to alterations in neuroplasticity. 
de Carvalho 





cohort studies, and animal 
studies 
Adults with depression 
treated with ADM, adults 
under influence of stressors 
Relapsers Vs Non-
relapsers 
Dysregulation of the HPA axis is partially attributable to an imbalance between GRs 
(glucocorticoid receptors) and MRs (mineralocorticoid receptors). Evidence has consistently 
demonstrated that GR function is impaired in major depression, resulting in reduced GR-
mediated negative feedback on the HPA axis. 
Hammen, 
2003 





Negative interpersonal events brought about by stress generation may increase risk of 
relapse in women.  
Hick & 
Chan, 2010 




Cognitive reactivity to sad mood is associated with depressive relapse following successful 
treatment. Rumination predicts the severity, duration, and recurrence of depressive 
symptoms. Several studies reported that rumination prolongs and intensifies depression by 









Explanatory style represents an example of the kind of depth cognitions likely to be involved 
relapse episodes. Explanatory style also predicted relapse after controlling for treatment 
type, and is suggested as a mediator of the effect of treatment on risk of relapse.  
Keller, 1996  Cohort studies  All ages of people with 




Most important predictor of recurrence is number of previous episodes. No other factors 
showed an association with risk of relapse without first controlling for the number of 
previous episodes. Probability of relapse within 6 months rose to 95% for those with 3 or 
more previous depressive episodes. Other risk factors were: double depression, onset after 
the age of 60, long duration of individual episodes, family history of affective disorder, 
comorbid anxiety disorder or substance abuse, and poor symptom control during 
continuation therapy. This latter factor is particularly important, becoming wholly symptom-
free had a profound effect on risk of relapse. 
Kerr et al., 
2013 
Neuroimaging studies and 
clinical trials 
mostly adults with 




The effect of Mindfulness practice on reducing the risk of depressive relapse may function as 
it enhances attentional control, possibly by acting upon the prefrontal cortical areas known 
to regulate the thalamocortical circuits.  
Kessler, 
1997 
Cohort studies and case-
control studies 
Adults with depression; 
adults vulnerable to 




Young age at first onset associated with recurrence. Childhood adversity is associated with 
increased risk of onset before 20 years old. Few of the childhood adversity factors continue 
to be associated with risk of recurrence. There is no difference in risk of recurrence by 
gender. 





Formerly depressed adults  Formerly depressed 
compared to never 
depressed adults 
Increased accessibility and activation of negative thinking patterns induced by sad mood 
were associated with increased risk of relapse. 






Adults with depression, 
adults under influence of 
stressors 
Depressed vs healthy 
controls 
Genetic factors are suggested to moderate the relationship between behavioural risk factors 
and relapse to depression.  Stress generation is tentatively proposed to provide the 




genetic sequencing studies, 
and animal studies 
adults with depression 
treated with Sleep 
Deprivation 
Depressed vs healthy or 
at risk controls 










Mostly adults with 




The stress sensitization and stress autonomy models provide very different accounts of the 
basic finding that life stress is more important for a first lifetime episode of depression than 
for a later recurrence. The stress sensitization model appears to provide the more 
parsimonious account of the existing data. Nonetheless, the stress autonomy model provides 
an important conceptual alternative. The authors suggest both models play important roles 





















Abbreviations: ADM – antidepressant medication; CT – cognitive therapy; DAH – differential activation hypothesis; DAS – dysfunctional attitude scale; GRs  - glucocorticoid receptors; HPA – hypothalamo-pituitary-
adrenal; MBCT- mindfulness based cognitive therapy; MBSR – mindfulness based stress reduction; MRs - mineralocorticoid receptors; REM – rapid eye movement; SES – socio-economic status; ST – standard; TAU – 
treatment as usual. 







Neuroimaging studies  adults with depression 




formerly depressed, vs 
healthy controls.  







Adults treated for depression 
or vulnerable to depression, 
and healthy controls 
Depressed, vulnerable 
to depression, vs 
healthy controls 
The authors report that: rumination, negative biases, memory problems and cortisol release 
all increase with successive episodes but sleep efficacy and social interaction ability diminish. 
Kindling may explain why first episodes are triggered by stressful life events and subsequent 
episodes can be triggered by lower levels of stress.  
Scher, 
Ingram & 
Segal, 2005  
Experimental studies  Children, adolescents, 
students, and adults - never 




remitted, vs recovered 
depressed. Within 
groups comparing 
vulnerability over time. 
The one study to directly investigate cognitive reactivity as a predictor of relapse found that 
it increases the risk of relapse. This supports the proposal that processes such as attention 
and interpretive biases play an important role in relapse.  
Scott, 2001  Clinical trials  Adults with depression  Between treatment 
groups 
Patients with residual depressive symptoms were found to have a 50–80% risk elapse. CT 
reduced risk of relapse by changing thinking style not thought content in particular reducing 
absolutist, dichotomous thinking. 
Segal et al., 
1996 




depressed vs never 
depressed 
Depression-related information processing (mediated by cognitive reactivity) may lead to 












Rumination, particularly brooding on past failures and anxiety (future-based ruminations) are 
associated with the course of depression. In Mayberg’s model depression is characterized by 
higher baseline amygdala activity, higher amygdala reactivity to emotional stimuli, and 
dysfunction between limbic and cortical circuits that regulate affective states. 40 
 
Table 6.                     
Factors associated and not associated with relapse/recurrence to depression in adults reported in each of the included non-systematic reviews, and 
proposed mechanisms of action. 
Study 
Citation 
Factors investigated for their association with relapse/recurrence    Proposed mechanisms of action 
















Rumination  Other     
Beckerman  
& Corbett,  
2010 
    ++  ++      Depressive relapse may be due to faulty thought processing 




++  ++            Duration of wellness 





++                None stated 
Costa e  
Silva, 2004 
            Decreased 
Neuroplasticity ++ 
Alteration of metabolism or atrophy in neural structures 
involved in the control of mood and emotions may play a key 
role in the etiology of depression.  
de Carvalho 
Tofoli et al., 
2011 
++              Early life stress leads to permanent changes in the HPA axis 
and may lead to the development of depression in adulthood 
Hammen, 
2003 
++                Maladaptive cognitions about attachment and dysfunctional 
interpersonal skills contribute to the stress generation and 
hence relapse. 
 
Hick & Chan, 
2010 
    ++      +    Small change of mood to one that is dysphoric may trigger 
negative attitudes, thinking patterns and beliefs, and these 
may be underlined by rumination. When this happens 
negative feelings worsen and intensify and magnify negative 
thoughts and feelings. This may generate even more 
overwhelming negative thoughts and negative attitudes 
setting off a depressive relapse.  41 
 
Hollon & DeRubeis, 
2009 
      +  ++    Hopelessness =  Change in readily accessible beliefs and expectations may 
mediate the reduction of acute distress, whereas change in 
underlying information-processing may play a larger role with 
respect to the prevention of relapse. 
Keller, 
1996 
              Double depression 





Kerr et al., 
2013 
+        ++  +  ++     Body-focused attentional practice enhances localized 
attentional control, thought to play a key role in regulating 
sensory input to sensory neocortex and in enhancing signal-
to-noise properties across the neocortex, thus acting against 
the information processing biases apparent in depressed and 
formerly depressed individuals which otherwise negatively 
impact on their ability to utilise social interactions and 
support and therefore increase their risk of relapse.  
Kessler, 
1997 
              Younger age ++; 
Demographics = = 
Inventories of stressful events predict subsequent 
depression. partly due to events causing depression but the 
reverse is also true. The association between stressful life 
events and depression is moderated by prior characteristics 
of the people exposed to the events and the environments in 
which these people are embedded. 
Lau et al., 
2004 
      ++  ++  ++      Cognitive reactivity is an independent predictor of depressive 
relapse; increased negative cognition(s) manifest during 
induced sad mood or a naturally occurring mild depressed 
mood are predictive of depressive relapse/recurrence. 
 





Dependent stress may interact with the underlying 
depressogenic vulnerability that produces it, thereby 
elevating risk for depression beyond what may be accounted 
for by either variable alone.  
Modell & Lauer, 
2007 





++                The stress sensitization model predicts that life events 
meeting minimal criteria for triggering recurrence are even 
more common given stress generation. In contrast, for the 
stress autonomy model, stress generation would have less 
powerful implications over time, given the proposed 
uncorrelated eventual relationship between life stress and 
recurrence. 
Palagini et al., 2013    ++            REM sleep may help regulate affective reactivity and 
emotional information processing in depression. Stress-
related REM sleep hyperactivation/disinhibition could affect 
adult neurogenesis and thus might endanger hippocampal 
integrity, thereby contributing to the development of mood 




+    +    +  +  +    Different symptoms of depression involve different patterns 
of neural activation that become associated during a first 
episode and that this could underlie the ‘kindling’ effect.  
Scher et al., 2005      ++  ++        Cognitive vulnerability may contribute to depression relapse 
and that vulnerability may originate in part from interactions 
that occur within the context of childhood attachment 
relationships. 
Scott, 2001          +  ++    Extreme Response 
Style (on self-report 
questionnaires) ++ 
The way depressed patients process depression related 
material, rather than the content of their thoughts may be 
critical in preventing relapse. 
Segal et al., 1996        ++        Once activated, depression-related patterns of processing 
may lead to behavioural processes which in turn increase risk 
of relapse.  
 
Sipe & Eisendrath, 
2012 





Catastrophic ruminations and threat avoidance may be 
accompanied by limbic dysfunction. Mindfulness may 
interrupt the cycle of rumination about past regrets or future 
fears, and enhance self-compassion, breaking the link 
between cognitive reactivity and escalating depressive 
symptoms.  
Key:  ++ good evidence of positive association with relapse; + some evidence/suggestion of positive association with relapse; = = good evidence of no association with relapse; = some evidence/suggestion of no 
association with relapse 
Abbreviations: CT – cognitive therapy; HPA – hypothalamo-pituitary-adrenal; REM – rapid eye movement; SSRI – selective serotonin reuptake inhibitor; ST – standard. 43 
 
Discussion 
From the twenty-one included non-systematic reviews there is some continuity with what 
was found in Study 1, with the addition of other variables and proposed mechanisms of 
action that may be helpful to consider for the consulting clinician. The matrix from the 
included reviews points to a role for cognitive processing and information processing 
biases, perhaps triggering ruminative thinking in the context of experiencing some change 
in mood, perhaps due to stressful life events. These factors were suggested to be 
associated with greater reactivity in the neocortical and limbic pathways and dysregulation 
of the HPA axis and REM sleep. However, given that the reviews were non-systematic and 
therefore of very low quality (although the quality of the studies reviewed therein may 
have been of reasonable quality but this was not reported on), the factors proposed to 
affect risk for relapse and their proposed mechanisms of action must be treated with great 
caution.  
  Recently a number of researchers have reconceptualised models of depression to 
consider relationships such as those noted above between various cognitive and 
information processing biases and the onset of depressive symptoms (e.g. Disner, Beevers, 
Haigh & Beck, 2011; Roiser et al., 2012). The ‘cognitive neuropsychological’ model of 
depression (e.g. Roiser et al., 2012) proposes that negative affective biases result in 
changes in monoamine transmission, giving rise to negative belief systems that 
subsequently result in the signature features of a depressive episode: anhedonia and 
dysphoria (Roiser et al., 2012). Such biases rely on both ‘bottom-up processes’ (as they may 
be triggered by emotionally salient stimuli, such as stressful life events), and ‘top-down 
processes’ (as cognitive mechanisms which are needed to inhibit reactions to emotionally 
salient but task-irrelevant information are known to function sub-optimally in depressed 
patients) (Castaneda et al., 2008; Clark et al., 2009b; Fales et al., 2008; Roiser et al., 2012). 
These authors have also suggested that evidence for the mechanisms proposed in the 44 
 
‘cognitive neuropsychological model’ of depression will be best delivered by neuroimaging 
studies and/or studies utilising an experimental paradigm to manipulate mood, cognitive 




The present study aims to systematically review neuroimaging and experimental studies to 
investigate any further factors proposed to be associated with relapse to depression in 
adults and the mechanisms of action for such factors.  
Methods 
A systematic review of experimental and neuroimaging studies was conducted in 
accordance with the preferred reporting items for systematic reviews (PRISMA) guidelines 
wherever possible (Moher et al., 2009).   
Search Strategy 
Studies were identified using a combination of keyword and subject heading searches on: 
CAB Global Health Archive 1910 to 1972, Cochrane CENTRAL Trial Register (searched on 
16
th November 2013), Embase 1947 to 2013 Week 47, International Pharmaceutical 
Abstracts 1970 to November 2013, Ovid MEDLINE 1946 to November Week 3 2013, 
PsycEXTRA 1908 to November 16, 2013, and PsycINFO 1806 to November Week 3 2013. 
Each database was searched individually and results were combined before removing 
duplicates. Search terms included variations of phrases such as “depression” or “major 
depression” or “major depressive episode” or “MDD” or “unipolar depression” or 
“depressive episode”, and “relapse” or “recurrence”, and “risk” or “explanatory factor”. A 
full list of all the searches conducted and results thereof can be found in Appendix II.  45 
 
Study Selection 
All search results were reviewed by a single reviewer using the same process as for Study 1. 
Hand searching of references from studies included in Studies 1 and 2 as well as the 
present study was then conducted in order to identify further studies for this review.     
Inclusion Criteria: Studies were included if: 1) they were neuroimaging or 
experimental studies; 2) they provided data on at least one explanatory factor for 
relapse/recurrence to depression; 3) they had some longitudinal measurement of 
depressive symptoms over a minimum of eight weeks and either a clinical interview to 
determine status of onset, remission, recovery, relapse, and/or recurrence, or used a well 
validated interviewer-rated or self-report measure(s) of depressive symptoms, or they 
made a cross-sectional comparison between groups of remitted and relapsed/recurrently 
depressed participants determined by diagnosis from a psychiatrist or with a clinical 
interview; 4) they included adults over the age of 18 years old; and 5) they were journal 
articles published in the English language.  
Exclusion Criteria: Studies were excluded if: 1) they were not neuroimaging or 
experimental studies; 2) they provided no data on any explanatory factors associated with 
relapse/recurrence to depression; 3) they were studies of populations with bipolar 
disorder, psychotic depression, seasonal affective disorder, depression secondary to 
organic brain disorders, or those focussing on relapse to other conditions (such as drug or 
alcohol misuse disorders) comorbid to depression; 4) they were studies of children or 
adolescents (i.e. those younger than 18 years old), including studies of the impact of 
parental depression on children, or studies of older adults only, and/or factors relevant 
only to a geriatric population; 5) they were not journal articles; and 6) they were not 
published in the English language.  46 
 
Data extraction and quality ratings 
Data were extracted from each included study by a single reviewer, on information 
relevant to the methods of participant recruitment; inclusion and exclusion criteria; how 
depressive status and/or symptoms were determined at baseline; the participants; and 
experimental interventions and/or means of neuroimaging. In addition, the comparisons 
drawn between or within groups of participants; the outcomes reported and the means by 
which these were recorded; and the main results of relevance to factors associated with 
relapse and any proposed mechanism(s) of action, were extracted by a single reviewer. 
Quality ratings for all included studies were established independently by two reviewers, 
with disputes resolved by consensus or by consultation with a third reviewer where 
necessary.  
  Study quality was assessed with criteria proposed by Kmet et al. (2004), using a 14-
item rating scale where each item is a question about how the study was conducted and/or 
reported, e.g. ‘Design evident and appropriate to answer study question?’. Each item has 
four possible responses ‘yes’, ‘partial’, ‘no’, or ‘n/a’; items are given a score of two if the 
answer is ‘yes’, one if the answer is ‘partial’, and zero if the answer is either ‘no’ or ‘N/A’. A 
summary score is then calculated by summing the score from the 14 items and dividing it 
by 28 minus the number of not-applicable items multiplied by two, to derive a total score 
of between zero and one. No grading of study quality is suggested by the authors (Kmet et 
al., 2004) so the GRADE categories (Guyatt et al., 2008) were used as discussed above 
(Study 1). The following was used to guide judgements of overall study quality: studies 
scoring between 0 and 0.25 were considered to be of very low quality; studies scoring 
between 0.26 and 0.50 as low quality; studies scoring between  0.51 and 0.75, or studies 
scoring above 0.75 but scoring 0 on the sample size item or not scoring 2 on items related 
to using appropriate outcome measures, conducting appropriate analyses, and being able 
to support conclusions with the data, were considered as moderate quality; and if the 47 
 
above criteria were met and the studies scored 0.76 or above they were considered as high 
quality.   
  Information extracted on factors proposed to be associated or not associated with 
relapse to depression, along with any proposed mechanisms of action, was used to build a 
matrix such that every proposed factor could be considered from the perspective of each 
included study. The strength of association between the factor and relapse/recurrence 
reported in each study was considered and entered into each cell of the matrix as in 
Studies 1 and 2 above.  
Results 
A total of 15 studies were found to meet inclusion criteria and were included in the present 
review (see Figure 3 for a flow diagram of study selection). 
Characteristics of the included studies 
Eleven of the 15 studies utilised experimental paradigms to manipulate cognitive 
processing, information processing, mood, or a combination thereof. One study included 
some neuroimaging, two were targeted neuroimaging studies with an experimental task, 
and two were quasi-experimental studies with laboratory-based measurements of 
cognitive processing or information processing but with no experimental manipulation (e.g. 
Risch et al., 2010 used an Implicit Association Test to measure the association between 
implicit self-esteem and recurrent depressive episodes though did not manipulate self-
esteem). 
Study Quality 
Seven of the included studies were judged to be of high quality (see Table 8) (Dai & Feng, 
2011; Franck, De Raedt, & De Houwer, 2007; Lethbridge & Allen, 2008; Morris, Rao & 
Garber, 2012; Nixon, Liddle, Worwood, Liotti & Nixon, 2013; O’Brien-Simpson, Di Parsia, 
Simmons & Allen, 2009; Segal et al., 2006),  a further seven were judged to be of moderate 48 
 
quality (Anderson et al., 2011; Chopra, Segal, Buis, Kennedy, & Levitan, 2008; Huffziger & 
Kuehner, 2009; Risch, et al., 2010; Sears, Newman, Ference & Thomas, 2011; Segal, Gemar 
& Williams, 1999; Watkins & Baracaia, 2002), and one study was judged as low quality 
(Moreno, George, Heninger, McGahuey & Delgado, 2000). The high quality studies 
focussed on a range of factors associated with relapse, with three of the seven (Dai & Feng, 
2011; Lethbridge & Allen, 2008; Nixon et al., 2013) considering cognitive biases (including 
rumination), information processing biases/affective biases, or some combination thereof, 
whereas six of the seven moderate quality studies reported on these factors (the exception 
being the study by Risch et al., 2010). The one low quality study focussed on manipulating 
mood with tryptophan depletion and reported on the relationship between dealing with a 
change in mood for the worse and relapse (Moreno et al., 2000).   49 
 
Figure 3. 
Flow diagram of study selection.  
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Table 7.             







Population Characteristics  Intervention details 
including method of 
delivery and setting  
Comparisons and Ns  Outcomes and How 
Recorded 










N= 230. Current Depressed mean 
age 38.6(10.9) mean 6.3(4.4) 
previous episodes, 53% on ADM; 
Remitted group mean age 
34.2(10.8) 3.0(2.2) previous 
episodes, 17% on ADM; Controls 
age 30.3(10.1). 159 female. 
Face Emotion Recognition 
Task. Participants are 
asked to correctly 
recognise expressions of 
anger, disgust, fear, 
happiness, sadness and 
surprise with intensities of 
30, 50, and 70%, and 
neutral expression. 
Healthy Controls N= 
101, Current 
Depressed N= 30,  
Remitted Depressed 
N= 99 
The number of correct items 
recognised, false positives, 
and reaction times for each 
item were recorded.   
Remitted group correctly identified a more 
emotions than did controls and those currently 
depressed. Participants with current depression 
had impaired accuracy owing to decreased 
discrimination as to whether an emotion was 
present. The effect was mainly driven by the 
negative emotions anger, fear and sadness. 
Chopra et al., 
2008 
HRSD and BDI  N= 55 (35 female), mean age 
38.8(10.1). 37 patients had 3 or 
more past depressions. 
Listened to ‘‘Russia under 
the Mongolian Yoke’’, 
while recalling a sad time 
in their lives. 
Relapsers (28) Vs Non-
Relapsers (27). 
Salivary cortisol samples 
taken at -25, 0, +25, +45 and 
+65 minutes relative to 
mood induction. Change in 
DAS score to assess 
relationship between 
cognitive reactivity and 
relapse. 
Dysfunctional attitudes in response to mood 
induction predicted relapse. Participants with 
three or more episodes were more likely to 
relapse. For patients with high cortisol at 25 min 
rates of relapse were equivalent regardless of 
past depression history. For patients with low 
cortisol at 25 min those with no/fewer past 
episodes of depression had lower rate of relapse. 




Groups were age and sex matched; 
mean ages: Normal Controls: 
25.71(3.72); Remitted depressed: 
27.53(6.36); MDD: 27.59(3.74). 60% 
of MDD group were outpatients 
with no comorbid disorders. 6 of 
MDD and 3 RMD taking ADM. 
Stroop Colour Word task - 
50 positive, neutral and 
negative words. Ignore 
meaning respond to 
colour. Brain EEG activity, 
HEOG and VEOG tracked. 
MDD (N=17), RMD 
(N=17), NC (N=17) 
Word accuracy, false positive 
rate, reaction time, ERPs and 
EEG latencies. 
MDD participants showed deficient behavioural 
and neurophysiological indices of attentional 
inhibition for negative words. This impaired 
inhibition of negative information was 
accompanied by reduced N1 amplitude and 
enhanced N450 component in these trials. 







Mean ages Never Depressed (ND) 
45.3(7.3) 8 males, Formerly 
Depressed (FD)43.8(9.4) 3 males, 
Currently Depressed (CD) 39.6(12.1) 
10 males. 
Participants were asked to 
rate how beautiful they 
found each letter of the 
alphabet.  
CD (N=28), FD (N=34), 
ND (N=33)  
BDI  at baseline for all three 
groups and 6 months follow-
up for ND and FD only. RSES 
at baseline only.  
CD patients had lower explicit self-esteem 
compared to FD and ND controls. After 
controlling for initial symptoms of depression 
higher levels of implicit self-esteem were 
associated with higher levels of depressive 







Mean ages: Rumination group 
51.37(11.82) 50% female, 
Distraction 45.95(12.96) 52% 
female, Mindful self-focus 
44.85(10.38) 48% female. Groups 
did not differ on baseline variables 
all ps> .10.  
Sad mood induction with 
negative autobiographic 
recall. Randomly assigned 
to one of three groups 
(rumination, distraction, or 
mindful self-focus).  
58 remitted patients, 
5 with residual 
symptoms and 13 with 
current MDD. 
Compared across 
induction groups - 
Rumination (n=24) 
Distraction (n=27) and 
Mindfulness (n=25).  
Response styles measured 
with RSQ. Habitual aspects of 
mindfulness using FMI-14 
and mood using PANAS.  
Controlling for baseline MADRS, there were 
differences between induced rumination and 
both mindfulness and distraction groups. 
Habitual distractive coping predicted less 
negative and more positive mood. Habitual 
mindfulness enhanced improvement of negative 






20 males, 32 females, mean age 
32.7(11.7). Mean number of 
previous episodes 1.94(range 1-6). 
Mean age of onset 24.42(10.25). 
Mood induction consisted 
of autobiographical recall 
of depressing experience 
followed by mood-
congruent music.  
48 of 52 completed 
follow up. 17 Relapsed 
(14 once, 3 twice) over 
the 12 months.  
BDI, SCID, if relapsed then 
life events questionnaire was 
also used. 
Changes in happy mood following a mood 
induction were associated with increased risk for 
relapse. Changes in depressed mood following a 
sad mood induction and changes in dysfunctional 
thinking did not predict relapse. 
Moreno et 
al., 2000 
HAM-D  N=12 all with history of MDE but in 
remission, and 12 age- and gender-
matched controls with no personal 
or family history of any mental 
disorder.  
Two TRP depletion tests, 
separated by 1 week. One 
full-strength and one 
quarter-strength. Double-
blind, crossover design. 
MDE over follow-up 
(N=9 from the 24 
participants) 
compared to no-MDE 
during follow-up 
(N=15). 
Behavioural ratings obtained 
at baseline and 5, 7 and 28 
hours after depletion. HAM-
D was completed weekly for 
1 month, and then monthly 
for 3 months. Retrospective 
HAM-D and SCID at 6 and 12 
months. 
An increase of 5 or more in HAM-D score during 
depletion predicted relapse. Relapse was not 
associated with age, gender, type of past 
treatment, length of remission, or number of 
past MDEs.  




N= 68, 32 remitted depressed (RD), 
and 36 never depressed (ND), mean 
age =23.39(3.88); 43 were female 
(63%). 
Randomly assigned to high 
stress or low-stress 
condition. Cortisol 
measured after a 10min 
rest, after a 10min 
preparation period, after 
the reading task, and the 
arithmetic task, after 
10mins rest and another 
10mins rest. 
RD vs ND  Trier Social Stress Test and 
salivary cortisol. LIFE 
administered each week 
during follow-up. The 
Perceived Events Scale was 
used to measure number 
and severity of stressful life 
events during follow-up. 
Individuals with high-anticipatory stress cortisol 
and more MDEs were at significantly greater risk 
of recurrence compared to individuals with low-
anticipatory stress cortisol and fewer MDEs. 
Individuals who showed higher cortisol reactivity 
to a relatively low-level stressor were at greater 
risk of experiencing subsequent depressive 
symptoms. 
Nixon et al., 
2013 
SCID & HAM-D  Controls (n=20) mean age 43(24-
63), 30% male, and Patients (n=20) 
mean age 45(25-63), 35% male. 
In fMRI Scanner after 
baseline images two 10-
min trials of a Go/No-Go 





and controls. Also 
compared recurrers 
(n=7) to non-recurrers 
(n=11). 
SCID conducted at 4-montly 
intervals for 1-year, clinical 
data gathered from case-
notes.  Accuracy of 
responses to task measured.  
Hypoactivity in BA 9 of the right dmPFC, believed 
to play a role in affective regulation was found in 
patients but not in controls. Some processing of 
negative experiences at this site may have a 
protective effect against depression as the 
dmPFC inhibits ventral, limbic regions allowing 





SCID and BDI  33 participants assessed in 
remission from depression, 25 
followed-up (19 female, 6 male; age 
range 20 to 63 years) 2 years later. 
9 Ps were on ADM. Duration of 
remission prior to testing ranged 
from 73 to 3820 days; Mean= 697 
days (SD 903).  
Startle probes were bursts 
of white noise at 100 dB. 
Startle reflex was 
measured by surface 
EMGs. Participants were 
assessed 1–2 weeks apart. 
Each time performing an 
affective picture viewing 
task, with startle probes. 
Participants induced to 
euthymic mood once and 
depressed mood once. 
Relapsers (n=7) Vs 
Non-relapsers (n=18), 
and participants that 
experienced residual 
depressive symptoms 
over the follow-up 
period (n=19) vs those 
that did not (n=6). 
SCID, LIFE used to track 
symptoms weekly over 2 
years and to take monthly 
measures of social support.  
Baseline startle magnitude predicted depressive 
symptoms and recurrence over the follow-up. 
Number of past episodes also predicted 
outcome.  
Risch et al., 
2010 
SCID and BDI  Currently Depressed (N=24): 13 
females, mean age 40.2(12.1); 
Recurrently Depressed (N=28):19 
females, mean age 50.1(10.9); 
Remitted Depressed (N=33) : 20 
females, mean age 40.1(13.1); 
Never Depressed (N=34): 20 
females, mean age 44.6(12.7). 
Implicit Association Test. 
Participants were asked to 
categorise words as fast as 
possible combined with a 
self-positive and a self-
negative task. Following 
the IAT completed the BDI 
and DAS. 
First-onset currently 
depressed patients vs 
recurrently depressed 
vs remitted depressed 
patients vs never 
depressed 
DAS and IAT  No significant correlation between implicit self-
esteem and the number of depressive episodes. 
First onset CD and RCD patients did not 
significantly differ in implicit self-esteem. 
Sears et al., 
2011 







Never Depressed (ND): N=38, Mean 
age 20.7(3.4), Previously Depressed 
(PD): N=15, Mean age 21.3(4.1), 
Dysphoric (DY): N=24, Mean age.   
160 colour images: 
depression-related, 
anxiety-related, positive, 
and neutral. Eye 
movements were 
recorded. Recognition 
memory test with the 160 
images and 160 new 
images. Asked to choose: 
sure old, guess old, sure 
new, or guess new. 
ND vs PD vs DY  Type of image initially fixated 
on in each trial, number and 
duration of fixations to each 
image type measured in 
milliseconds. Signal 
detection measure d-prime, 
used for recognition memory 
accuracy. 
PD and DY participants attended to positive 
images less than ND participants and PD 
attended to anxiety-related images more than 
ND or DY. PD and DY had poorer recognition 
memory than ND. There was no interaction 
between group and image type.  






HRSD and BDI 
scores. VAS and 
DAS also used.  
CBT Group (N=25): Mean age 
40.5(10.7), 10 males, mean 
previous episodes 6(10.0); PT 
Group (N=29), Mean age 39.7(8.0), 
12 males, mean previous episodes 
3.6(2.1).  
Completed VAS then 
modified Stroop task and 
then listened to Russia 
Under the Mongolian Yoke 
with sad autobiographical 
recall for 10mins.VAS 
again after completing 
Stroop Task. 
Remitted depressed 
CBT Vs PT. Pre 
induction vs post 
induction. Relapsers 
(N=14) compared to 
non-relapsers (N=16). 
DAS. Relapse using SCID and 
BDI. Only 30 agreed to take 
part in the follow up, 10 CBT, 
20 PT.  
The PT group showed a greater increase in 
cognitive reactivity compared against the CBT 
group. DAS at time of testing predicted relapse 
status for 75% of those that did not relapse, and 
64.4% of those that did. Changes in DAS after 
mood induction increases risk of relapse.  53 
 







DAS and VAS 
pre-post 
induction and 
BDI-II prior to 
mood-
induction.  
ADM (N=40), mean age 
39.65(11.49), 23 females, 14 first 
episode, mean previous episodes 
1.65(0.48), mean HDRS score 
5.23(2.77), mean DAS pre mood-
induction 134.73(28.09). CBT group: 
(N=59) mean age 38.17(10.95), 36 
females, 13 first episode, mean 
previous episodes 1.71(0.46), mean 
HDRS 5.29(2.80), mean DAS pre 
mood-induction 128.17(30.04).  
ADM condition: treated 
first-line antidepressant 
medications for 6 months. 
CBT condition: 20 
individual weekly sessions 
of CBT. Mood induction 
using 'Russia under the 
Mongolian Yoke' played at 
half speed and recalling a 
time in their life that made 
them sad.  
99 participants 
induction and entered 
an 18-month clinical 
follow-up. Main 
comparison was 
relapsers (n=42) vs 
non-relapsers (n=57).  
Patients completed BDI-II 
and HDRS-17 bimonthly for 
18 months post mood-
induction. If consistently in 
depressed range given LIFE. 
Judged to have relapsed if 
they were given a diagnosis 
of MDE at any time during 
the follow-up. Other 
outcome measures were DAS 
and VAS.  
After controlling for history of depression 
cognitive reactivity is a meaningful predictor of 
relapse irrespective of previous treatment 
modality. Each 16 point increase of the DAS 
following mood-induction increased the risk of 
relapse by 42%. Patients with marked increases 
in cognitive reactivity had higher relapse rates 
(69%) than those with minimal increases in 
cognitive reactivity (30%) or with marked 




SCID and BDI  Currently Depressed N=32: mean 
age 42.3(12.8), 24 females. 81.2% 
on ADM, current episode length 
mean 8.7(9.2) months, age at first 
onset 21.5(8.3), mean previous 
episodes 6.2(3.4).  Recovered 
Depressed N=26: Mean age 
41.8(9.9), 18 females. 15.4% 
currently on ADM, mean age of first 
onset 27.6(12.9) and mean previous 
episodes 3.1(2.6). Never Depressed 
N=26: mean age 36.1(12.2), 16 
females, none currently on ADM. 
Randomly allocated to the 
conditions (no questions, 
n=27; state-oriented, 
n=29; process focused, 
n=28). Participants were 
presented with scenarios 
and asked to think of best 
solution to each one. They 
were presented with extra 
material based on their 
allocated condition.  
Within-groups 
comparisons were 





(N=26) and Never 
Depressed (N=26). 
BDI, Mood measure rating 
mood 0 (I do not feel at all 
despondent) to 100 (I feel 
extremely despondent). RRS 
measuring how often one 
responds to a sad mood with 
rumination. The Means-Ends 
Problem-Solving Test (MEPS) 
measuring ability to 
conceptualise step-by-step 
means of achieving a goal.  
Within the no question condition: The currently 
depressed group produced significantly less 
effective solutions than the recovered depressed 
and never depressed groups. In the state-
oriented condition: Both the currently depressed 
and recovered depressed groups produced 
significantly fewer relevant means and less 
effective solutions than the never depressed 
group. Within the process-focussed condition: 
there was no effect of group. The currently 
depressed group were more despondent than 
the recovered depressed and never depressed 
groups. 
Abbreviations: ADM – antidepressant medication; ANOVA – analysis of variance; BA – Brodmann’s area; BAI – Beck Anxiety Inventory; BDI/BDI-II/BDI-II-NL – Beck Depression Inventory; CAS – clinical anxiety scale; 
CBT - cognitive behaviour therapy; CD – currently depressed; CH – correct hit; CI – confidence interval; CSI –chronic somatic illness; DAS – Dysfunctional attitude scale; db – decibel; df – degrees of freedom; dmPFC – 
dorsal medial pre-frontal cortex; DP – double button press; DSM-IV/DSM-III – Diagnostic and Statistical Manual of Mental Disorders 4
th/3
rd Edition; EC – error commission; EEG – electroencephalography; EMG – 
electromyography; ERP – event related potentials; FD – formerly depressed; FMI-14 Freiburg Mindfulness Inventory; HAM-D – Hamilton depression rating scale; HEOG – horizontal electrooculography; HRSD - 
Hamilton rating scale for depression; IAT – implicit association test; ICD-10 – International Classification of Diseases 10
th Edition; LIFE – Longitudinal interval follow-up evaluation; MADRS – Montgomery-Asberg 
Depression Rating Scale; MBCT –Mindfulness based cognitive therapy; MDD – major depressive disorder; MDE – major depressive episode; MEPS – Means ends problem solving test; ms – millisecond; NC – never 
disordered controls; ND – never depressed; NLPT - RCT – randomised controlled trial; PANAS – Positive and Negative Affect Schedule; PSR – psychiatric status rating;  PT – pharmacotherapy; rACC – right anterior 
cingulate cortex; RCD – recurrently depressed; RDC – research diagnostic criteria; RMD – remitted depressed; RRS – Ruminative response scale; RSES- Rosenberg Self-Esteem Scale; RSQ - Response Styles 
Questionnaire; SADS-L – schedule for affective disorders and schizophrenia lifetime version; SCID – Structured Clinical Interview for DSM-IV; SD – standard deviation; TRP – tryptophan; VAS – visual analogue scale; 







Table 8.  



























































































































































































































































































































































































































































































































































































































of N/A Items 
x2) 






Anderson et al., 2011  1  2  2  2  N/A  N/A  N/A  2  1  1  0  0  2  1  14  22  0.64  Moderate 
Chopra et al., 2008  1  2  1  1  N/A  N/A  N/A  2  1  2  0  2  2  2  16  22  0.73  Moderate 
Dai  & Feng, 2011  2  2  1  2  N/A  2  N/A  2  1  2  0  1  2  2  19  24  0.79  High 
Franck et al., 2007  2  2  2  2  N/A  N/A  N/A  2  1  2  0  0  2  2  17  22  0.77  High 
Huffziger & Kuehner, 
2009 
2  2  1  2  2  0  0  2  1  2  0  0  2  2  18  28  0.64  Moderate 
Lethbridge & Allen, 2008  2  2  1  2  N/A  N/A  N/A  2  1  2  1  2  2  2  19  22  0.86  High 
Moreno et al., 2000  0  1  0  1  1  0  0  1  1  1  0  0  1  2  9  28  0.32  Low 
Morris et al., 2012  2  2  1  2  1  0  0  2  1  2  2  2  2  2  21  28  0.75  Moderate 
Nixon et al., 2013  2  2  2  2  N/A  N/A  N/A  2  1  2  2  1  2  2  20  22  0.91  High 
O'Brien-Simpson et al., 
2009 
2  2  1  2  N/A  N/A  N/A  2  1  2  0  2  2  2  18  22  0.82  High 
Risch et al., 2010  2  2  1  2  N/A  N/A  N/A  2  1  2  0  0  2  2  16  22  0.73  Moderate 
Sears et al., 2011  2  2  1  1  N/A  N/A  N/A  1  1  2  0  0  1  2  13  22  0.59  Moderate 
Segal et al., 1999  2  2  1  2  N/A  N/A  N/A  2  1  2  0  0  2  2  16  22  0.73  Moderate 
Segal et al., 2006  2  2  2  2  1  0  0  2  2  2  1  2  2  2  22  28  0.79  High 
Watkins & Baracaia, 
2002 
2  2  1  2  1  1  0  2  1  2  0  1  2  2  19  28  0.68  Moderate 55 
 
Table 9.                   
Factors associated and not associated with relapse/recurrence to depression in adults reported in each of the included experimental and 




Factors investigated for association with relapse/recurrence to depression  Proposed mechanisms of action 

















Other   
Anderson  
et al., 2011  
Moderate 
  ++          Depression is associated with abnormalities in face emotion 
recognition which differ according to current mood state. The 
increased bias to recognise emotions in remitted depression is a 
possible mechanism of susceptibility to depression, although the effect 
was small 
Chopra et al.,  
2008  
Moderate 
++  +    ++        Combination of high cortisol and three or more prior episodes 
increased risk of relapse. Cortisol and cognitive predictors of relapse 
were not associated with each other; they might represent separate 
vulnerabilities to relapse. 
Dai  & Feng,  
2011 
High  
    ++          MDD and RMD participants showed deficient attentional inhibition of 
negative material. 
Franck et al., 
2007  
High 




Severity of last 
episode ++ 
A higher implicit self-esteem reveals a vulnerability for depression 




      ++      Induced rumination maintained rather than exacerbated negative 





++    ++          Dysfunctional 
thinking = 
Change in dysfunctional thinking following sad mood induction did not 
emerge as a causal risk factor for depressive relapse. However, 
affective reactivity to the mood induction, specifically the degree of 
reduction in happy mood, emerged as an independent predictor of 
relapse. Finally, life stress was also a strong and significant predictor of 
relapse. 56 
 
Moreno et al.,  
2000,  
Low  




last episode and 
demographics, 
all = = 
How a formerly depressed patient responds to a change in mood for 
the worse can determine whether or not they will relapse. 
Morris et al., 
2012,  
High 
+  ++              Individual differences in HPA function during remission may serve as an 
indicator of vulnerability to recurrent depression. 
Nixon et al., 
2013,  
High  
+      ++  ++      Hypoactivity in 
right dmPFC 
and right ACC 
++ 
The importance of dmPFC and rACC processing within the time-frame 
utilised in the present study may lie in early, adaptive reappraisal of 
negative experiences, and a failure to do this may lead to vulnerability 
to depressive relapse. 
O'Brien-Simpson 
 et al., 2009  
High 




Inhibited baseline startle may be a reliable endophenotypic marker of 
biological predisposition to recurrent depression 
Risch et al.,  
2010  
Moderate 
        ++ 
(Implicit) 
  None stated 
Sears et al., 
2011  
Moderate 
  ++          Information processing biases are not transient symptoms of 
depression but are instead an important vulnerability factor. 
Segal et al.,  
1999  
Moderate 
++    ++        None stated 
Segal et al.,  
2006 
High 
  ++            A mild negative mood experienced by someone with a history of 
depression, can trigger some of the cognitive features of a depressed 
episode. The presence of such reactivity in recovered patients signals a 






+    +  ++    ++    Psychosocial 
impairment 
post MDE ++ 
One possible mechanism of relapse in recovered depressed patients is 
state-oriented ruminative responses to a stressful life event leading to 
impaired social problem solving and further escalation of the stressful 
situation. 
Key:  ++ good evidence of positive association with relapse; + some evidence/suggestion of positive association with relapse 
          = = good evidence of no association with relapse; = some evidence/suggestion of no association with relapse 
          - -   good evidence of negative association with relapse; - some evidence/suggestion of no association with relapse  57 
 
Matrix of factors associated/not associated with relapse 
Several factors were endorsed as positively associated with relapse/recurrence for which 
there was good evidence from high quality experimental or neuroimaging studies. The 
three studies rated as high quality and the six studies rated as moderate quality to 
investigate cognitive biases or information processing biases all suggested a positive 
association between the presence of such biases and the risk for relapse. There was also 
good evidence for cognitive reactivity as a risk factor for relapse from two high, three 
moderate, and one low quality study. The precise role of stress was not clear from the 
studies, although four of the studies reported positive associations between experiencing 
stress and relapse. One high quality and one moderate quality study reported good 
evidence of a positive association between HPA axis dysregulation and relapse, though the 
latter reported that this was only the case for those patients that had a history of three or 
more previous depressive episodes. The neuroimaging studies reported good evidence for 
dysregulation and/or morphological alterations in areas related to emotional and 
information processing and relapse, in particular hypoactivity in neocortical and limbic 
areas (particularly the dmPFC and rACC) induced by a stimulus (Nixon et al., 2013) and 
reduced hippocampal volume measured in a resting state (Kronmuller et al., 2008).  
  There were few concretely proposed mechanisms of action from the included 
studies, though there were some consistencies in the tentative proposals made and two of 
the studies (Nixon et al., 2013; Segal et al., 2006) were somewhat more definitive. Overall, 
the studies proposed a role for dysfunction in neural networks responsible for information 
processing or affective and cognitive processing in response to either stress/anticipation of 
stress (which may be influenced by dysfunction in the HPA axis) or a change in mood, which 
prevents appropriate reappraisal of negative experiences. When accompanied by 
ruminative thinking styles, this prolongs the negative mood state and prevents the patient 58 
 
from recognising and utilising social cues and social support, and thus confers greater risk 
for relapse.  
Discussion 
From the 15 included studies there was some consistency with the results of Studies 1 and 
2; cognitive biases including rumination and information processing biases (also referred to 
as affective biases) were found to be associated with greater risk for relapse, as were 
dysfunction in the HPA axis, incurring stressful life events, and greater reactivity to a 
negative change in mood. In addition, the studies reviewed provided evidence for 
hypoactivity and morphological alterations in neocortical and limbic regions underlying the 
above biases and impacting upon the ability to manage stress or changes in mood.
  The matrix from the included studies also supports the mechanisms proposed in 
Study 2: providing greater evidence for the assertion that in formerly depressed patients 
there is greater risk of relapse/recurrence when the neural networks responsible for 
information processing and cognitive processing dysfunction in response to stress (which 
may also be influenced by dysfunction in the HPA axis) or a change in mood (particularly 
from a positive to neutral mood), thus preventing appropriate reappraisal of negative 
experiences. The suggestion is that this can trigger rumination about the negative 
experiences, thus maintaining the resulting negative mood and preventing the patient from 
finding solutions to their problems or from recognising and utilising social cues and social 
support. Taken together these factors are proposed to lead to a greater likelihood of 
relapse to depression. 
General Discussion 
Study 1 demonstrated that only the presence of residual sub-syndromal symptoms after 
acute phase treatment and the experience of some form of maltreatment during childhood 
are well supported as risk factors for relapse to depression. There were other factors 59 
 
potentially linked to relapse but without good evidence to support them. Study 2 
highlighted several other factors as potentially linked to relapse, such as information 
processing and cognitive biases, ruminative thinking, and HPA axis and REM sleep 
dysregulation. However, the studies reviewed were of very low quality by virtue of being 
non-systematic and so these potential associations were not able to be considered as valid. 
Study 3 systematically reviewed experimental and neuroimaging studies based on the 
suggestion by Roiser and colleagues (2012) that such study designs are needed in order to 
provide evidence for components proposed in the ‘cognitive neuropsychological’ model of 
depression (e.g. Roiser et al., 2012). The study showed that there is evidence for the 
associations between the biases proposed in Study 2 and relapse to depression, and that 
these biases are associated with dysregulation at the neural level.  
Studies 2 and 3 also investigated mechanisms proposed by authors of the reviewed 
studies to consider the nature of the relationships between the factors identified as 
conferring risk for relapse and the outcome (relapse/recurrence) itself. These have been 
used to develop the conceptual framework shown in Figure 4.  
The conceptual framework points to a need for studies of interventions targeting 
any or all of the following in order to reduce the risk of relapse: cognitive reactivity or stress 
reactivity; cognitive and information processing biases; and dysfunction in the HPA axis and 
neocortical and limbic regions. Further, trials of relapse prevention interventions should 
ensure patients have a complete absence of depressive symptoms before ending 
treatment, wherever possible. Clinicians may also want to consider the role of any 
childhood maltreatment suffered by their patients in formulating their depression and 
planning any relapse prevention interventions.   60 
 
Figure 4.  





There are several limitations to the present studies. Study 1 was hampered by a paucity of 
systematic reviews of risk factors of relapse to depression, and in particular systematic 
reviews that had a stated aim to identify/consider the relative strength of multiple risk 
factors for relapse. The three included systematic reviews that did attempt to do this were 
all of low or very low quality and so the results from these studies were necessarily treated 
with caution. However, the study was nonetheless able to support the consensus view 
(Campbell, 2009) with regard to residual symptoms, and question it with regard to the 
number of previous episodes, and further, was able to add to the consensus view with the 
finding of an additional risk factor – childhood maltreatment.  
  Both Studies 1 and 2 were limited by a lack of reporting on the quality of the 
studies reviewed therein. While the quality of the reviews was judged, it may be the case 
that some of the lower quality reviews included high quality studies and therefore the 
findings from these may have effectively been ‘downgraded’ by the quality criteria being 
applied at the level of the review and not at the level of the included studies. Further, the 
reviews included in Studies 1 and 2 did not include a number of studies that may have been 
relevant to the present review. As a part of the systematic review process, a large number 
of cohort studies, RCTs and case control studies (128 studies) were identified that reported 
on risk factors for relapse/recurrence but these studies were not included in the reviews 
which made up Studies 1 and 2. This may be a consequence of the aims of the included 
reviews, which as noted were generally not focussed on specifically identifying risk factors 
for relapse to depression, but instead focussed on treatment efficacy of relapse prevention 
interventions and reported on factors identified as associated with relapse as secondary 
aims. What is more, it is by no means guaranteed that the results of Studies 1 and 2 would 
have been altered if RCT and cohort studies were included.  62 
 
Most studies that have sought to identify risk factors for depressive relapse have 
been hampered by methodological weaknesses and inconsistencies (Burcusa & Iacono, 
2007). For example, many of the longitudinal studies have used hospital readmission rates 
to determine relapse/recurrence and thus introduced selection bias as this may only 
account for the most severe of cases, those with greatest access to healthcare/greatest 
healthcare utilisation, or those most likely to be treated as inpatients (Hatch et al., 2011; 
Hatch & Thornicroft, 2012). Furthermore, many of the RCTs have required participants to 
be free of comorbid mental health problems, but this may not be representative of the 
clinical population (Kessler et al., 1996; 2007), and in addition many of the RCTs and cohort 
studies (in particular the long-term large scale cohort studies) have suffered from high 
drop-out/loss-to-follow-up therefore introducing further bias in the interpretation of their 
results (Burcusa & Iacono, 2007).  
  Another potential limitation arose in the use of categorical statements of study 
quality in Studies 1 and 3. Neither the AMSTAR (Shea et al., 2007) nor criteria developed by 
Kmet et al. (2004) include guidance on making statements about the overall quality of 
reviewed studies. However, in order to bring a common framework to the present article as 
a whole, it was decided that using the categories proposed by Guyatt and colleagues (2008) 
in the GRADE system would be most appropriate. Further,  it was important to not only use 
the outcomes from the AMSTAR or Kmet quality rating criteria but to add to these 
considerations from other best available quality rating systems/statements such as PRISMA 
(Moher et al., 2009) and the Cochrane Reviewer’s Handbook (Higgins & Green, 2008). As 
such the present review suggested quality ratings for articles reviewed in Studies 1 and 3 
but these were used only to guide considerations about the validity of the results from each 
included study and not to concretely weight the degree of evidence as is commonly done in 
a quantitative synthesis. 63 
 
  Further limitations were apparent as six articles across Studies 1, 2 and 3 were 
excluded after reading the abstracts (despite being considered as relevant) as they were 
not published in the English language. There was no budget for a translation of these 
studies so it may be that they would have contributed further to our understanding of 
relapse/recurrence. In addition, the reviewed studies primarily used the Frank et al. (1991) 
definitions of relapse and recurrence, but which may have led to a degree of bias in the 
results as they tend to compare people who do not relapse over the study period with 
people that do relapse without separating out those that have had multiple previous 
episodes and those that have had their first lifetime episode, thus potentially under-
sampling those that only ever have a single lifetime episode (Monroe & Harkness, 2011).   
  Finally, despite the knowledge of cognitive and information processing biases 
having been discussed in the literature for quite some time, there appears to be little 
utilisation of it in the consulting room. Further when it is utilised it has not significantly 
improved relapse prevention interventions as none of these have greater than a small-to-
medium effect size in preventing relapse (Clarke et al., in press). It may be that depression 
as a category and/or relapse/recurrence as a singular construct, might be better 
represented by novel nosological systems seeking to define disorders by clusters of 
behavioural and/or functional experiences and underlying biology, rather than by the 
presence of a certain number of a group of diffuse symptoms (Cuthbert & Insel, 2010; Insel 
et al., 2010). As such, it may not be possible to significantly improve existing interventions 
for relapse prevention until such a time as these novel nosological systems are in place. 
Conclusion 
Taken together these three studies have demonstrated that: 1) the current consensus view 
of relapse is not entirely supported by the evidence base and needs amending; 2) there are 
no factors that are supported by studies able to provide the strongest level of evidence for 
the prognosis or aetiology of a disease conducted with high quality and which have utility in 64 
 
guiding the treating clinician in reducing their patient’s risk of relapse/recurrence to 
depression; and 3) there are, however, a number of factors which to date had not 
previously been systematically reviewed that these studies suggest play a role in conferring 
risk for relapse. These are information processing and cognitive biases, reactions to stress 
and/or changes in mood, and persistent ruminative thinking in response to negative 
experiences that may be targeted in psychological interventions aimed at preventing 
relapses/recurrences.  Further, the three studies have identified several potential 
mechanisms for the action of such risk factors and have considered the inter-relationships 
between these factors to propose a conceptual framework that may help guide future 
research into relapse/recurrence to depression. On the basis of this we might hypothesise 
that research investigating the causal pathways between either childhood maltreatment or 
acute-phase treatment outcomes for depressed patients, and dysfunction in the neocortical 
and limbic pathways that control processing of affective information and/or cognitive 
control, might shed greater light on the associations linking the factors identified herein. In 
addition, the conceptual framework points to a need for studies of interventions targeting 
the identified mechanisms, for trials of relapse prevention interventions to ensure patients 
have an absence of depressive symptoms before ending treatment, and for clinicians to 
consider the role of childhood maltreatment in their formulations with patients, particularly 
when planning any relapse prevention stage of treatment. Knowledge from studies 
accounting for these factors might allow the treating clinician to target their interventions 
at mechanisms operating at the level of the individual, which may help improve their 
patient’s chances of prolonging a period without relapse to depression or avoiding it 
altogether. However, implicit in this is that the concept of depression as a single disorder is 
valid. Newer nosological sysytems based on functional experiences and/or underlying 
biology may change this view. One advantage of taking the approach in the current article is 65 
 
that the conceptual framework may also contribute to the knowledgebase of relapse to 
depression if and when such systems come in to common use. 66 
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Can we learn more about relapse to depression by understanding 
patient trajectories throughout treatment and beyond? A study of 
patients treated in primary care mental health services.75 
 
Abstract 
Aims: To analyse data from service users of a primary care mental health service to identify 
risk factors for the presence of residual symptoms of depression post-treatment and for 
relapse, and to determine what factors impact the rate of relapse. A prospective study was 
used to investigate the relationship between cognitive control and depressive symptoms. 
Method: Logistic regression models were built comparing 54 relapsers to non-relapsers 
(n=13,072), and comparing those with residual symptoms (n=11,515) to those without 
(n=9,709). Kaplan-Meier plots were used to compare survival based on factors identified in 
the multivariable regression models. Cox proportional hazards models were built to 
consider the multivariable effects of factors in the model on the hazard rate of relapse. An 
algorithm developed by Saunders et al. (submitted) was used to determine the distribution 
of service users across eight latent profiles based on factors measured pre-treatment. For 
the prospective study a sample of 64 service users treated for depression at ‘Step 2’ were 
recruited and cognitive control was measured at every treatment session. Results: Residual 
symptoms were an important predictor of relapse to depression and of relapsing more 
quickly as was attending ten or more sessions. For those with a GAD-7 score recorded this 
was the strongest predictor of relapse. High GAD-7 scores, attending fewer than ten 
sessions, not completing treatment and being in receipt of benefits were all risk factors for 
relapsing more quickly. The latent profiles of those that relapsed was different from non-
relapsers and those that remained recovered though not from those that had residual 
symptoms at the end of treatment or those that stayed depressed throughout treatment 
and beyond. Cognitive control was able to predict the presence of residual symptoms of 
depression. Conclusions: Cognitive control can be used to predict levels of depressive 
symptoms post-treatment in a clinical setting. However, relapse was not measured 
prospectively in conjunction with cognitive control and so the exact nature of the 
relationship between these factors is yet to be determined.    76 
 
Introduction 
Depression is one of the most common mental health problems worldwide, causing 
significant impairments in social functioning, having an adverse effect on physical health, 
increasing the risk of mortality from all causes, in particular from suicide, and therefore 
resulting in a heavy burden for sufferers and health services alike (Murray & Lopez, 1996; 
Prince et al., 2007). Long-term prospective studies have reported that up to 80% of those 
with depression will relapse at least once (Judd, 1997; Kessler & Wang, 2009; Mueller et al., 
1999; Murray & Lopez, 1996; Roiser, Elliot & Sahakian, 2012), with an average of 
approximately four episodes per sufferer, each lasting approximately 20 weeks (Judd, 
1997). Therefore, it is of great importance that treatments for depression are not only 
successful at relieving symptoms so service users can recover from the index episode, but 
that they are also successful in reducing the risk of relapse to further episodes (Teasdale et 
al., 2000).  
Treatment for Depression in Primary Care Services 
The majority of service users in the UK presenting for psychological treatment for 
depression are seen in primary care services (Cape, Whittington, Buszewicz, Wallace, & 
Underwood, 2010). In England and Wales treatment follows a stepped-care model based 
on the National Institute for Health and Clinical Excellence (NICE) Guidelines for Depression 
(NICE, 2010). The majority of service users are seen in Improving Access to Psychological 
Therapies (IAPT) services where approximately two thirds of patients are treated at ‘Step 
2’, which for the most part involves once-weekly 30-minute sessions of guided self-help 
interventions based on cognitive behavioural therapy (CBT) and behavioural activation 
(Dimidjian et al., 2006). For those attending at least two of these ‘Step 2’ intervention 
sessions 55-56% recover from their depressive episode (Clark et al., 2009a; Richards & 
Suckling, 2009). However, there is no routine follow-up after treatment in IAPT services so 77 
 
very little is known about those that relapse into depression, the risk and protective factors 
for relapse, and the rate at which relapse occurs following treatment (Clark et al., 2009a). 
The Current State of Knowledge on Relapse 
The majority of studies of relapse to depression focus on specific sub-groups of the 
population receiving treatment, for example by excluding those with comorbid mental 
health problems or only including those that are deemed able to make use of a particular 
type of therapy (Burcusa & Iacono, 2009). In these studies populations tend to be drawn 
from secondary care centres or involve convenience sampling, thus either being 
unrepresentative of the whole population of depressed patients or introducing a high risk 
of selection bias. This therefore makes it difficult to interpret findings of such studies for 
the large population of those presenting to health services with significant depressive 
symptoms. In addition, early studies of relapse to depression used different definitions of 
relapse making it difficult to compare results across studies (Monroe & Harkness, 2011). 
Although most researchers now follow the definition of relapse proposed by Frank and 
colleagues (1991), it has recently been suggested that further biases may have been 
introduced by researchers not separating out those that have suffered a first life-time 
episode of depression from those that have suffered multiple previous episodes (Monroe & 
Harkness, 2011). In so doing such studies potentially lead to spurious conclusions about the 
risk and protective factors for relapse and the course of depression by combining results 
from those that have and have not already suffered past relapses (Buckman, Fearon & 
Pilling, submitted; Monroe & Harkness, 2011).  
  The current consensus view of relapse to depression is that only the presence of 
residual symptoms post-treatment and having a history of two or more depressive 
episodes prior to the index episode are significant predictors of relapse (Campbell, 2009). 
However, a recent systematic review suggests that this latter factor may not be a reliable 
predictor of relapse to depression, although maltreatment during childhood is considered 78 
 
to be an important risk factor (Buckman et al., submitted). This review highlighted a 
number of affective and information processing biases that have been proposed to have 
significant roles in relapse to depression, though they have not been studied sufficiently to 
make firm conclusions about their relationships with relapse (Buckman et al., submitted). 
Given the paucity of factors identified to reliably predict relapse to depression, it is not 
surprising that clinicians cannot accurately predict who will relapse following treatment or 
when relapses are most likely to occur (Beckerman & Corbett, 2010; Buckman et al., 
submitted; Hughes & Cohen, 2009; Roiser, et al., 2012). It is also unsurprising therefore 
that there are no relapse-prevention treatments with more than a small-to-medium effect 
size for preventing relapse (Clarke, Mayo-Wilson, Kenny, & Pilling, in press).  
The Cognitive Neuropsychological Model of Depression 
In an attempt to better understand the nature of depression some recent studies have 
sought to explain the course of depression from a neuropsychological perspective. The 
‘cognitive neuropsychological’ model of depression (e.g. Roiser et al., 2012) proposes that 
the negative affective biases commonly demonstrated in depressed patients (such as 
selectively attending to negatively valenced information and selectively ignoring positively 
valenced information) are present to a lesser degree prior to an episode of depression 
(Roiser et al., 2012). These negative affective biases are thought to result in changes in 
monoamine transmission giving rise to negative belief systems/schemata which 
subsequently result in the signature features of a depressive episode: dysphoria and 
anhedonia (Clark, Chamberlain, & Sahakian, 2009b; Pringle, Browning, Cowen, & Harmer, 
2010; Robinson & Sahakian, 2008; Roiser et al., 2012). Further, this model proposes that 
the negative affective biases rely on both ‘bottom-up processes’ as they may be triggered 
by emotionally salient stimuli, such as stressful life events, and ‘top-down processes’ as 
cognitive mechanisms which are needed to inhibit reactions to emotionally salient but task-
irrelevant information are known to function sub-optimally in depressed patients 79 
 
(Castaneda et al., 2008; Clark et al., 2009b; Fales et al., 2008; Roiser et al., 2012). 
Experimental and neuroimaging studies have demonstrated that depressed patients exhibit 
deficits in the construct posited to underlie this top-down process: cognitive control 
(Castaneda et al., 2008; Channon, Baker, & Robertson, 1993; Desseilles et al., 2009; Elliot et 
al., 1996; Fales et al., 2008; Siegle, Thompson, Carter, Steinhauer, & Thase, 2007).  
Cognitive Control 
Cognitive control includes functions such as being able to selectively attend to certain 
information whilst ignoring distractions, being able to wilfully and quickly engage or 
disengage attention from a given stimulus, and being able to remember and mentally 
manipulate information (after it has stopped being presented/disappeared). It is 
noteworthy that patients who have recovered from a depressed episode have been 
observed to exhibit impaired cognitive control (Smith, Muir, & Blackwood, 2006), and as 
such it may be that impaired cognitive control is related to the presence of residual 
symptoms in formerly depressed patients, the risk factor most reliably associated with 
relapse (Buckman et al., submitted; Campbell, 2009). However, to date there have been no 
studies known to this author of the relationship between depressive symptoms and 
cognitive control in clinical settings, and no longitudinal studies investigating cognitive 
control and either residual depressive symptoms or relapse to depression. Therefore the 
nature of the relationships between cognitive control, residual symptoms of depression 
post-treatment, and relapse to depression are yet to be understood.   
Research Questions and Hypotheses 
If cognitive control underlies the negative affective biases that are fundamental to causing 
depressive episodes, then it may be hypothesised that those with a greater degree of 
cognitive control post-treatment would be less likely to relapse than those with a lesser 
degree of cognitive control post-treatment. This may or may not be mediated by the 80 
 
presence of residual symptoms of depression post-treatment. Therefore, if it were possible 
to determine the degree of cognitive control that each patient exhibits at the start and end 
of their IAPT treatment, it may be possible to identify those at greatest risk of relapse. 
Aims 
The present study therefore aims to:  
1)  Analyse data in a dataset from an inner London Trust’s IAPT services based on 
information gathered pre, during and post-treatment to determine and predict the 
trajectory of patients through their contact with these services, in order to 
understand more about who finishes treatment with residual symptoms of 
depression, who relapses, when relapses occur and what confers risk for relapsing 
and for relapsing more quickly.  
2)  To determine whether the IAPT treatment for depression affects levels of cognitive 
control, whether there is a relationship between any reported changes in cognitive 
control and changes in depressive symptomology, and to consider the relationship 




The IAPT Services Dataset: All patients seen in IAPT services across England and 
Wales give information regarding their demographics, such as age, gender, and ethnicity, at 
their first contact with the services. They then complete self-report measures of symptoms 
of depression and anxiety, along with other information related to work and social 
functioning and any other relevant symptomology, at every contact with the services (Clark 
et al., 2009a; IAPT, 2011). The inner London Trust’s IAPT services have been operating since 
2007 and the data collected from patients seen in these services from that time until the 81 
 
present are held anonymously in a database and are used to evaluate the services’ 
performance against various nationally determined targets and against other IAPT services 
nation-wide (e.g. Clark et al., 2009a; IAPT, 2012). Over the course of the last five years a 
number of service users seen in these IAPT services have returned for further treatment, 
some of whom have relapsed to depression. In the current study, these relapsers are 
compared to those that did not return to the IAPT services having relapsed to depression, 
to form a naturalistic retrospective cohort study to meet aim 1 above.  
Prospective Study: To meet aim 2 (above) all service users starting treatment for 
depression at ‘Step 2’ within the inner London Trust’s IAPT services between September 
2013 and April 2014 were asked for consent to participate in a prospective study.  
Design 
The present study is based on two linked but separate sub-studies, as they are linked the 
results and discussion are presented together as one overall study.  The first sub-study 
consists of a secondary data analysis of a large database of service users referred to the 
IAPT services, some of whom returned to the service thus forming a naturalistic 
retrospective cohort study. The second is a prospective cohort study of service users 
receiving ‘Step 2’ interventions for depression. 
Participants 
For the database analysis, only service users meeting criteria for caseness on the Patient 
Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) at the start of their 
treatment were included in the analyses. For analyses specifically relating to relapsers to 
depression, additional inclusion criteria were: 1) scoring below the criteria for caseness on 
the PHQ-9 at the point of discharge from the IAPT services; and 2) subsequently 
experiencing a clinically significant increase in score on the PHQ-9 from the time of 
discharge to the time of return to the services.    82 
 
  For the prospective study Psychological Wellbeing Practitioners (PWPs) working 
within the IAPT services sought consent from all service users engaged in ‘Step 2’ 
interventions for depression that met criteria for caseness on the PHQ-9 and had a working 
diagnosis of depression.  
Measures 
The data contained in the IAPT database consists of scores on a range of routine measures 
used in all IAPT services. At every contact with the IAPT services clients are asked to 
complete a PHQ-9 (Kroenke et al., 2001), a Generalized Anxiety Disorder scale (GAD-7) 
(Spitzer, Kroenke, Williams, & Lowe, 2006) the IAPT phobias scale (IAPT, 2011), and the 
Work and Social Adjustment Scale (W&SAS) (Mundt, Marks, Shear & Greist, 2002).  
The PHQ-9 (Kroenke et al., 2001) is a nine item measure of depressive symptoms 
designed for use with primary care patients. Respondents are asked to rate how bothered 
they have been by a list of symptoms, such as “Little interest or pleasure in doing things” 
over the past two weeks, on a scale of zero (“Not at all”) to three (“Nearly every day”). The 
cut-off for caseness is suggested as a score of 10 such that scoring 10 or above indicates 
clinically significant self-reported symptoms of depression (Kroenke et al., 2001).  
The GAD-7 (Spitzer et al., 2006) is a seven item measure of general anxiety 
symptoms and has utility in identifying those with other common anxiety disorders such as 
panic disorder, social anxiety disorder, and post-traumatic stress disorder (IAPT, 2011). The 
GAD-7 uses the same format and scale as the PHQ-9. Items include symptoms such as 
“Feeling nervous, anxious or on edge”. The cut-off for caseness is a score of eight or above 
indicative of clinically significant symptoms of generalised anxiety. 
The IAPT Phobias scale (IAPT, 2011) is used to identify those with significant levels 
of anxiety that may be missed by the GAD-7, for example those with agoraphobia or a 
specific phobia. Respondents are asked to rate how much they would avoid each of three 
situations on a scale from zero (“would not avoid it”) to eight (“always avoid it”). The three 83 
 
items are: “Social situations due to a fear of being embarrassed or making a fool of myself”; 
“Certain situations because of a fear of having a panic attack or other distressing symptoms 
(such as loss of bladder control, vomiting or dizziness)”; and “Certain situations because of 
a fear of particular objects or activities (such as animals, heights, seeing blood, being in 
confined spaces, driving or flying)”.  This scale is not validated as a screening instrument, 
however there is a suggested cut-off of a score of four or more on any of the three items 
indicating significant levels of phobic anxiety (IAPT, 2011).  
The W&SAS (Mundt et al., 2002) is a five-item measure of the impact of mental 
health problems on functioning: (1) at work; (2) in the home; in leisure activities (both (3) 
social and (4) private); and in (5) family relationships. Respondents are asked to rate the 
degree of problems they have with each of the five areas on a scale of zero (“not at all”) to 
eight (“very severely”). A cut-off score of 20 has been suggested to indicate significant 
difficulties in functioning (Mundt et al., 2002).  
Additional measures used in prospective study only: Participants in the 
prospective study completed the Attentional Control Scale (ACS) (Derryberry & Reed, 
2002), and the Beck Depression Inventory (BDI-II; Beck et al., 1996). The BDI-II was used as 
it is deemed to be more sensitive to depressive symptomology than the PHQ-9 and 
therefore better able to inform the analyses of the relationship between cognitive control 
and depressive symptoms.  
The ACS is a 20-item self-report measure asking participants to rate how frequently 
they experience the phenomenon presented in each question on a four-point scale from 
“almost never” to “always”. The ACS includes items related to focussing attention (e.g. “My 
concentration is good even if there is music in the room around me”), shifting attention 
(e.g. “After being distracted or interrupted, I can easily shift my attention back to what I 
was doing”), and flexible control of thinking (e.g. “I can become interested in a new topic 
very quickly if I need to”). Higher scores indicate less resistance to interference, greater 84 
 
ability to disengage from threat-related stimuli, and greater activation of neural areas 
related to top-down emotion regulation (Gyurak & Ayduk, 2007; Mathews, Yiend, & 
Lawrence, 2004).   
The BDI-II (Beck et al., 1996) is a 21-item measure of depressive symptomology 
with respondents asked to rate how they have been feeling in relation to each item over 
the last two weeks on a scale of zero to three, for example: ‘Sadness: 0 “I do not feel sad.”, 
1 “I feel sad much of the time”, 2 “I am sad all the time”, 3 “I am so sad or unhappy that I 
can’t stand it”’.  Higher overall scores represent greater severity of depressive 
symptomology. The conventionally used cut-offs for the BDI-II are as follows: scores 
between 0-13 are deemed representative of ‘minimal’ levels of depression; scores between 
14-19 are indicative of ‘mild’ levels of depression; scores between 20-28 are indicative of 
‘moderate’ levels of depression; and scores between 29-63 indicate ‘severe’ levels of 
depression (Beck et al., 1996).  
Procedure 
Prospective Study: PWPs working within the IAPT services recruited and sought 
consent from service users on their case-load that were engaged in ‘Step 2’ interventions 
for depression. Each participant was asked to complete a BDI-II at their first and last 
treatment session and an ACS at every contact with the PWP, in addition to the self-report 
measures collected as standard at every contact within IAPT services (see above).  PWPs 
then engaged the service users in treatment exactly as they would have done were they 
not participating in the present study with participation not impacting upon their 
treatment within the IAPT services in any way.  
Analysis - The IAPT Services Database 
Primary Outcomes: Relapse was defined on the basis of scores on the PHQ-9. 
Relapsers were those that scored above the cut-off for caseness at the start of their 85 
 
treatment, below the cut-off for caseness at the end of their treatment, and then above 
the cut-off for caseness again on their return to the IAPT services. In addition, only those 
that experienced a clinically significant increase (50% or greater) in PHQ-9 score from end 
of treatment to the point of their return to the services were classified as having relapsed 
to depression.   
A second primary outcome was also used: the presence or absence of ‘residual 
symptoms’ of depression post-treatment. Kroenke and colleagues (2001) report that a 
significant number of non-depressed individuals endorse several items on the PHQ-9, and 
as a result they suggest that scores between zero and four on the PHQ-9 all represent the 
absence of depressive symptomology.  Therefore the presence of residual symptoms of 
depression was defined as obtaining a score of greater than four on the PHQ-9 at the end 
of treatment.  
In addition to investigating the trajectory through the IAPT services of those that go 
on to relapse and those that have residual depressive symptoms at the end of treatment, 
two other sub-groups of those that returned to the service were used to inform the 
analyses relating to a latent profile analysis (see p.86). These were those that remained 
well after treatment, and those that failed to recover from their depressive episode both 
during their IAPT treatment and beyond.  These two groups and those that relapsed to 
depression were identified from all service users that returned to the IAPT services over the 
study period. Returners were any service users that were discharged from the services for 
any reason and then had further sessions in the services any time from two weeks after 
their initial discharge.   
In order to ensure the accuracy of the relapse and return variables the number of 
sessions post-discharge, the purpose and means of contact, the duration of the sessions 
and whether or not any self-report symptom measures were completed at these time 
points were recorded. Those with only one session post-discharge that lasted less than 15 86 
 
minutes, or those with only a telephone contact  with no symptoms measures completed 
(regardless of the duration) were not considered as having returned to the services, and 
therefore were not considered as potential relapsers.  
Risk and Protective Factors: Due to the small number of relapsers many of the 
categorical variables such as ethnicity and marital status were recoded into binary 
variables.   
Statistical Methods 
All analyses were performed using STATA version 12.0. (StataCorp, 2011). Univariable 
logistic regression models were built independently to assess the effects of potential risk 
factors on relapse and residual symptoms respectively. Odds ratios (ORs) and 95% 
confidence intervals (CIs) are presented, and for continuous variables that were 
approximately normally distributed independent t-tests are also presented. Continuous 
variables were entered into the regression models as linear continuous variables with ORs 
representing the OR for a one-point increase in that variable (e.g. a one point increase in 
score on the PHQ-9). Multivariable logistic regression models were built with indicator 
variables entered on the basis of a priori assumptions (such as that the presence of residual 
symptoms would be predictive of relapse) and on the strength of univariable associations. 
Models were compared using Likelihood Ratio Tests (LRTs).  
Survival analyses were conducted using the Kaplan-Meier method with Log-rank 
Tests (LR tests) used to consider the impact of risk-factors on the survival function of 
relapsers. Cox proportional hazards models were built using relapse as the dependent 
variable and time to relapse taken as the time from initial discharge from the services until 
the time at which criteria for relapse were met (either on or after return to services), 
measured in days. These Cox regression models were used to assess the impact of the risk 
factors identified from the logistic regression models on the hazard rate of relapse. Hazard 
ratios (HRs) and 95% CIs are presented.  87 
 
An algorithm was developed (by Saunders, Cape, Fearon & Pilling, submitted) from 
an exploratory Latent Profile Analysis (LPA) of 16,636 service users who had treatment in 
the IAPT services between September 2008 and March 2012. The algorithm uses the 
posterior probabilities from the exploratory LPA to calculate the probabilities of 
membership to each of the eight profiles, and based on these probabilities determines 
which profile each individual run through the algorithm is most likely to belong to. It does 
this using information gathered at the start of treatment on the following variables: age, 
gender, ethnicity (treated as binary – ‘White’ or ‘Non-White’), PHQ-9, GAD-7 and W&SAS 
scores (all treated as continuous variables), caseness on the IAPT Phobias scale (treated as 
a binary variable), whether or not the service user was prescribed psychotropic 
medications, and whether or not they were receiving benefits.  For the present study the 
algorithm was used to determine the distributions of latent profile membership of 
relapsers, non-relapsers, those with residual symptoms, those that remained well after 
treatment, and those that failed to recover from their depressive episodes. The distribution 
of relapsers across the latent profiles was then compared with each of the other groups 
listed above using Chi-squared Goodness of Fit tests. Saunders and colleagues (submitted) 
also conducted a validation of the algorithm using a sample of 9,856 patients that had 
complete data at the end of treatment. This allowed those authors to determine the 
probability of recovery for each of the eight profiles, with those in profile 1 having the 
highest rate of recovery and those in profile 7 the lowest (Saunders et al., submitted). By 
comparing the proportions of each of the service users in the groups listed above across 
each of the eight profiles, it is possible to draw tentative conclusions about how well these 
profile memberships differentiate those in each of the identified groups. The results of this 
analysis might therefore inform us as to whether we can identify service users most at risk 
of relapse based only on information gathered at the start of their treatment and help the 
service consider means of structuring treatment in an attempt to reduce this risk. 88 
 
Analysis – The Prospective Study 
Primary Outcomes: For the prospective study the primary outcome was the 
presence or absence of residual symptoms of depression at the end of treatment. This was 
defined as described above.  
Explanatory Factors: PHQ-9 and ACS scores at the start and end of treatment were 
used to derive change scores for each measure respectively. The pre-treatment scores and 
the change scores were then treated as explanatory factors to consider the relationship 
with residual symptoms of depression post-treatment.  
Statistical Methods  
All analyses were performed using STATA version 12.0. (StataCorp, 2011). Pearsons 
correlations were calculated for scores on the ACS and both BDI-II and PHQ-9 to consider 
whether any association between cognitive control and depressive symptomology was 
present. Linear and logistic regression models were used to determine whether ACS scores 
pre-treatment and the change in ACS score from start to end of treatment were predictive 
of the presence of residual symptoms post-treatment, controlling for the confounding 
effect of pre-treatment depressive symptomology. For linear regressions the proportion of 
the variance explained by the model (R
2), F-tests, and beta-coefficients with respective t-
tests and p-values are presented. Logistic regressions used ACS scores and change scores 
entered as continuous variables and are presented as described above.  
Ethical Approval 
Ethical approval for both parts of the study was granted by the West London NHS Research 
Ethics Committee, reference number: 13/LO/0684, with local R&D approval granted by 
Noclor, Camden and Islington NHS Foundation Trust, reference number: 121619. Copies of 
letters confirming the ethical approvals can be found in Appendix VI. 89 
 
Results 
The IAPT Services Dataset 
Descriptive Statistics 
21,275 service users were referred to the IAPT services between December 2007 and May 
2013 and met criteria for caseness on the PHQ-9 at the start of their treatment, Mean (SD) 
= 17.01(4.64). 92% of the sample also met criteria for caseness on the GAD-7 at the start of 
their treatment, Mean (SD) scores = 14.49(4.49).  The sample had a Mean (SD) age at 
referral of 38.27(13.14) years. More than two-thirds of the sample were female 13,623 
(66.24%), and of ‘any white’ ethnicity 12,876 (69.60%). Given the inclusion criteria the vast 
majority of the sample were referred with unipolar depressive disorders 14,726 (87.04%), 
of which 5,336 (31.54% of the whole sample) were referred with mixed anxiety and 
depression. More than two-thirds of the sample were engaged in ‘Step 2’ interventions 
(69.97%). One third of the sample received cognitive behavioural therapy (CBT) (33.20%) as 
their main treatment within the service, with 31% receiving guided self-help, and 15% 
involved in non-guided self-help interventions.  
At the end of treatment 11,515 (54.25%) service users had residual symptoms of 
depression. A small number of the sample returned to the IAPT services for further 
treatment any time between their initial discharge and the end of May 2013 (522; 2.45%). 
182 (34.87%) of these did not have a PHQ-9 score recorded at any point after their return 
to the services so could not be considered in the analysis of relapse to depression. It is 
unclear as to why there was no recorded PHQ-9 after returning to the services for these 
service users. There were no differences in symptom measure scores or number of sessions 
attended between those with and without a PHQ-9 score upon return. Those without a 
PHQ-9 score on their return were more likely to be treated at ‘Step 3’ (p=.0028). They also 90 
 
cancelled more sessions (p=.0014) and ‘did not attend’ more sessions (p=.0009) than those 
with a PHQ-9 score upon their return.  
Of the 355 returners that did have a PHQ-9 score recorded after their return 54 
(15.21%) relapsed to depression, 155 (43.66%) remained recovered from their depressive 
episodes whilst 89 (25.07%) failed to recover from their depressive episode. It is unclear 
why those that remained recovered returned to the services. There were no differences 
with relapsers in terms of anxiety symptoms measure scores or levels of caseness on the 
GAD-7 (p=.069) or Phobias scale (p=.26), or in terms of the number of sessions attended 
post-return (p=.64). Compared to relapsers they were as likely to be attending for just one 
post-treatment review session, and as likely to be returning for anxiety related problems.  
Residual Symptoms 
Descriptive statistics and univariable associations between explanatory factors measured at 
the start of treatment and the presence or absence of residual symptoms of depression at 
the end of treatment can be found in Table 1. Similarly, descriptive statistics and 
univariable associations between explanatory factors measured at the end of treatment 
and residual symptoms of depression can be found in Table 2.  91 
 
Table 1. 
Comparison of those with and without residual symptoms of depression at the end of 
their treatment based on factors measured at the start of treatment. 




OR(95%CI)  p-value 
Total    9,709(45.75)  11,515(54.25)     
Demographics           
 
 









  Sex         
  Male  3,181(34.01)  3,741(33.52)  1 
.56    Female  6,172(65.99)  7,421(66.48)  1.02(0.96-1.08) 
  Married/Civil 
Partnership 
       
  Yes  480(23.80)  674(25.41)  1 
.21    No  1,537(76.20)  1,979(74.59)  1.09(0.95-1.25) 
  Ethnicity         
  Any White Ethnicity  5,607(68.87)  7,231(70.14)  1 
.064    Non-White  2,543(31.13)  3,079(29.86)  0.94(0.88-1.00) 
  Employment Status          
  Employed  4,330(50.60)  5,629(49.60)  1 
.16    Not Employed 
 
 
4,228(49.40)  5,720(50.40)  1.04(0.98-1.10) 
  Receiving Benefits         
  Yes  1,417(32.55)  2,075(33.43)  1 
.046    No  2,936(67.45)  3,952(65.57)  0.92(0.85-0.99) 
  Overall Diagnostic 
Group 
       
  Unipolar Depressive 
Disorders   6,441(86.62)  8,253(87.40)  1 
.13 
  Other  995(13.38)  1,190(12.60)  0.93(0.85-1.02) 
  Step at Start of 
Treatment 
     
 
  2  6,785(70.33)  7,967(69.79)  1 
0.40    3  2,863(29.67)  3,449(30.21)  1.03(0.97-1.09) 
 








  General Anxiety 
Symptoms 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  GAD-7 Score  14.20(4.62)  14.72(4.37)  t(21111)=8.40 
1.02(1.20-1.03) 
<.0001 
  GAD-7 Caseness         
  Yes  8,684(90.45)  10,719(93.11)  1.43(1.29-1.58) 
<.0001    No  917(9.55)  793(6.89)  1 
  Phobic Anxiety 
Symptoms 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  Social Anxiety Score  3.12(2.57)  3.42(2.57)  t(17916)=7.63 
1.05(1.03-1.06)  <.0001 
  Panic Score  2.55(2.72)  2.85(2.76)  t(17878)=7.31 
1.04(1.03-1.05)  <.0001 
  Specific Phobia Score  2.29(2.75)  2.49(2.78)  t(17871)=4.67 
1.03(1.02-1.04) 
<.0001 
  Work and Social 
Adjustment 




Note: Numbers do not add up to totals due to missing data 
 
  W&SAS Score  20.46(9.18)  21.97(8.88)  t(17804)=10.86 
1.02(1.02-1.02) 
<.0001 
  Prescribed Medication     
   
  Yes  3,965(45.53)  4,824(47.09)  1 
.032 
  No  4,744(54.47)  5,420(52.91)  0.94(0.89-0.99) 
  Long Term Health 
Condition 
     
 
  Yes  552(7.61)  763(8.60)  1.14(1.02-1.28) 
.023    No  6,699(92.39)  8,110(91.40)  1 93 
 
Table 2.            
Comparison of those with residual of depression and those without residual symptoms 
based on factors measured at the end of treatment. 




OR(95%CI)  p-value 
Total    9,709(45.75)  11,515(54.25)     
Demographics           
  Employment Status          
  Employed  1,734(62.17)  5,341(49.67)  1 
<.0001    Not Employed  1,055(37.83)  5,384(50.33)  1.67(1.53-1.81) 
  Receiving Benefits         
  Yes  326(20.46)  1,945(35.68)  2.16(1.89-2.46) 
<.0001    No  1,267(79.54)  3,506(6432)  1 
Treatment           
  Step         
  2  3,231(61.29)  5,118(49.39)  1 
<.0001 
  3  2,041(38.71)  5,245(50.61)  1.62(1.52-1.74) 
  Stepped Up         
  Yes  719(13.68)  2,138(20.74)  1.65(1.51-1.81) 
<.0001    No  4,537(86.32)  8,170(79.26)  1 
  General Anxiety 
Symptoms 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
  GAD-7 Score  3.13(2.75)  11.67(5.40)  t(13746)=74.14 
1.72(1.68-1.76) 
<.0001 
  GAD-7 Caseness         
  Yes  131(5.66)  8,280(72.42)  43.78(35.46-54.06) 
<.0001 
  No  2,184(94.34)  3,153(27.58)  1 
  Clinically Significant 
Change in GAD-7  
       
  Yes  2,053(88.68)  2,609(22.82)  0.038(0.032-0.044) 
<.0001 
  No  262(11.32)  8,824(77.18)  1 
  Phobic Anxiety 
Symptoms 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
  Social Anxiety Score  1.03(1.45)  3.11(2.44)  t(11572)=38.19 
1.78(1.72-1.84) 
<.0001 
  Panic Score  0.70(1.36)  2.52(2.60)  t(11559)=31.48 
1.61(1.55-1.66) 
<.0001 
  Specific Phobia Score  0.86(1.75)  2.19(2.60)  t(11538)=22.60 
1.35(1.31-1.39)  <.0001 
  Clinically Significant 
Change in Phobia Scale  
       
  Yes  1,315(60.88)  2,518(26.70)  0.23(0.21-2.60) 
<.0001    No  845(39.12)  6,911(73.30)  1 
  Work and Social 
Adjustment 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
  W&SAS Score  5.94(5.74)  18.92(9.57)  t(11511)=60.62 
1.26(1.25-1.27) 
<.0001 
  Clinically Significant 
Change in W&SAS  
       
  Yes  84(3.89)  197(2.11)  0.53(0.41-0.69) 
<.0001    No  2,078(96.11)  9,154(97.89)  1 
  Prescribed 
Medication 
       
  Yes  1,004(36.78)  3,994(47.01)  1 
<.0001    No  1,726(63.22)  4,502(52.99)  0.66(0.60-0.72) 
  Number of attended 
sessions 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
    2.90(4.18)  6.47(5.67)  t(21222)=51.38 
1.21(1.20-1.22)  <.0001 
  Attended 10+ 
sessions 
       
  Yes  773(7.96)  2,527(21.95)  3.25(2.98-3.55)  <.0001 94 
 
  No  8,936(92.04)  8,988(78.05)  1   
  Completed 
Treatment  
       
  Yes  3,024(31.15)  5,470(47.50)  2.00(1.89-2.12) 
<.0001 
  No  6,685(68.85)  6,045(52.50)  1 
Note: Numbers do not add up to totals due to missing data  


















The multivariable analyses combining pre-treatment and end of treatment factors revealed 
a logistic regression model predictive of the presence of residual symptoms at the end of 
treatment: Cox & Snell R
2=.42, Model χ
2(9)=3515.36, p<.0001, N=8,403. Odds-ratios and LRT 
p-values for individual risk and protective factors are given in Table 3. Only factors with 
significant LRT p-values when testing a model with the factor included against a model 
without the factor included, were kept in the overall model.  
Caseness on either the GAD-7 or Phobias scale at the end of treatment 
independently increased the odds of having residual symptoms of depression post-
treatment. In addition to anxiety measure scores post-treatment, the PHQ-9 score recorded 
at the start of treatment and being on psychotropic medications at the end of treatment 
were also independent risk factors for residual symptoms. Completing treatment rather 
Table 3. 
Multivariable model of residual symptoms of depression post-treatment. 
Risk Factor  OR(95%CI)*  p-value
# 
GAD-7 Caseness at End of Treatment     
Yes  6.76(5.12-8.92)  <.0001 
No  1 
Clinically Significant Change in GAD-7 Score     
Yes  1  <.0001 
No  5.53(4.47-6.84) 
W&SAS Caseness at End of Treatment     
Yes  4.52(3.34-6.12)  <.0001 
No  1 
PHQ-9 Score at First Contact  1.09(1.07-1.11)  <.0001 
Completed Treatment      
Yes  0.49(0.41-0.59)  <.0001 
No   1 
Clinically Significant Change in Phobias Scale  Score 
Score 
   
Yes  1  <.0001 
No  1.63(1.41-1.90) 
Prescribed Medication at End of Treatment     
Yes  1.34(1.16-1.55)  .0001 
No  1 
Phobia Scales Caseness at End of Treatment     
Yes  1.40(1.14-1.72)  .0012 
No  1 
Attended 10 or More Sessions     
Yes  0.81(0.69-0.94)  .0054 
No  1   
*Adjusted for GAD-7, W&SAS, and Phobias scale caseness at the end of treatment, clinically significant 
change in GAD-7 and Phobias scale scores, PHQ-9 score at the start of treatment, attending ten or more  
sessions, and being prescribed medication at the stage of ending treatment.  
 # p-values
 from LRTs 
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than being discharged for any other reason and attending ten or more treatment sessions 
were protective factors: they conferred lower risk of having residual symptoms at the end 
of treatment. This model was used to inform the analysis of relapsers.  
Relapse to Depression 
Of those service users that had the potential to be classified as relapsing to depression (by 
being above the cut-off for caseness on the PHQ-9 at the start of treatment and below the 
cut-off for caseness on the PHQ-9 at the end of treatment), 54 met the criteria for having 
relapsed. These 54 were compared to 13,072 (99.59%) service users that either did not 
return or did not meet the inclusion criteria for relapse.  Descriptive statistics and 
univariable associations between explanatory factors measured at the start of treatment 
and relapse are shown in Table 4, with descriptive statistics and univariable associations 
between explanatory factors measured at the end of treatment and relapse shown in Table 
5. After their return relapsers had between one and 24 additional treatment sessions, 
Median (IQR) = 4(16). 97 
 
Table 4. 
Comparison of relapsers and non-relapsers based on factors measured at the start of 
treatment. 
Explanatory Factors  Non-Relapsers 
N(%) 
Relapsers 
N(%)  OR(95%CI)  p-value 
Total    13,072(99.59)  54(0.41)     
Demographics           
 
 
Age at referral (years)  Mean(SD)  Mean(SD)  Per 10-year increase 
1.16(0.97-1.37)   
   
37.89(13.63)  40.78(13.76) 
t-test 
t(13124)=-1.58  .17 
  Sex         
  Male  4,239(33.59)  22(41.51)  1 
.22 
  Female  8,380(66.41)  31(58.49)  0.71(0.41-1.23) 
  Married/Civil Partnership         
  Yes  699(25.13)  6(50.0)  2.98(0.96-9.27) 
.048    No  2082(74.87)  6(50.0)  1 
  Ethnicity         
  Any White Ethnicity  7,876(70.57)  40(78.43)  1 
.22 
  Non-White  3,285(29.43)  11(21.57)  0.66(0.34-1.29) 
  Employment Status          
  Employed  6,395(53.80)  27(50.0)  1 
.58 
  Not Employed 
 
 
5,491(46.20)  27(50.0)  1.16 
  Receiving Benefits         
  Yes  1,836(29.41)  14(34.15)  1.24(0.65-2.38) 
.51 
  No  4,407(70.59)  27(65.85)  1 
Treatment            
  Overall Diagnostic Group         
  Unipolar Depressive 
Disorders  
8,874(86.73)  37(78.72)  1   
.11    Other  1,358(13.27)  10(21.28)  1.77(0.88-3.56) 
  Step at First Treatment 
Session 
       
  2  9,133(70.27)  29(47.54)  1 
.0001 
  3  3,864(29.73)  32(52.46)  2.61(1.58-4.32) 
  Depressive Symptoms  Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  PHQ-9 Score 




  General Anxiety 
Symptoms 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  GAD-7 Score  13.97(4.59)  14.15(4.31)  t(13016)=-.28 
1.01(0.95-1.07)  .78 
  GAD-7 Caseness         
  Yes  11,682(90.11)  50(92.59)  1.37(0.49-3.80) 
.54    No  1,282(9.89)  4(7.41)  1 
  Phobic Anxiety Symptoms  Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  Social Anxiety Score  2.99(2.50)  2.89(2.54)  t(10204)=0.30 
0.98(0.88-1.10)  .76 
  Panic Score  2.40(2.65)  2.72(2.70)  t(10176)=-0.88 
1.04(0.95-1.15)  .34 
  Specific Phobia Score  2.16(2.68)  2.15(2.62)  t(10176)=0.04 
1.00(0.90-1.10)  .97 
  Work and Social 
Adjustment 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  W&SAS Score  19.99(8.88)  20.24(9.18)  t(10128)=-0.21 
1.00(0.97-1.03)  .84 
  Prescribed Medication         
  Yes  5,140(43.91)  22(46.81)  1 
.69    No  6,565(56.09)  25(53.19)  0.89(0.50-1.58) 
Note: Numbers do not add up to totals due to missing data. 98 
 
Table 5. 
Comparison of relapsers and non-relapsers based on factors measured at the end of 
treatment. 




OR(95%CI)  p-value 
Total    13,072(99.59)  54(0.41)     
Demographics           
  Employment Status          
  Employed  3,768(62.70)  28(51.85)  1 
.10    Not Employed  2,242(37.30)  26(48.15)  1.56(0.91-2.67) 
  Receiving Benefits         
  Yes  725(21.58)  15(39.47)  1 
.008    No  2,635(78.42)  23(60.53)  0.42(0.22-0.81) 
Treatment           
  Step         
  2  4,852(57.98)  10(16.67)  1   
  3  3,517(42.02)  50(83.33)  6.90(3.49-13.64)  <.0001 
  Stepped Up         
  Yes  1,288(15.27)  19(31.67)  2.57(1.49-4.45)  .0005 
  No  7,145(84.73)  41(68.33)  1 
  Depressive Symptoms  Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
  PHQ-9 Score  2.25(3.12)  5.93(2.75)  t(13124)=-8.65 
1.37(1.26-1.59) 
<.0001 
  Clinically Significant Change  
in PHQ-9 Score 
     
 
  Yes  12,617(96.52)  47(87.04)  0.24(0.11-0.54) 
.0002    No  455(3.48)  7(12.96)  1 
  Residual Symptoms on PHQ         
  Yes  3,387(25.89)  44(72.13)  7.41(4.22-13.00)  <.0001 
  No  9,694(74.11)  17(27.87)  1   
  Any symptoms on PHQ         
  Yes  5,385(41.19)  52(96.30)  37.11(9.00-153.00)  <.0001 
  No  7,687(58.81)  2(3.70)  1   
  General Anxiety Symptoms  Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  GAD-7 Score  5.31(3.69)  8.00(3.70)  t(5722)=-5.28 
1.16(1.10-1.23) 
<.0001 
  GAD-7 Caseness         
  Yes  1,263(22.27)  31(58.49)  4.92(2.83-8.54)  <.0001 
  No  4,408(77.73)  22(41.51)  1 
  Clinically Significant Change 
in GAD-7 Score 
       
  Yes  3,884(68.49)  30(43.40)  0.60(0.35-1.04) 
.067 
  No  1,787(31.51)  23(56.60)  1 
  Phobic Anxiety Symptoms  Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  Social Anxiety Score  1.51(1.70)  2.40(1.89)  t(5190)=3.75 
1.28(1.11-1.42)  .0002 
  Panic Score  1.04(1.65)  1.85(2.02)  t(5183)=3.56 
1.23(1.10-1.39)  .0004 
  Specific Phobia Score  1.10(1.92)  1,42(2.08)  t(5184)=1.21 
1.08(0.95-1.22) 
.23 
  Clinically Significant Change  
in Phobia Scales Score 
     
 
  Yes  2,551(49.62)  20(37.74)  0.62(0.35-1.08) 
.085    No  2,590(50.38)  33(62.26)  1 
  Work and Social Adjustment  Mean(SD)  Mean(SD)  t-test 
OR(95%CI)   
  W&SAS Score  9.59(7.16)  13.15(8.16)  t(5184)=3.57 
1.06(1.03-1.10) 
.0004 
  Clinically Significant Change  
in W&SAS Score 
     
 
  Yes  194(3.78)  0   
.15 
  No  4,940(96.22)  52(100)   
  Prescribed Medication         
  Yes  1,945(37.13)  13(35.14)  0.92(0.47-1.81)  .80 99 
 
  No  3,294(62.87)  24(64.86)  1 
  Number of attended 
sessions 
Mean(SD)  Mean(SD)  t-test 
OR(95%CI) 
 
    4.05(5.02)  16.13(7.19)  t(13124)=17.62 
1.18(1.15-1.21) 
<.0001 
  Attended 10+ sessions         
  Yes  1,672(12.79)  42(77.78)  23.86(12.48-45.65)  <.0001 
  No  11,400(87.21)  12(22.22)  1   
  Completed Treatment          
  Yes  5,207(39.83)  44(81.48)  6.65(3.34-13.23) 
<.0001 
  No  7,865(60.17)  10(18.52)  1 










Multivariable analyses revealed two separate logistic regression models predictive 
of relapse, shown in Table 6 and Table 7 respectively. Both models are presented and 
describe potentially different relationships with relapse to depression. Table 6 shows that 
the presence of residual symptoms of depression and having attended ten or more sessions 
during contact with the IAPT services was predictive of relapse: Cox & Snell R
2=.20, Model 
χ
2(2)=152.32, p<.0001, N=13,142. No other factors were retained in the model. Table 7 
shows an alternative model. For the smaller number of service users with a recorded GAD-
7 score at the end of treatment, this score was a more important risk factor for relapse 
than was the presence of residual symptoms on the PHQ-9 at the end of treatment. In 
addition, being in receipt of social-welfare ‘benefits’ and having completed treatment 
compared to having been discharged for any other reason were independent risk factors 
for relapse. Cox & Snell R
2=.20, Model χ
2(2)=88.23, p<.0001, N=3,299. As so many service 
users were missing a GAD-7 at the end of treatment, further analyses were performed to 
consider why this may be the case and whether or not those with and without a GAD-7 
score are distinct enough to suggest they represent different populations of those that go 
on to relapse. 
There were 7,402 service users missing a GAD-7 score at the time of their discharge 
from the IAPT services. Compared to those with a recorded GAD-7 score those missing a 
GAD-7 at the end of treatment attended fewer sessions (Mean (SD) =1.26 (1.10) compared 
to 6.80 (5.75), p<.0001)) and were more likely to be engaged in non-guided self-help 100 
 
interventions (40% compared to 4%). They therefore had fewer face-to-face contacts in 
which to complete the GAD-7. Those missing the GAD-7 at the end of treatment were also 
less likely to have a diagnosis of anxiety disorders (2.51% compared to 6.01%) or mixed 
anxiety and depression (21.47% compared to 29.81%), and they had significantly higher 
PHQ-9 scores at the beginning of treatment compared to those with a GAD-7 score (Mean 
(SD) = 17.58 (4.66) and 15.32 (4.17) respectively, p<.0001). Although for these analyses 
only those at or above caseness on the PHQ-9 at the start of treatment and below caseness 
at the time of discharge were included, service users missing a GAD-7 score at the end of 
treatment were more likely to have had a clinically significant change in PHQ-9 score from 
start to end of treatment compared to those with a recorded GAD-7 score at the end of 
treatment (100% compared to 92%, p<.001). It appears probable therefore that those 
missing a GAD-7 at the end of their treatment were more likely to be treated specifically for 
depression alone (rather than for a mixture of anxiety and depression or for a construct 
overlapping the two conditions such as low self-esteem or wellbeing) and this may have 
influenced the decision either of their treating clinicians or of the service user themselves 
to not complete a post-treatment GAD-7. 
 
Table 6. 
Multivariable model of explanatory factors measured at the end of treatment as risk 
factors for having relapsed to depression, based on all 13,142 service users that had the 
potential to relapse.  
Risk Factor  OR(95%CI)*  p-value
ǂ 
Attended ten or more sessions     
Yes  16.90(8.87-32.19)  <.0001 
No  1 
 
Residual Symptoms on PHQ at end of treatment     
Yes  3.13(1.73-5.65) 
.0001 
No  1 
*Adjusted for attending ten or more treatment sessions and residual symptoms of depression 










As well as considering risk factors for relapsing at any point post-treatment, analyses were 
conducted to determine risk factors for relapsing more quickly; what factors effect survival 
without relapse; and what affects the hazard rate of relapse. Survival analyses were 
performed with univariable tests of the factors identified in the above multivariable logistic 
regression models used as a starting point for considering which factors might effect 
survival time.  
Survival Analysis of Relapsers  
Kaplan-Meier survival analysis methods were used to compare relapsers to all those that 
were depressed at the start of treatment and not at the end of treatment.  The number of 
days from the time of the initial discharge to relapse ranged from 14 to 674 days with a 
Mean (SD) of 128.67 (123.73) and median of 98 days. Cumulative percentages of time to 
relapse were as follows: 5% relapsed within 18 days, 10% within 28 days, 25% within 59 
days, 50% within 98 days, 75% within 151 days, 90% within 239 days, 95% within 336 days, 
and 99% within 674 days.   
Independent t-tests were used to compare mean survival in days by the factors 
identified in the logistic regression models described above. Those with residual symptoms 
of depression at the end of treatment (Mean (SD) = 99.33 (72.18) days) relapsed more 
Table 7. 
Alternative multivariable model of relapse based on 3,299 service users with a recorded 
GAD-7 score at the end of treatment.  
Risk Factor  OR(95%CI)*  p-value
ǂ 
GAD-7 Caseness at End of Treatment 
   
Yes  7.01(3.53-13.91) 
<.0001 
No  1 
Number of Attended Sessions  1.14(1.10-1.18)  <.0001 
Receiving Benefits at End of Treatment   
  Yes  2.51(1.26-5.00) 
No  1  0.009 
Completed Treatment 
   
Yes  4.79(1.09-21.13) 
0.038 
No  1 
*Adjusted GAD-7 caseness at the end of treatment, the number of session attended receiving benefits and completing 
treatment. 
ǂ p-values from LRTs  102 
 
quickly than those without residual symptoms of depression (Mean (SD) = 209.44 (221.04) 
days), t(54)=2.83, p=.0066. Those that met criteria for caseness on the GAD-7 at the end of 
treatment (Mean (SD) = 91.42 (98.58) days) relapsed more quickly than those that did not 
(Mean (SD) = 182.13 (170.88) days) t(53)=2.47, p=.017. There were non-significant 
differences in the survival time of those that attended ten or more sessions (Mean (SD) = 
148.12(154.30) compared to those that did not (Mean (SD) = 73.46(39.84) (t(54)=1.72, 
p=.092), those that completed treatment (Mean (SD) = 140.06(149.73) days) compared to 
those that did not (Mean (SD) = 82.33(47.67) days) (t(54)=1.14, p=.26), and those receiving 
benefits  (Mean (SD) = 100.9(75.83)) compared to those not receiving benefits at the time 
of initial discharge (Mean (SD) = 153.09(175.01)), (t(37)=1.12, p=.27).  
Log rank tests showed significant differences in survival functions for those with 
and without residual symptoms at the end of treatment (p=.027) (see Figure 1), those 
meeting criteria for caseness on the GAD-7 at end of treatment and those not (p=.0061) 
(See Figure 2), and for those attending less than ten sessions compared to those attending 
more than ten (p=.0082) (See Figure 3). There was no difference in survival function for 
those receiving or not receiving benefits at the time of their discharge from IAPT services 
(p=.38), or for those that did or did not leave due to completing treatment (p=.075).  
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Figure 1. 
Kaplan-Meier survival estimates of relapsers split by residual symptoms of depression at 
the end of treatment.  
 
Figure 2. 
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Kaplan-Meier survival estimates of relapsers split by attending ten or more sessions of 
treatment. 
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A Cox proportional hazards model was built to consider the multivariable impact of 
the risk factors identified above on the hazard rate of relapse, Wald χ
2 (4)=20.91, p=.0003.  
The model consisted of a total of 5,948 days at risk with 42 relapses over that period, and 
showed that caseness on the GAD-7 at the end of treatment, attending less than ten 
session of treatment, being in receipt of benefits at the end of treatment, and younger age 









To this point the analyses have concerned risk for relapse or a proxy of this 
(residual symptoms post-treatment) based on factors primarily measured at the end of 
treatment. Pre-treatment factors have been considered, though when entered in to multi-
variable models they had little impact upon either the odds of relapse or the rate of 
relapse. However, additional analyses were conducted using an algorithm based on a LPA 
conducted by Saunders et al. (submitted). The algorithm uses variables measured pre-
treatment only to determine membership to one of eight latent profiles, from which 
recommendations regarding the likely trajectory of service users from start to end of 
treatment can be made. Using this algorithm to determine the distribution of service users 
across the eight latent profiles in each of the groups relevant to the present study (outlined 
below), it is possible to draw tentative conclusions regarding the ability of this algorithm to 
be utilised to identify those at greatest risk of relapse pre-treatment.  
Table 8.    
Cox proportional hazards model of relapse to depression after treatment.  
    Risk Factor  HR(95%CI)*  p-value
ǂ 
  GAD-7 Caseness at End of Treatment     
  Yes  3.53(1.76-7.30)  <.0001 
  No  1 
  Receiving Benefits at End of Treatment     
  Yes  2.74(1.28-5.86)  .009 
  No  1 
  Attended Ten or More Sessions     
  Yes  1  .016 
  No  3.32(1.26-8.80) 
  Age at referral (by one year increase)  0.97(0.94-0.99)  .038 
*Adjusted for GAD-7 caseness at the end of treatment, receiving benefits at the end of treatment, 
attending ten or more treatment sessions, and age at referral. 
ǂ p-values from LRTs  106 
 
Use of Algorithm Based on a Latent Profile Analysis 
The algorithm developed by Saunders and colleagues (submitted) was used to determine 
the proportions of each of the following groups of service users across each of the eight 
latent profiles: relapsers; non-relapsers; those with residual symptoms at the end of 
treatment; those that returned to the services but were not depressed on their return (i.e. 
those that remained well); and those that returned to the service as depressed but were 
never considered in the analysis of relapsers as they were depressed at the end of their 
treatment (i.e. those that stayed depressed). Using the distribution of relapsers across the 
latent profiles as a basis for comparison, there were differences in the distributions of 
profiles between the relapsers and non-relapsers: χ
2(7)=93443.37, p<.0001, and between 
relapsers and those that remained recovered: χ
2(6)=17.96, p =.006, but not between 
relapsers and those that stayed depressed: χ
2(6)=7.20, p =.41, or between relapsers and 
those that had residual symptoms: χ
2(6)=8.75, p =.27. Further inspecting Table 9, it can be 
seen that none of those that the algorithm determined are most likely to be assigned to 
profile 1 belonged to the relapsers or stayed depressed groups. For profile 2 there was a 
greater probability of belonging to the remained recovered group. Those in profile 7 were 
far more likely to belong to the stayed depressed group than all other groups, with the 
biggest difference being between this group and those in the remained recovered group.    
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Table 9.  













  13,072  54  11,515  155  89 
Profile 1   350(2.68)  0  153(1.33)  1(0.65)  0 
Profile 2   3331(25.48)  13(24.07)  2279(19.79)  52(33.55)  8(8.99) 
Profile 3  58(0.44)  1(1.85)  31(0.27)  0  0 
Profile 4  608(4.65)  2(3.70)  378(3.28)  7(4.52)  2(2.24) 
Profile 5  1457(11.15)  7(12.96)  1478(12.84)  25(16.13)  17(19.10) 
Profile 6  1540(11.78)  7(12.96)  1218(10.58)  17(10.97)  7(7.89) 
Profile 7  1897(14.51)  6(11.11)  2352(20.43)  8(5.16)  33(37.08) 




In addition to the analyses of residual symptoms and relapsers from the IAPT dataset, a 
prospective study was conducted to collect data on a factor proposed as playing a key role 
in relapse - cognitive control - in order to investigate the relationship between cognitive 
control and being at greater risk of relapse post-treatment by having residual symptoms of 
depression.  
Descriptive Statistics 
Between September 2013 and April 2014 64 patients were recruited to the prospective 
study. The majority of respondents were female (39(70.91%)), ethnically ‘white’ 
(41(77.36%)), with ages at referral ranging from 17-65 years old (Mean (SD) =35.36(12.15)). 
Scores on the symptoms measures at the start of treatment were as follows: PHQ-9 Mean 
(SD) = 16.25(5.26), GAD-7 Mean (SD)=13.05(4.94) with 76.36% of respondents reaching 
caseness, BDI-II Mean (SD) = 29.68(10.97) (completed by only 38(59.38%) participants)) 
with the majority of respondents in either the moderately depressed (10(26.32%)) or 
severely depressed (22(57.89%)) categories.  Scores on the ACS at the beginning of 
treatment ranged between 25 and 66, Mean (SD)=45.82(9.13).  108 
 
Study participants attended between 1-18 sessions within the IAPT services (Mean (SD) = 
5.41 (2.72)), with 42 (65.62%) completing treatment during the study period. Eight 
(17.02%) participants were stepped up from Step 2 to Step 3 during the course of the 
study.  
  Thirty-five of the 42 participants that completed treatment over the study period 
completed an end of treatment PHQ-9, with 20 (57.14%) still at or above caseness for 
depression and 15 (42.86%) below caseness, having recovered from their depressive 
episode based on PHQ-9 scores.  
Comparison with Population from which the Sample was Drawn 
A population of 3,292 service users were eligible for the prospective study. From this a 
sample of 64 (1.94%) service users were recruited.  There were no differences between 
those recruited and those not recruited in terms of gender (p=.38), primary diagnosis 
(p=.20), proportions of those prescribed psychotropic medications at the start of their 
treatment (p=.42), or start of treatment symptoms measures: PHQ-9 scores (p=.36), GAD-7 
scores (p=.53), level of caseness of on the phobias scales (p=.032), and W&SAS score 
(p=.16). However, those recruited were less likely to be of non-white ethnicity than those 
not recruited (12.50% and 35.51% respectively, p=.002) and were on average younger 
(Mean (SD) = 33.45 (12.03) years old) than those not recruited (Mean (SD) = 38.03 (13.37) 
years old), t(3290)=2.56, p=.024.   
Relationship Between Cognitive Control and Depressive Symptoms 
 Across all participants, scores on the ACS and BDI-II were highly correlated r=-0.67, n=40, 
p<.0001. However, only 12 BDI-IIs were completed at the end of treatment so analyses use 
end of treatment PHQ-9 scores instead. Scores on the ACS and PHQ-9 were moderately 
correlated at the start of treatment r=-0.55, n=43, p=.0001 and at the end of treatment r=-
.48, n=36, p=.0033.  109 
 
For the ACS change scores were calculated by subtracting the start of treatment 
score from the end of treatment score, and for the PHQ-9 they were calculated by 
subtracting the end of treatment score from the start of treatment score. There was a 
moderate correlation between the change in PHQ-9 scores and change in ACS scores from 
beginning to end of treatment r=0.59, n=31, p=.0004. There was a difference in the 
direction and degree of change in the ACS scores for those that recovered from their 
depressive episode based on PHQ-9 scores from start to end of their treatment. The Mean 
(SD) change in ACS score for those that did not recover from their depressive episode was   
-3.26 (7.16) points (the minus number indicating their scores on the ACS decreased from 
the start of treatment to the end of treatment). This is compared to a Mean (SD) change of 
4.25(7.36) points on the ACS for those that recovered from their depressive episodes, 
t(29)=2.81, p=.0087. In addition, taking just those that experienced a positive change of any 
degree in ACS score from start to end of treatment was associated with a greater 
probability of recovery from depression from start to end of treatment (OR (95%CI) = 5.60 
(0.98-32.11), p=.029).  
Of those that completed treatment 78% had residual symptoms of depression at 
the end of their treatment, predicted by the degree of change in participant’s ACS scores 
from the start to the end of their treatment after controlling for baseline levels of 
depression, R
2=.29, F(2,28)=5.63, b=-.024, t(30)=-2.75, p=.010. For every one point increase 
in ACS score after controlling for PHQ-9 scores at the start of treatment, the odds of having 
residual symptoms decreased (OR (95%CI) = 0.79 (0.65-0.97), p=.025.  
ACS scores at the start of treatment were used to prospectively predict the 
presence of residual symptoms at the end of treatment, though this effect was non-
significant after controlling for PHQ-9 scores at the start of treatment: R
2=.25, F(2,40)=6.62, 




Residual symptoms were found to be an important predictor of relapse to depression and 
of relapsing more quickly. Attending ten or more sessions was also a predictor of relapse 
(though attending fewer than ten was associated with an increased hazard rate of relapse). 
  A minority of service users had a GAD-7 score recorded at the end of treatment; for 
those that did, the presence of residual symptoms on the PHQ-9 was no longer an 
important predictor of relapse. GAD-7 score at the end of treatment was the strongest 
predictor of relapse. Other important factors to increase the risk of relapse were having 
attended more treatment sessions, having completed treatment, and being in receipt of 
benefits at the time of ending treatment.  
  More than three-quarters of relapses occurred within six months of discharge from 
the IAPT services. As well as higher PHQ-9 scores at the beginning of treatment, higher 
GAD-7 scores, attending fewer than ten treatment sessions, not completing treatment, and 
being in receipt of benefits were all risk factors for relapsing more quickly and were related 
to a higher hazard rate of relapse.   
  The latent profiles of those that relapsed were different from non-relapsers and 
those that remained recovered, though not from those that had residual symptoms at the 
end of treatment or those that stayed depressed throughout treatment and beyond.  
The prospective study found that the level of self-reported cognitive control 
changes as the level of self-reported symptoms of depression also change. There were 
differences in the direction and degree of change in cognitive control for those that 
recovered from their depressive episode over the course of treatment compared to those 
that did not. Both the magnitude of change in cognitive control and the absolute level of 
cognitive control post-treatment can be used to predict the presence of residual symptoms 111 
 
of depression at the end of treatment after controlling for baseline depression, though the 
level of cognitive control at the start of treatment cannot.  
Interpretation 
The IAPT Dataset Analysis 
Finding that residual symptoms are related to the risk of relapse is in keeping with the 
wider literature (Buckman et al., submitted; Campbell, 2009). However, the findings 
relating to the relationship between symptoms of anxiety at the end of treatment and 
relapse to depression were unexpected. Given the high number of service users missing a 
GAD-7 score at the end of treatment, it may be that those with a recorded score represent 
an important and substantially different sub-group of the population of IAPT patients 
presenting with depression at the start of treatment. The fact that those with a recorded 
GAD-7 score were more likely to present to services with anxiety disorders or mixed anxiety 
and depression, were seen for more sessions, and proportionally fewer of them 
experienced clinically significant changes in their PHQ-9 scores pre-treatment to post-
treatment, suggests that they may well have been engaged in more anxiety focussed 
interventions despite their depression. If this is the case it may be that there was some 
systematic bias by clinicians in the services asking far fewer service users treated only for 
depression to complete GAD-7s compared to those they were treating for primary or 
secondary anxiety disorders. Nonetheless, for this sub-group residual symptoms of anxiety 
were more strongly predictive of relapse to depression than were residual depressive 
symptoms. Given the higher number of this sub-group originally diagnosed with mixed 
anxiety and depression, it might be the case that relapses (which were determined only by 
PHQ-9 scores, not by anxiety symptom measures) were of the same nature as their index 
episodes, though this was not measured in the present study. 112 
 
Finding that attending more treatment sessions was related to a greater risk of 
relapse, but those that attended fewer than ten sessions relapsed more quickly than those 
that attended ten or more, may be explained by the fact that most of the relapsers were 
treated at Step 3. Step 3 interventions tend to include a greater number of sessions than 
are offered at Step 2, reflecting the fact that at Step 3 service users tend to be suffering 
either with more complex and difficult to treat disorders (such as posttraumatic stress 
disorder) or with higher levels of disorder and dysfunction than service users treated at 
Step 2.  Levels of symptom severity and dysfunction did not differ between relapsers and 
non-relapsers at the start of treatment. However,  proportionately twice as many relapsers 
were stepped up from Step 2 to Step 3 during the course of their treatment compared to 
non-relapsers and their mean end of treatment symptom measure scores were significantly 
higher than those of the non-relapsers (across all measures), which may explain the 
findings related to the numbers of sessions attended. 
Finding that those completing their treatment were likely to survive without 
relapse longer than those not completing their treatment was expected and may further 
explain the findings related to number of sessions attended. Attending more treatment 
sessions and completing treatment might confer benefit in preventing relapse given that a 
greater number of therapeutic interventions can be delivered, including specific relapse 
prevention techniques that tend to be covered towards the end of treatment, and/or 
greater time spent focussing on particular interventions which might make the difference 
in preventing relapse. In addition, among those not completing treatment are service users 
that declined treatment after having started it and others that self-discharged. These 
factors might describe a population that were not finding treatment useful for them or that 
were not able to engage appropriately in it at that time. As a whole group they might 
therefore have been more likely to relapse more quickly, but they may also have been less 
likely to re-present to the same services for treatment when any relapses occurred, thus 113 
 
may have been underrepresented in the relapser group as a whole so seemingly being at 
lower risk of relapse overall. The relationship between receiving social-welfare ‘benefits’ at 
the time of discharge and relapse is somewhat more difficult to interpret and requires 
further investigation for sound conclusions about this relationship to be drawn. It may be 
the case that this is a proxy variable for factors commonly associated with adverse health 
outcomes such as lower socio-economic status or lower educational attainment (Adler & 
Ostrove, 1999), though this is by no means assured.   
  As the latent profile of relapsers was significantly different from non-relapsers, it is 
plausible that the algorithm developed by Saunders et al (submitted) may be used to help 
identify service users at greater risk of relapse based on pre-treatment factors alone. 
However, as the profiles of relapsers were not different from those that stayed depressed 
throughout their contact with the services, it may be that the algorithm is of less use in 
differentiating those that have a higher likelihood of relapse from those that are likely to 
not do well/not recover from their episode by the end of IAPT treatment.   
Prospective Study 
The findings relating to cognitive control are in keeping with the wider literature based on 
laboratory and neuroimaging studies as cognitive control has been considered by several 
authors to play a pivotal role in the neural mechanisms of depression (e.g. Roiser et al., 
2012). 
Strengths and Limitations 
There were two separate elements to this study.  
The secondary analysis of the IAPT services dataset:  Perhaps the greatest 
limitation of this secondary data-analysis is that significant selection biases may have been 
introduced in the analysis of relapsers. Epidemiological studies suggest approximately two-
thirds of patients treated for depression will relapse within two-years of completing 114 
 
treatment (e.g. Mueller et al., 1999).  Given that this study included all service users seen 
within the IAPT services over a five year period, having a sample of just 54 relapsers from a 
potential 13,142 suggests that a great number of relapses have occurred without service 
users being re-referred to these IAPT services. However, given that the only difference 
between relapsers and non-relapsers prior to starting treatment was found to be their 
marital status, it is likely that the relapser group does sufficiently represent IAPT service 
users treated for depression.  
Despite the small number of relapsers this study was able to confirm expectations 
from the wider literature relating to residual symptoms and relapse to depression, and was 
also able to identify risk factors for a potentially distinct sub-group of relapsers not 
previously described in the literature on relapse to depression in adults. However, due to 
the limitations of a secondary data analysis and given that the history of depression in each 
patient is not routinely measured in the IAPT services, as with previous studies the present 
study took no account of whether service users were presenting to the services with their 
first lifetime episode of depression or any subsequent episode. As such, the study was 
unable to differentiate between those that had previously experienced relapse(s) to 
depression and those that were experiencing their first depressive relapse. This may have 
led to the conflating of results from these potentially different groups, thus introducing 
significant bias (Monroe & Harkness, 2005). Similarly, the IAPT services do not routinely ask 
service users about a history of childhood maltreatment. The present study was therefore 
not able to include this factor in any analyses. As this has been shown to be an important 
predictor of relapse (Buckman et al., submitted), it may well be that some of the 
relationship between the factors identified as conferring risk for relapse in the present 
study might have been attributable to the unmeasured confounding effect of childhood 
maltreatment.  115 
 
  The present study included analyses of multiple explanatory and outcome 
variables, increasing the probability of Type 1 errors. As recommended by Rothman (1990), 
Bonferroni (or equivalent) adjustments were not made as these assume that data are 
independent. However, given the strength of the associations and p-values returned by 
most of the inferential tests it is unlikely that these associations were due to chance alone. 
This is despite the small number of relapsers and therefore low power in the analyses.  
  There were no significant interactions found between any of the variables 
identified in the multivariable models (interaction data are not presented in the results 
section), suggesting that the observed effects are not due to effect modification. However, 
along with the known factors which may be confounding the relationships observed, such 
as childhood maltreatment, there may be several unknown confounders of the relationship 
not accounted for in the present study.  
The prospective study: This is the first study (known to this author) to have 
prospectively measured cognitive control and symptoms of depression in the context of a 
routine clinical setting. In so doing the study has shown that cognitive control can be 
measured quickly with a self-report measure, and with utility. In addition unlike many 
previous studies of relapse to depression, the present study focussed on primary care 
patients, many of whom had not only unipolar depression but also comorbid anxiety 
problems, and so findings should be generalizable to the wider population presenting with 
depression in UK health services.  
As with the secondary data-analysis it is possible that significant selection biases 
may have been introduced in the prospective study analyses. Only 64 participants were 
recruited to the study from 3,292 service users that were eligible. Prospective study 
participants were not randomly selected, thus the possibility of further significant selection 
bias cannot be ruled out. However, no differences were found on any of the symptom 
measures between the prospective study sample and the population from which the 116 
 
sample was drawn. There were differences in age and ethnicity, though the impact of these 
factors is difficult to determine. However, neither age nor ethnicity were found to be risk 
factors for having residual symptoms of depression post-treatment nor for relapse in the 
secondary data-analysis.  
Conclusions and Implications 
This is the first study in a clinical setting (known to this author) to use a self-report measure 
of cognitive control to show that levels of cognitive control change in accordance with 
levels of depressive symptoms. It is also the first study to prospectively measure cognitive 
control alongside depressive symptoms in the context of routine clinical practice, therefore 
being able to show that cognitive control can be used to predict levels of depressive 
symptoms post-treatment. However, relapse was not measured prospectively in 
accordance with cognitive control and so the exact nature of the relationship between 
these factors is yet to be determined. To this end the prospective study will continue to 
collect data for up to one year post-treatment for each of the recruited service users; on 
the basis of findings from the survival analysis it can be expected that approximately 95% 
of relapsers will be captured in this time period.  
  While for the majority of patients residual symptoms of depression are the most 
important predictor of relapse to depression, for those with significant comorbid levels of 
anxiety it may be that residual symptoms of anxiety represents a more important predictor 
of relapse. In addition, several treatment-related and socio-demographic factors have been 
found to be related to relapse for the first time such as being in receipt of benefits. The 
exact nature of these relationships is difficult to determine and may warrant further 
investigation in future studies. Furthermore, this is the first study to relate an algorithm 
based on a Latent Profile Analysis of IAPT service users with outcomes beyond the end of 
treatment. It showed that use of the algorithm can help differentiate between those most 
likely to benefit from treatment within the IAPT services and remain recovered and those 117 
 
that are most likely to either not benefit from IAPT treatment by staying depressed, or 
those that will benefit at the point of discharge but that may be at greater risk of relapsing 
post-treatment. This suggests that a prospective study trialling the use of this algorithm is 
warranted.  118 
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Overview 
This critical appraisal will focus on three areas of import to the conducting of the 
prospective study reported on above and one area related to the analysis of the inner 
London Trust’s Improving Access to Psychological Therapies (IAPT) services database. 
Firstly, the appraisal will focus on the theoretical underpinnings of the research and discuss 
why conducting research in this field, in this manner, is particularly important. Secondly, it 
will discuss the context in which the research was carried out and how this impacted upon 
the research process. Thirdly, the appraisal will discuss some of the methodological choices 
made in conducting the research, potential problems as a result of these choices and 
considerations on the implications of the research in relation to these choices.  
Theoretical Considerations and Background 
The research literature on relapse to depression has to date delivered little in the way of 
usable interventions in clinical settings to prevent relapse (Clarke et al., in press). There is 
surprisingly little research in this area given that the problem of relapse has been 
recognised for many decades; it is now nearly two decades since the start of the global 
burden of disease study which reported that depression is one of the largest contributors to 
life lost world-wide including adjustment for years of life lived with disability (Murray & 
Lopez, 1996). Much of the extant literature on relapse to depression has taken one of two 
forms: there are a number of epidemiological studies using large cohorts of depressed 
patients to determine risk factors for relapse, particularly focussing on socio-demographics 
and life events; and there are a number of theoretically informed clinical trials which have 
used prospective follow-up to create nested case-control studies after breaking 
randomisation. From this literature has come a perhaps somewhat self-perpetuating 
consensus view that relapse can only be predicted by the presence of residual symptoms of 
depression post-treatment and by a history of multiple previous episodes of depression 
(Campbell, 2009). Added to this there is the view that stressful life events play a part in 125 
 
relapse, but there is no consensus as to whether a stress-generation or autonomy-stress 
model fits best and both have been equally supported in prospective studies (e.g. Monroe 
& Harkness, 2005).  This consensus view though has offered little to clinicians seeking to 
help their clients prevent or stave off relapse.  
It is almost tautological to state that residual symptoms of depression are the 
biggest risk factor for relapse. In addition, despite residual symptoms having been so 
reliably linked with relapse, the literature has to date not answered questions such as what 
degree of residual symptoms are important for predicting relapse; and whether there is a 
critical/tipping point before which risk for relapse is negligible and beyond which it 
increases greatly. There is also no consensus on what kind of symptoms are most important 
or if all are equally important, and there is no clear line on what sort of depression and 
what sort of relapses clients experience. There have been many proposed subdivisions of 
the diagnostic category of depression including diagnoses such as: ‘anxious depression’, 
‘atypical depression’, ‘endogenous depression’, ‘melancholic depression’, ‘reactive 
depression’, ‘recurrent depression’ and others, but these have featured little in the 
literature on relapse.  
While there has been little of use to clinicians from the large-scale epidemiological 
studies of relapse to depression, there has also been relatively little in the way of effective, 
theoretically informed therapeutic interventions to prevent relapse to depression (Clarke et 
al., in press). The majority of patients with depression are given anti-depressant 
medications and these are effective at preventing relapse so long as they are taken 
continually in the prescribed manner. However, even then they are not universally 
effective; there are clear problems with adherence partly due to unwanted side-effects and 
further problems with the continual cost of prescribing anti-depressants (Geddes et al., 
2003). There have been several 'new dawns' for relapse prevention psychotherapies with 
first Interpersonal Psychotherapy (IPT) (e.g. Frank, Kupfer, Perel, & Cornes, 1990; 126 
 
Weissman, Kasl, & Klerman, 1976), then Cognitive Behavioural Therapy (CBT) (e.g. Fava, 
Rafanelli, Conti & Belluardo, 1998), and more recently Mindfulness Based Cognitive 
Therapy (MBCT) (e.g. Teasdale, Segal, Williams, Ridgeway, Soulsby, & Lau, 2000) all 
proposed to provide a ‘leap forward’ in preventing depressive relapse. However, all three 
therapies have been found to be equivalent, having only a small-to-medium effect size and 
each reducing the relative risk of relapse by approximately 25% (Clarke et al., in press). 
It can be argued that there has been very little overlap between the 
epidemiological studies and the trials of psychological theory-based therapeutic 
interventions. So, it could be that combining both the epidemiological, observable factors 
and the understanding of the psychologically-informed, latent factors may help us better 
understand the mechanisms behind relapse to depression and use this to inform the 
development and delivery of therapeutic interventions that may be able to deliver greater 
effectiveness at preventing relapse. This is not to contend that the therapies mentioned 
above were not produced on theoretical grounds with sound arguments for being effective 
at preventing relapse - they were - but these theories were arguably focussed only at the 
level of the unobservable/latent psychological factors without a grounding in the wider bio-
psycho-social context of relapse to depression, which can be delivered only when 
accounting for the epidemiological and neuropsychological research literature too (Roiser, 
Elliot & Sahakian 2012). The prospective study was therefore conceived to focus on the 
combination of the epidemiologically defined risk factors, such as residual symptoms of 
depression, and one particular neuropsychologically proposed latent factor - cognitive 
control - in order to investigate risk for relapse to depression. 
Context in which the Research Took Place 
This research project was set-up and conducted in a context in which the National Health 
Service (NHS) faced (and continues to face) greater austerity than known in the sector 
perhaps since its inception in 1948 (Appleby, Crawford, & Emerson, 2008). Along with a 127 
 
proposed £20bn of savings needed to be made across the sector (Department of Health 
(DoH), 2010), came changes in the commissioning of services (e.g. DoH, 2010; Walshe, 
2010), and the need to provide greater evidence of cost-effectiveness  and effectiveness of 
interventions by meeting nationally and locally defined Commissioning for Quality and 
Innovation (CQUIN) targets (NHS England, 2013). Given that IAPT services grew out of a 
policy document claiming that they could save the NHS and the government considerable 
sums of money by returning people with depression and anxiety back to work (Layard, 
Clark, Knapp, & Mayraz, 2007), such services are under greater pressure than most to 
deliver against these targets (Stolk, Hofman, Hafner, & Janta, 2014). As a result, conducting 
prospective studies in clinical settings, perhaps in particular in IAPT services, with the hope 
of delivering the necessary quality in order to give results sufficient credibility and utility, 
has become ever more difficult.  
The present prospective study was set in an inner London Trust’s IAPT services. 
Collectively these services have become somewhat of a centre of excellence for research in 
primary care mental health and subsequently there are many requests and demands on the 
services to facilitate, conduct and run research projects for a wide range and number of 
stakeholders.  
In the context of a Doctorate in Clinical Psychology (D.Clin.Psy) course trainees are 
on placement three days a week and at University approximately one day a week whilst 
conducting the major research project. It is therefore a sizeable challenge to sufficiently 
project-manage the research at a local level within these time constraints, and this is made 
more difficult in settings where there are no additional resources free or available to 
facilitate this. Given the demands on the IAPT services listed above, no such resources were 
available for the present study. As a result, recruitment and data collection for the study 
had to be done by Psychological Wellbeing Practitioners (PWPs) who were already 
stretched by the need to meet their targets (IAPT, 2012) and by being asked to hold in mind 128 
 
multiple research studies operating within the service simultaneously. Without the 
motivation and problem solving that comes from having an in situ research coordinator 
(Alvarez, 2013) it is not surprising that so few service users were recruited. Further, it was 
not possible (despite efforts) to negotiate a slightly lower weekly contact target for the 
PWPs so that they could have the necessary extra time to recruit for this study.  
The difficulties with recruitment meant that whilst the prospective study aimed to 
include both three and six month follow-up appointments for each participant in order to 
prospectively gather data on relapse, this was not possible within the time-frame for the 
thesis. However, the study will continue to collect data up to 12 months post-treatment 
and the follow-up appointments will go ahead nonetheless.  
Methodological Choices and Potential Difficulties 
There were several difficult choices to make in the course of conducting the prospective 
study, all of which had potentially large implications for the study as a whole. Firstly, whilst 
cognitive control is usually and most reliably measured using experimental paradigms 
either with computer based tasks or in neuroimaging scanners (Nęcka, Sobczyk, & Śmieja, 
2012), in order for measurement of cognitive control on the scale proposed for the 
prospective study to become feasible it was necessary to find a way of measuring it to fit 
with the current IAPT structure of sessions. At ‘Step 2’ sessions are only 30 minutes long 
including time for service users to complete the standard self-report measures. Therefore it 
was important that any means of measuring cognitive control to be utilised in the present 
study be short in length and simple to administer. As a standalone measure the Attentional 
Control Scale (ACS; Derryberry & Reed, 2002) is both adequately reliable and valid, but it 
was not designed to be used in mental health services or in settings such as the IAPT 
services where measures are repeated at every contact and often on a weekly basis 
(Derryberry & Reed, 2002). The ACS makes no reference to timescale in the instructions for 
the respondent and the wording of the items makes it such that a respondent might 129 
 
consider it to refer to static, unchangeable states rather than transient experiences. The 
measure could be adapted by adding a phrase such as "over the last seven days..." in either 
the instructions to the respondent or as a prefix to each question. However, it has not been 
validated with such statements included, and so it was decided not to change the original 
structure of the ACS.  It seems possible therefore that when completing the measure 
participants might have found it confusing to be given the measure repeatedly without 
some time related context. It may be the case that as they were completing symptom 
measures which have the instruction that respondents answer with reference to the last 
seven days only, when answering the ACS they assumed the same time scale applied. 
Equally, it could be the case that if participants were unsure of the applicable timescale and 
they asked the PWPs for advice, this may also have been the PWP’s understanding. Either 
way there were changes in ACS scores for nearly all those that completed the measure, 
suggesting that this may not have caused much of a problem. It therefore proved feasible 
to use the ACS in this context and it may well be able to inform services about those that 
may be at greater risk of relapse in order to target them with alternative or additional 
interventions.  
  As discussed above, resources available for Doctorate in Clinical Psychology 
research projects are limited. This coupled with the ethical complications of 
paying/compensating participants for their time in research related to their own health-
care meant that it was an easy decision to make not to pay participants, yet it was clearly a 
potentially costly one to the recruitment process (Church, 1993).  A systematic review by 
Edwards and colleagues (2002) showed a doubling in the odds of response (albeit to postal 
surveys) when monetary incentives were offered for participation. In addition, this 
systematic review showed that questionnaires were more likely to be completed when 
coming from universities rather than from healthcare organisations (Edwards et al., 2002). 
As previously discussed it was not possible to have anyone other than the service user’s 130 
 
own PWP asking them for consent to participate in the present study. Therefore it may be 
that these contributed to the very low response-rate in the prospective study. However, 
some of the recommendations of Edwards and colleagues (2002) were able to be followed, 
such as choosing a brief questionnaire (rather than a longer one) and printing the 
questionnaires in colour.  
No analysis of a large dataset is without its problems. One of the most surprising 
things to come out of conducting this research was that there appeared to be 
proportionally very few service users that returned to the services, therefore the number of 
relapsers was particularly small and certainly less than envisaged prior to starting the 
analyses. Some reasons as to why so few may have returned to the service are discussed in 
Part 2 of this thesis, though to briefly summarise: it may be the case that many service 
users were experiencing relapses after finishing treatment though were not being re-
referred to the services due to personal choice or perhaps that their General Practitioners 
(GPs) (who are responsible for approximately 80% of all referrals to the IAPT services) had 
decided that as a relapse had occurred after treatment in IAPT, a different approach should 
be trialled next in the hope of preventing further relapses. This may therefore have led to 
such patients being referred elsewhere and so not returning to the IAPT services. As a result 
of having relatively few relapsers in the analyses the models built based on relapse were 
more susceptible to the impact of missing data than they might have otherwise been. One 
example of this is that the relationship between scores on the Generalized Anxiety 
Disorders scale (GAD-7) and relapse might have been unduly affected by missing data. It 
was decided that multiple imputation methods should not be used as despite having a large 
sub-set of the dataset with which to base the imputation on, it is possible that those with 
and without the GAD-7 scores represented different populations, so making any potential 
imputation invalid. However, using list-wise deletion to remove those with missing data 
from the analyses not only greatly reduced the power but also may have introduced 131 
 
systematic selection bias, as those missing the data may have represented a different 
population of relapsers than those with recorded data on the GAD-7. This is particularly 
problematic as whilst non-systematic bias and a reduction in power may tend to bias results 
towards the null, a systematic bias could lead to erroneous conclusions in either direction 
(e.g. Kirkwood & Sterne, 2003). Therefore, in presenting the findings from the logistic 
regression models despite GAD-7 scores confounding the relationship between residual 
depressive symptoms and relapse for those with a recorded GAD-7 score, it was decided 
that models both with and without GAD-7 scores as a risk factor for relapse should be 
included. While this may have led to a somewhat greater difficulty in interpreting the 
findings in relation to relapse, it allowed for the consideration of the possibility that there 
are different patterns of risk factors across two potentially different sub-populations in the 
sample. As such, it highlighted an interesting and potentially new way of thinking about risk 
factors for relapse in a possibly distinct sub-population of service users presenting to 
primary care services with depression.    
Conclusions 
There have been many difficulties in conducting a prospective study in a clinical setting 
seeking to combine the investigation of factors at the observable and latent levels. Against 
the backdrop of austerity leading to reduced flexibility in contact targets for the PWPs 
recruiting and collecting data, and in the context of a D.Clin.Psy with few resources to 
project manage the research and the limitation in time allowed for the research to take 
place, the length of time taken to recruit participants and the number recruited led to an 
inability to collect data prospectively on relapse for a sufficient number of participants. The 
present study had to be reduced in scale and the aims adjusted accordingly, such that the 
focus of the prospective study was only on residual depressive symptoms as an outcome 
and not on relapse. However, despite all these difficulties the study was able to deliver 
results not previously found before, furthering knowledge about risk factors for residual 132 
 
symptoms of depression and proving that there is utility in using self-report measures of 
cognitive control in primary care mental health services to consider service users risk of 
residual symptoms after treatment and therefore those most likely to relapse. With the 
continuation of the prospective study to collect data on relapse up to 12 months post-
treatment, these findings can be extended and the conclusions drawn from the study can 
gain yet greater utility. The study made no attempt to improve the therapeutic 
interventions delivered to prevent relapse, but by contributing to a better understanding of 
the phenomenon it is hoped that even this modest D.Clin.Psy research project can lead to 
an improvement in the knowledgebase on relapse and potential advancements at the 
therapeutic level further into the future.     133 
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Abstract 
Objectives: To determine what factors confer risk for relapse to depression after acute 
phase treatment in adults and to consider the mechanisms by which they might operate.  
Design: This study consisted of meta-reviews of systematic and non-systematic reviews of 
studies reporting on risk factors for relapse to depression in adults, and a systematic-review 
of neuroimaging and experimental studies investigating risk factors for relapse and 
potential mechanisms of action of these risk factors.  
Data sources: Bibliographic databases: CAB Global Health Archive, Cochrane CENTRAL Trial 
Register, Cochrane Database of Reviews, Embase, International Pharmaceutical Abstracts, 
MEDLINE, Prospero, PsycEXTRA and PsycINFO, hand searching of reference lists and 
citations of included studies, and contact with experts in the field for unpublished reports.  
Study eligibility criteria:  We included studies that reported on at least one risk factor for 
relapse/recurrence to depression in adults 18 years old or above utilising a number of types 
of intervention. In Study 1 we included only systematic reviews of clinical trials, cohort 
studies or case-control studies which had reviewed studies that used well validated 
methods of determining depression onset/remission/recovery/relapse/recurrence. In Study 
2 we included non-systematic reviews of any study designs, and in Study 3 we included 
neuroimaging and experimental studies that either had some longitudinal measurement of 
depressive symptoms over a minimum of eight weeks and used well validated methods of 
determining depressive onset/remission/recovery/relapse/recurrence, or that made cross-
sectional comparisons between groups of remitted and relapsed/recurrently depressed 
participants determined by diagnosis from a psychiatrist or with a clinical interview.  
Study appraisal and synthesis: To judge study quality in Study 1 the AMSTAR criteria along 
with items from PRISMA and the Cochrane Reviewer’s Handbook were used, study quality 
was not assessed in Study 2, and in Study 3 criteria developed by Kmet, Lee and Cook 
(2004) were used to assess study quality. Each of the three stages of the present review 
involved a narrative synthesis with the formation of a matrix to consider each risk factor 
identified as associated with relapse/recurrence from the perspective of each reviewed 
study. Studies 2 and 3 included data on proposed mechanisms of action of the risk factors 
identified and these were used to derive a conceptual framework with which to consider 
directions for future research into relapse/recurrence to depression in adults.  
Results:  Only the presence of residual sub-threshold symptoms after acute phase 
treatment and the experience of some form of childhood maltreatment are well supported 
with strong evidence from high quality systematic reviews as risk factors for relapse to 
depression. There are a number of factors which to date had not previously been 138 
 
systematically reviewed that these studies suggest play a role in conferring risk for relapse 
but which are not supported in the literature with the same degree of high quality 
evidence. These factors are: information processing and cognitive biases, reactions to stress 
and/or changes in mood, and persistent ruminative thinking in response to negative 
experiences, these may be brought about by dysfunction in neocortical and limbic 
structures (particularly the dmPFC and rACC) and dysfunction in the HPA axis and with REM 
sleep.  Further, the studies have identified several potential mechanisms for the action of 
such risk factors and have considered the inter-relationships between these factors to 
propose a conceptual framework which may help guide future research into 
relapse/recurrence to depression.  
Limitations: There was a paucity of high quality systematic reviews and very few that had 
the stated aim of identifying risk factors for relapse to depression. A large number of cohort 
studies and clinical trials identified in the literature searches were not included in the 
systematic and non-systematic reviews reviewed in Studies 1 and 2. Those that were 
included may have introduced various biases by using definitions of relapse and recurrence 
that result in the under-sampling of those that only ever have a single lifetime episode of 
depression, by suffering from high attrition rates, and by other inconsistencies across the 
studies in their inclusion and exclusion criteria.  
Conclusions: Taken together these three studies have demonstrated that the consensus 
view of relapse may need amending, that there are no factors supported by studies able to 
provide the highest level of evidence for the prognosis or aetiology of a disease, conducted 
with high quality, providing strong evidence, which have utility in guiding the treating 
clinician in reducing their patient’s risk of relapse/recurrence to depression. There are 
however a number of factors which to date had not previously been systematically 
reviewed that these studies suggest play a role in conferring risk for relapse. By considering 
the inter-relationships between these factors these studies were used to propose a 
conceptual framework which may be used to help guide future research into 
relapse/recurrence to depression in adults.  
Implications of key findings: It may be that the current diagnostic systems impact the 
ability of researchers to identify risk factors for relapse to depression that have utility in the 
consulting room. However, irrespective of this, future studies would do best to investigate 
the relationships between cognitive and information processing (or affective) biases and 
relapse to depression to consider potential means by which these might be manipulated to 
reduce the risk of relapse for depressed patients.  139 
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Searches  Results 
CAB Global Health Archive 1910 to 1972   
1. (depression or Depressive disorder or Major depression or Unipolar depression or MDD).mp.   3255 
2. (risk adj5 relapse).mp.   47 
3. 1 and 2  1 
4. (bipolar or bipolar disorder or manic depression).mp.  145 
5. (alcohod abuse or drug abuse).mp.  290 
6. (alcohol abuse or drug abuse).mp.   359 
7. 4 or 6  504 
8. 3 not 7  1 
   
Cochrane CENTRAL Trial Register (searched on 16
th November 2013)   
1. ("Depression" or "MDD" or "Unipolar" or "Depressive"):ti,ab,kw (Word variations have been searched)  29363 
2. ("relapse" or "Recurrence" or "remission"):ti,ab,kw (Word variations have been searched)  41714 
3. ("Bipolar" or "schizophrenia" or "psychosis" or "schizoaffective"):ti,ab,kw (Word variations have been searched)  12304 
4. #1 and #2  293 
5. #4 not #3  282 
   
Cochrane Database of Reviews (searched on 16
th November 2013)   
1. ("Depression" or "MDD" or "Unipolar" or "Depressive"):ti,ab,kw (Word variations have been searched)   95 
2. ("relapse" or "Recurrence" or "remission"):ti,ab,kw (Word variations have been searched)  156 
3. ("Bipolar" or "schizophrenia" or "psychosis" or "schizoaffective"):ti,ab,kw (Word variations have been searched)  31 
4. #1 and #2  23 
5. #4 not #3  23 
   
Embase 1947 to 2013 Week 47   
1. exp recurrent brief depression/ or exp major depression/ or exp depression/ or exp long term depression/  323279 
2. (depression or Depressive disorder or Major depression or Unipolar depression or MDD).mp.  460246 
3. 1 or 2  486582 
4. relapse.mp.  154579 
5. recurrence.mp.  338066 
6. 4 or 5  461682 
7. 3 and 6  12839 
8. (risk adj5 relapse).mp.  19560 
9. 8 and 3  1444 
10. ((relapse or recurrence) adj5 depressi*).mp.  4673 
11. 9 or 10  5379 
12. bipolar.mp.  77167 
13. bipolar disorder/ or bipolar mania/ or bipolar depression/ or bipolar II disorder/ or bipolar I disorder/  40107 
14. exp schizoaffective psychosis/  6134 
15. alcohol abuse/  19526 
16. drug abuse/  43593 
17. 12 or 13 or 14 or 15 or 16  103069 
18. 11 not 17  1068 
19. ((risk or odds or chance or probability) adj5 relapse).mp.  20885 
20. 3 and 19  1538 
21. 11 or 20  5417 
22. 21 not 17  1150 
   
Embase 1947 to 2013 Week 47 Search for Review Articles Only   
1. exp recurrent brief depression/ or exp major depression/ or exp depression/ or exp long term depression/  323279 
2. (depression or Depressive disorder or Major depression or Unipolar depression or MDD).mp.  460246 
3. 1 or 2  486582 
4. relapse.mp.  154579 
5. recurrence.mp.  338066 
6. 4 or 5  461682 
7. 3 and 6  12839 
8. (risk adj5 relapse).mp.  19560 
9. 8 and 3  1444 
10. ((relapse or recurrence) adj5 depressi*).mp.  4673 
11. 9 or 10  5379 
12. bipolar.mp.   77167 
13. bipolar disorder/ or bipolar mania/ or bipolar depression/ or bipolar II disorder/ or bipolar I disorder/  40107 
14. exp schizoaffective psychosis/  6134 
15. alcohol abuse/  19526 
16. drug abuse/  43593 
17. 12 or 13 or 14 or 15 or 16  103069 
18. 11 not 17  1068 
19. ((risk or odds or chance or probability) adj5 relapse).mp.  20885 
20. 3 and 19  1538 141 
 
21. 11 or 20  5417 
22. 21 not 17  1150 
23. systematic review.mp. or "systematic review"/  98424 
24. meta analysis.mp.  115569 
25. literature review.mp.  55934 
26. 23 or 24 or 5  221228 
27. 22 and 26  77 
   
International Pharmaceutical Abstracts   
1. (depression or Depressive disorder or Major depression or Unipolar depression or MDD).mp.  8151 
2. (risk adj5 relapse).mp.  276 
3. 1 and 2  38 
4. (bipolar or bipolar disorder or manic depression).mp.  1426 
5. (alcohol abuse or drug abuse).mp.  6685 
6. (alcohol abuse or drug abuse).mp.  6865 
7. 4 or 6  8239 
8. 3 not 7  31 
   
Ovid MEDLINE 1946 to November Week 3 2013   
1. exp major depression/ or exp "depression (emotion)"/  73699 
2. ((relapse or recurrence) adj5 depressi*).mp.  1406 
3. bipolar disorder/ or affective psychosis/ or mania/  30705 
4. exp Schizoaffective Disorder/  37751 
5. 3 or 4  65458 
6. exp Depressive Disorder, Major/  18234 
7. exp Depressive Disorder, Major/ or exp Depressive Disorder/ or exp Depression/  148814 
8. 2 or 7  149074 
9. Bipolar Disorder/  30705 
10. 8 not 9  139693 
11. Child/  1339552 
12. 10 not 11  129087 
13. 2 and 7  1146 
14. 13 not 19  1054 
15. 14 not 11  1001 
16. Substance-Related Disorders/  76481 
17. 15 not 16  990 
   
Ovid MEDLINE 1946 to November Week 3 2013 Search for Review Articles Only   
1. exp major depression/ or exp "depression (emotion)"/  73699 
2. ((relapse or recurrence) adj5 depressi*).mp.  1406 
3. bipolar disorder/ or affective psychosis/ or mania/  30705 
4. exp Schizoaffective Disorder/  37751 
5. 3 or 4  65458 
6. exp Depressive Disorder, Major/  18234 
7. exp Depressive Disorder, Major/ or exp Depressive Disorder/ or exp Depression/  148814 
8. 2 or 7  149074 
9. Bipolar Disorder/  30705 
10. 8 not 9  139693 
11. Child/  1339552 
12. 10 not 11  129087 
13. 2 and 7  1146 
14. 13 not 19  1054 
15. 14 not 11  1001 
16. Substance-Related Disorders/  76481 
17. 15 not 16  990 
18. Systematic review.mp  37815 
19. literature review.mp  38952 
20. meta analysis.mp  67893 
21. 18 or 19 or 20  127903 
22. 17 and 21  33 
   
PsycEXTRA 1908 to November 16, 2013   
1. exp Postpartum Depression/ or exp Recurrent Depression/ or exp Atypical Depression/ or exp Endogenous 
Depression/ or exp Reactive Depression/ or exp Treatment Resistant Depression/ or exp Major Depression/ 
4479 
2. (risk adj5 relapse).mp.  55 
3. 1 and 2  9 
4. exp Bipolar Disorder/ or exp Mania/  729 
5. mental health/  6267 
6. exp Alcohols/  393 
7. exp Alcohol Abuse/  3771 
8. exp Drug Abuse/  12931 142 
 
9. 7 or 8  12931 
10. 4 or 9  13625 
11. 3 not 10  9 
   
Prospero (searched on 16
th November 2013)   
"Depression" OR "Depressive" OR "MDD" OR "Unipolar". In all fields.  227 
   
PsycINFO 1806 to November Week 3 2013   
1. exp major depression/ or exp "depression (emotion)"/  111027 
2. recurrent depression/  617 
3. exp Relapse Prevention/ or exp "Relapse (Disorders)"/  6945 
4. 1 or 2  111027 
5. ((relapse or recurrence) adj5 depressi*).mp.  1939 
6. 3 and 4  1133 
7. 6 or 5  2229 
8. 7  2229 
9. limit 8 to (human and English language and journal article)  1598 
10. bipolar disorder/ or affective psychosis/ or mania/  21943 
11. exp Schizoaffective Disorder/  2568 
12. 10 or 11  24023 
13. 9 not 12  1382 
14. exp Child Psychopathology/  1426 
15. 13 not 14  1381 
Substance abuse.mp  27069 
exp Drug Abuse/  85848 
exp Alcohol Abuse/  38362 
16 or 17 or 18   85848 
15 not 19  1320 
   
PsycINFO Search for Review Articles Only   
exp major depression/ or exp "depression (emotion)"/  110021 
(depression or Depressive disorder or Major depression or Unipolar depression or MDD).mp.  213339 
recurrent depression/  613 
1 or 2 or 3  213628 
relapse.mp.  17745 
recurrence.mp.  5591 
exp Relapse Prevention/ or exp "Relapse (Disorders)"/  6898 
5 or 6 or 7  22074 
4 and 8  5177 
exp "Literature Review"/ or exp Meta Analysis/  25128 
systematic review.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & 
measures] 
8537 
meta analysis.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & 
measures] 
14296 
10 or 11 or 12  42663 
9 and 13  192 
exp Bipolar Disorder/  18849 
exp Alcohol Abuse/  38107 
exp Drug Abuse/  85184 
exp Drug Addiction/  11194 
15 or 16 or 17 or 18  103406 
14 not 19  161 
((relapse or recurrence) adj5 depressi*).mp.  1920 
20 and 21  52 
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Study 1:  
Reviewed 
Studies 
Databases searched and years 
included 
Search terms  Inclusion Criteria  Exclusion Criteria 
Beshai et 
al., 2011 
PsycINFO and PubMed years 
not stated 
keywords only: "relapse", "recurrence", "prevention", 
"depression", "cognition", "mindfulness", 
"interpersonal" AND "therapy" 
a) adult participants (18 or over), b) employing some form of psychotherapy, c) 
psychotherapy used as a standalone procedure targeting relapse/recurrence 
prevention d) used either a treatment  or non-treatment control group 
None Stated 
Clarke et 
al., in press 
CENTRAL, Embase, Medline, 
and PsycINFO and PROQUEST 
from beginning of databases to 
2012  
Keywords and MeSH terms: depression’ and ‘long-
term/ relapse/recurrence’ using a highly sensitive RCT 
filter 
Randomised controlled trials of non-pharmacological interventions were included if 
participants were adults who had experienced an episode of major depression and 
partially or fully recovered. There was a minimum follow-up period of 12-months 
from the start of the intervention.  
None Stated 
Feng et al., 
2012 
Cochrane Library, EBSCO Host, 
Medline OVID, ProQuest 
Medical Library, and PubMed, 
all 2000-2010, hand searching.  
Keyword and MeSH terms: group therapy, cognitive 
therapy, cognitive behavioural therapy, CBGT, 
psychotherapy, depression, relapse, and recurrence 
Participants diagnosed using: ICD-10, DSM-III/IIIR/IV/IV-TR or RDC, were over 18 
years old and could be any gender or race; RCT design with at least one group 
undergoing CBGT; written in English; results presented on level of depression and 
relapse rate; and studies had sufficient data to calculate effect size. 
CBGT taking place 
over the phone or 
the Internet. 
Hardeveld 
et al., 2010 
PsycINFO and Medline, plus 
hand searching of references. 
All searched January 1980-
August 2008 
Keywords only: 'Recur*', 'Relaps*', 'Depress*', 
'Predict*' and 'course'. 
English Language, adult population only; naturalistic cohort studies of subjects with 
MDD diagnosed by interview of checklist based on RDC/BCC, DSM-III/III-R/IV or ICD-
9/10; course measured by standardised instrument/checklist, minimum follow-up 6 
months, at least 50 participants, criteria of remission/recovery/relapse/recurrence 









Medline, PsycINFO, Embase, 
Cochrane Library, all 1988-
2008, hand searching.  
Keyword and MeSH terms: Given in tables for each 
database. 
1) Follow-up period of 10+ years 2) adults over 18 3) at least 1 group with unipolar 
depressive disorder, 4) description of ADM treatment 5) at least 1 clinical or 
psychosocial outcome, excluding suicide or mortality, 6) Published in English. Same 
inclusion criteria for studies of nondrug treated individuals, but statement that 
participants had not received ADMs. 
Studies that 
examined only 
suicide or mortality 
. 
Kok et al., 
2013 
PubMed, Embase, PsycINFO. 
Searched from beginning of 
databases to 4th December 
2012. 
Keyword and MeSH terms: ‘depression or depressive 
disorder or major depression were combined with 
heart diseases or gastrointestinal diseases or diabetes 
mellitus or arthritis, rheumatoid or asthma or HIV or 
neoplasms and incidence or follow-up studies or 
prognos* or predict* or course or outcome or relaps* 
or recur* or remis* or epidemiology. 
In English, Dutch, Spanish, Polish or German. (1) longitudinal measurement of 
course of depression (2) numbers or percentages of recurrence presented a) 
diagnosis with interview or questionnaires based on DSM-III/III-R/IV (3) follow-up of 
6+ months (4) data collected on patients with and without chronic somatic illnesses 




Medline, PsycINFO, and 
Embase. Searched from 
beginning of the databases to 
December 2010 
Keywords: child*maltreatment, child*abuse, child* 
neglect, early experience. depress*, mood disorder, 
MDD, recurrence, persistence, chronic, duration, 
length, improvement, response, remission, treatment, 
psychotherapy, CBT,  pharmacotherapy, 
antidepressant, SSRI 
Childhood maltreatment including physical abuse, sexual abuse, neglect, or family 
conflict or violence); depressive disorder in population-based or clinical samples; 


























Number of included 
studies 
Beckerman & Corbett,2010  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Belsher & Costello, 1988  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Burcusa & Iacono, 2007  PSYCINFO and Science Citation Index 
Expanded. Hand searching 
Not stated  Keywords  "Recurrence" "Recurrent" "depression" 
"risk" "correlate" 
Not Stated  Not Stated  51 
Costa e Silva, 2004  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
de Carvalho et al., 2011  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Hammen, 2003  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Hick & Chan, 2010  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Hollon & DeRubeis, 2009  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Keller, 1996  None stated  N/A  N/A  N/A  N/A  N/A  N/A 
Kerr et al., 2013  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Kessler, 1997  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Lau et al., 2004  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Liu, 2013  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Modell & Lauer, 2007  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Monroe & Harkness, 2005  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Palagini et al., 2013  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Robinson & Sahakian, 2008  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Scher et al., 2005  None stated  N/A  N/A  N/A  N/A  Not Stated  30 
Scott, 2001  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Segal et al., 1996  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 
Sipe & Eisendrath, 2012  None stated  N/A  None stated  None stated  Not Stated  Not Stated  Not stated 146 
 
Study 3:  
Reviewed 
Studies 
Inclusion Criteria  Exclusion Criteria  How Sample Recruited 
Anderson 
et al., 2011 
aged 18–60, in good physical health. Control group with no personal 
history of psychiatric disorder or a family history of treated 
depression; currently depressed participants met criteria for MDE; 
and remitted depressed group were in full remission with no current 
psychiatric disorder, a history of at least two prior MDEs (one lasting 
at least 2 months) and a MADRS score < 13. 
Current/past physical illness or disability; current alcohol or 
drug dependence/harmful use; history of bipolar affective 
disorder, psychosis, dementia or mental impairment; taking 
psychoactive medications (apart from ADM, antipsychotics or 
lithium). Anxiety disorders not pre-dating diagnosis of MDD. 
From Larger sample of 2004 Primary Care Patients in 2 UK 
centres supplemented with psychiatric outpatients with 
history of depression 
Chopra et 
al., 2008 
Not Stated  Not Stated  Phase 1: 301 patients with MDD were randomized to receive 
CBT or ADM. Phase 2: participants who remitted underwent 
mood provocation protocol and followed-up for 18 months. 
Dai  & 
Feng, 2011 
Chinese-speaking adults aged 18-40. NCs: score of <5 on BDI and 
BAI, and no history of depressive disorder or other psychological 
disturbance from SCID. For RMD: scoring <8 on HRSD and at least 
two previous MDEs, most recent onset at least 8 weeks ago. MDD  
group: scoring 20+ on the HRSD and diagnosis from psychiatrist 
according to the DSM-IV criteria. 
Severe head trauma and learning disabilities, current or 
lifetime psychotic symptoms, bipolar disorder and alcohol or 
substance abuse within the past 6 months. All participants 
had normal or rectified eyesight with no colour blindness, and 
were right-handed.  
NC Group: Participants recruited via advertising on university 
bulletin boards. RMD Group: recruited through 
psychotherapists, and were screened to determine recovery 




Currently depressed group: DSM-IV diagnosis of MDD, HRSD score 
of 13+ and BDI score 20+. Formerly Depressed: past diagnosis of 
MDD given by a psychiatrist/clinical psychologist, received ADM or 
psychotherapy during the episodes, symptom free for at least one 
month. HRSD score <13 and BDI-II <20. Never depressed: screened 
with the MINI and included if they reported no prior history of 
depression. HRSD score <13 and a BDI-II <20. 
 
For Never Depressed: any past psychological disorder based 
on self-report questionnaire.  
Currently depressed were recruited from psychiatric hospitals 
in Belgium. Formerly depressed and never depressed recruited 
using media advertisements in Belgium. All participants were 




MDD single or recurrent episode, and Dysthymic Disorder according 
to ICD-10 at index admission 
Not stated  3.5 year follow-up assessment, of,patients originally recruited 
during their inpatient treatment at the Central Institute of 




Meeting DSM-IV-TR criteria for 1+  previous episodes of MDD.  Current depression within 10 weeks of first testing session. 
History of psychosis or bi-polar disorder. Inability to speak 
English, and/or inability to provide informed consent.  
Recruited via advertisements placed around the University of 
Melbourne, in the Herald Sun newspaper, and via email 
newsletters to post-graduates at the University.  
Moreno et 
al., 2000 
Not Stated  Not Stated  methods described in a previous report detailing the acute 




Remitted Depressed group: past diagnosis of MDD according to 
DSM-IV criteria assessed with the SCID-I.  
Current MDD, past bi-polar disorder, PTSD or health 
conditions known to influence HPA function and non-
prescription drugs that can affect cortisol levels. 
Recruited from graduate and undergraduate programs at 
Vanderbilt University.  
Nixon et 
al., 2013 
2+ previous episodes MDD diagnosed with SCID, currently in 
sustained remission/recovery with normalized function for 3+ 
months and a HAM-D score <8. 
co-morbid Axis I psychiatric disorder; personality disorder; 
drug/alcohol disorder; untreated medical disorder; any 
previous or current central nervous system disease; or fMRI 
safety issues. Controls were excluded if there was evidence of 
current or past psychiatric disorder. 
Recruited via referral from general adult psychiatric clinics in 
Nottingham, UK. Controls recruited via posters 





Previous MDD, but did not meet criteria for diagnosis of MDD at the 
time of testing. 
Drug or alcohol abuse or dependence, history of brain injury 
or central nervous system disease. 
Not stated 
Risch et al., 
2010 
DSM-IV criteria for MDD or recurrent MDD, currently in remission.  Depression with psychotic symptoms, bipolar disorder, PTSD, 
organic psychiatric disorders, substance-abuse related 
disorders, schizophrenia, schizoaffective disorders, borderline 
personality disorder, or acute suicidality. RD patients: >18 on 
BDI. ND: no current or past depression.  
Recruited from the outpatient psychiatric clinics of the 
Friedrich Schiller University of Jena and the Sophien and 
Hufeland Clinic of Weimar, Germany. 
Sears et 
al., 2011 
Previously depressed group: 1+ episode of MDD over past 2 years 
and BDI score <7. Never depressed group: BDI scores <7 and no 
history of MDD during past 2 years. Dysphoric group: BDI scores > 
19, classified as ‘‘previously depressed’’ based on their responses on 
the self-report inventory. 
Previously depressed group: experiencing depressive 
symptoms at time of testing, male gender.  
Recruited via an online research participation system for 
undergraduates at University of Calgary and through campus 
advertisements. Participated  in exchange for extra course 
credit or $20.00 (CAN).  
Segal et al., 
1999 
All participants were between the ages of 18 and 65 years old, met 
minimum eighth-grade education requirement or were able to 
complete assessment instruments unassisted, and spoke English as 
their primary language. Only chose if their most recent episode of 
depression met criteria for a primary diagnosis of MDD. 
a) Current diagnosis of bipolar affective disorder, substance 
abuse disorder, or schizophrenia, and b) a trial of ECT within 
the past 6 months. ` 
From one of two outpatient clinics offered through the Clarke 
Institute of Psychiatry's Mood and Anxiety Disorder Division 
and the Depression Clinic.  
Segal et al., 
2006 
Diagnosis of MDD according to DSM-IV, aged 18-65 years, minimum 
eighth-grade education, able to read English and to provide 
informed consent. Post-treatment evaluations were based LIFE 
interview and HDRS-17. Remission was defined as minimal 
symptoms for a12+ weeks, no longer meeting diagnostic criteria for 
MDE, and a HDRS-17 score < 11. These were used to determine 
eligibility for the mood provocation phase of the study. 
 
(1) Current diagnosis of bipolar disorder, substance abuse 
disorder, schizophrenia, or borderline personality disorder, 
(2) a trial of electroconvulsive therapy within the past 6 
months, and (3) a score of <12 on HDRS. 
Recruited by referrals from the Mood and Anxiety Disorders 
Program at the Centre for Addiction and Mental Health or 




Aged 18-65 years old. Currently depressed: met criteria for MDD on 
SCID and score 16+ on the BDI. Recovered Depressed: did not meet 
criteria for current MDE on SCID, 1+ previous episodes, scored <15 
on BDI. Never Depressed did not meet criteria for any past or 
current diagnosis of MDE on the SCID and scored <15 on the BDI   
None stated  Currently depressed: recruited from both inpatient and 
outpatient settings. Recovered Depressed: recruited from a 
self-help charity for depression. Never Depressed: no 
comment on method of recuitment. 148 
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Details of Studies Excluded From the Literature Review 




Study 1.  
Study Citation  Comments on 
Inclusion 
Study design of 
included studies 
Study population  Type of 
Intervention  
Comparisons 
of relevance to 
relapse 
How outcomes recorded   Main Results 
Bourgon & Kellner, 2000. 
The Journal of ECT. 
Vol.16(1), Mar 2000, pp. 
19-31. 
Doesn't state how 
relapse is measured in 





ECT  relapsers vs non-
relapsers 
Relapse recorded but not stated 
how. 
The only reported predictive symptom was the 
presence of delusions. Medication resistance 
before ECT was the also reported as predicting 
relapse. The DST and TRH tests were considered as 
biological markers that could predict relapse.  
Santos, et al.,2013.  
Clinical Practice & 
Epidemiology in Mental 
Health, 2013, 9, 221-237 
No data on factors 
related to relapse 
despite statements 
about them.  
The studies were 
RCTs, prospective 
cohorts, cross-
sectional studies and 
case-control studies 
no limitation of age, 
young 
women with 













by the symptoms 
of depression and 
the scores of 
depression scales  
Self-report measures of: 
depression, positive and 
negative affect, gratitude, hope, 
stress, resilience, life 
satisfaction, self-esteem, 
automatic thoughts, happiness, 
and meaning and mindfulness. 
Positive psychology interventions were reported to 
impact depressive symptoms as well as resilience 
and coping abilities to reduce relapses. 
Oestergaard & Moldrup, 
2011. Journal of Affective 
Disorders. Vol.131(1-3), 




Studies included RCTs 
of combined 
psychotherapy and 
ADM vs ADM alone . 






Remission and relapse rates 
from self-report measures, in 
particular HAM-D 
ADM patients had higher risk of relapse up to 12 
months after treatment. 
Vittengl, Clark, 
Dunn, & Jarrett 2007. 
Journal of Consulting & 
Clinical Psychology. 




RCTs  Adults 18+ with MDD  CT or CBT  relapsers vs non-
relapsers 
Mostly DSM criteria using HRSD, 
or diagnosed in outpatient 
settings. 
Approximately half of all responders to A-CT 
relapse within 2 years if not receiving continuation-
phase treatment. A-CT reduces relapse relative to 
ADM whether continued in conjunction with ADM 
or not. C-CT reduces risk of relapse compared with 
no treatment conditions, and or compared with 
ADM.  








RCTs  Adults with MDD   CBT  Not stated  HAM-D  There was a non-significant trend towards acute 
phase CBT patients having lower risk of relapse 
than acute phase ADM patients. 
 
Geddes, et al., 2003.  
Lancet.  361(9358): p 653-




RCTs  Adults with MDD  ADM  Proportions 




Mostly DSM/RCD criteria  Meta-analysis results revealed that continuation 
ADM reduced the risk of relapse.  
Chiesa & Serretti 2011.  
Psychiatry Research 187 
(2011) 441–453 
Nothing directly on 
mechanism/predictors 
of relapse but some 
tentative statements 
about things 
hypothesised to be 
related to relapse 
RCTs  Adults with psychiatric 
disorders 




scores, scores in 
remitted vs non-
remitted  
Differences in 1-year relapse 
and recurrence rates in patients 
suffering from MDD assigned to 
MBCT or to a control group 
Only one study found that MBCT was comparable 
to established treatment options. Reported that 
MBCT had an additive effect to usual care for 
reducing residual symptoms.  150 
 
 
Study 2.  
Study Citation  Comments on Inclusion  Study design of 
included studies 






Abrams, Meyers & 
Shamoian, 1989. 
Biological Psychiatry. 
Vol.26(6), Oct 1989, 
pp. 551-564. 
Geriatric Depression  only    Mixed age adults with 
depression  
relapsers vs non-relapsers    History of 3+ episodes was the strongest clinical or demographic 
predictor time to relapse. However recent studies have not found 
this to be the case but these studies did separate relapse from 




82, 2005 Aug 15. 
Geriatric Depression  only  A mixture of cohort 
studies, trials, and 
cross-sectional 
studies, and others 
Mostly older adults  Not stated  Not stated   
Auerbach, Webb, 
Gardiner & Pechtel, 
2013. Journal of 
Psychotherapy 
Integration. Vol.23(3), 
Sep 2013, pp. 222-235. 





some child and 
adolescent 
  Depressed Vs healthy controls or 
cognitively vulnerable 
Mostly areas of 
activation on 
neuroimaging 
Findings suggest that depressed individuals spend more time 
attending to depressogenic stimuli which exacerbates negative 
affect and likely, maintains depressive symptoms. Such attentional 
and information processing biases are central components of the 
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Identifying the risk factors for relapse to depression after treatment 
Participant Information Sheet 
You are being invited to take part in a research study. Before you decide whether to 
take part, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
feel free to discuss it with others if you wish. If there is anything that is not clear or 
if you would like more information, please ask us. Your participation in this study is 
completely voluntary. 
 
What is the purpose of this study? 
Interventions for depression from IAPT services are very effective with the majority 
of people getting better. Unfortunately some people get depressed again (relapse) 
after they finish treatment. The reasons for relapse are not fully understood but 
some researchers suggest that it is related to people’s cognitive control. Cognitive 
control is about being able to remember and use pieces of information and also 
being able to pay attention to certain things whilst ignoring distractions. We believe 
that when cognitive control is impaired it can increase the chances of having 
residual (left over) symptoms of depression after treatment. Having residual 
symptoms is one of the main risk factors to relapsing to depression. However, little 
research has been done on this as of yet.  
We want to ask you to fill in a brief questionnaire on cognitive control on 
several occasions as part of this research because we believe that by recording this 
we can find out more about who is likely to relapse after treatment, and if this 
happens we want to consider how we can best help prevent relapse for people in 
future.  
 
What does taking part involve? 
If you agree to take part, you will be asked to sign a consent form. 
As a part of your treatment in this IAPT service you will be asked to 
complete some very brief questionnaires with your IAPT clinician at the beginning of 
every treatment session. Every person that is seen in IAPT services fills in the same 
questionnaires each time they come for treatment. You doing this helps your IAPT 
clinician to look at how you are feeling week to week which helps them with 
planning your treatment. By everyone filling these questionnaires in it also allows 
NHS services to understand how effective they are at helping people with 
depression as a whole.  
 
Another part of this study is for the researchers to use information from the 
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Islington NHS Foundation Trust IAPT services which have been collected over the 
last five years. This will help the researchers understand the relationship between 
symptoms people have when they start treatment and any symptoms they still have 
when they finish treatment. This could help identify people who might get 
depressed again after they have finished their treatment. Information from the 
questionnaires you and everyone else in Camden and Islington IAPT services 
complete will only be able to seen by the researchers once all personal identifiers 
have been removed so that it is fully anonymous. This means they can’t identify any 
individual people who have filled the questionnaires in. 
For this study we would like you to complete one additional short 
questionnaire at the beginning of each treatment session which is about cognitive 
control (this takes approximately 5 minutes each time) and another questionnaire 
at your first and last treatment sessions (this takes about 10 minutes each time) 
which is about symptoms of depression. In order for us to learn more about relapse 
we would then like you to complete these same two questionnaires again at 3 
months and 6 months after the end of your treatment with the IAPT service. It does 
not involve anything else on your part. You will be seen for sessions at your IAPT 
service just the same as you would if you weren’t taking part in this research and 
there is nothing extra you need to do to take part.  
 
Why have you been chosen?  
We are inviting everyone starting treatment for depression between July-
September 2013 in IAPT services in Camden and Islington NHS Foundation Trust to 
take part in this study.  
 
What will happen to my information? 
All information collected about you during the course of the study will be kept 
strictly confidential and stored in secure premises at UCL. Your name and contact 
details will be stored separately from the data collected. Both sets of information 
will be kept securely according to the requirements of the Data Protection Act 1998.  
It is likely that the results of this study will be published, but only group 
results will be presented and no individual’s health will be discussed. Your name will 
not appear on any publications or reports about this research. Your participation is 
strictly confidential.  
 
Do I have to take part?  
No. It is up to you to decide whether or not to take part in this study. In other 
words, this is voluntary. If you do not take part, you will still have access to your 
routine care in this IAPT service. If you do decide to take part you are still free to 
stop your participation at any time and have any research data withdrawn without 
giving a reason. If you decide to take part, you will be given this information sheet 
to keep and be asked to sign a consent form. 
 
Are there any risks? 
There are very minimal risks to taking part in this study. If you feel upset or concerned 
about filling in the questionnaires involved in this study please share your concerns with 
your IAPT clinician or GP, who will be able to help.  212 
 
This study has received ethical approval from West London Research Ethics 
Committee (Ref: 13/LO/0684). All information gathered as a result of this study will be kept 
strictly confidential.  
 
What are the benefits of this research? 
By taking part in this study, you will contribute to a better understanding and 
treatment of depression with the potential to help us find ways of reducing the risk 
of people having residual symptoms when they finish treatment and relapsing to 
depression. As taking part only involves filling in questionnaires when you come to 
the IAPT service for your routine treatment you will not be paid to take part in this 
research and travel expenses are unable to be covered.  
 
What happens when the research study stops? 
Throughout the study and afterwards, your IAPT clinician or therapist will continue 
to treat you as s/he feels is best for you and with your agreement. 
 
If I have any concerns 
If you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated by members of staff due to your participation in the 
research, NHS or UCL complaints mechanisms are available to you. Please ask your 
IAPT clinician if you would like more information on this. In the unlikely event that 
you are harmed by taking part in this study, compensation may be available. If you 
suspect that the harm is the result of negligence on the part of the Sponsor 
(University College London) or your IAPT service, then you may be able to claim 
compensation. After discussing this with your IAPT clinician, please make the claim 
in writing to Professor Stephen Pilling who a Principal Investigator for the research 
and is based at University College London (using the address below). The Principal 
Investigator will then pass the claim to the Sponsor’s insurers, via the Sponsor’s 
office. You may have to bear the costs of the legal action initially, and you should 
consult a lawyer about this. 
 
Next Steps 
If you have read through this information sheet and are happy to take part, then the 
first thing to do is to complete the enclosed consent form and return it to your IAPT 
clinician or send it to our research team in the envelope provided.  
 
Contact Details 
If you need any further information to help you decide whether to take part in the 
study, or if there is anything you do not understand, please contact: 
 
Joshua Buckman, MSc, Trainee Clinical Psychologist 
Research Department of Clinical, Educational & Health Psychology 
University College London, 1-19 Torrington Place, London WC1E 7HB 
email: Joshua.buckman.11@ucl.ac.uk, phone: 020 7679 2000 
 





Consent Form 13 June 2013 Version 4.10 West London REC reference number: 13/LO/0684213 
1 copy for participant, 1 copy for researcher, 1 copy for medical notes 




Title of project: Identifying the risk factors for relapse to depression after treatment 
Head Researcher: Joshua Buckman 
 
Participant Consent Form 
 
Participant ID number:  
                                                                                                                                                                   
                                                                                                                                                                                Please initial below  
1.   I confirm that I have read the information sheet dated 13.06.13 (version 3) and 
have been given a copy.  I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
2.   I understand that my participation is voluntary and I am free to withdraw at  





3.   I understand that this study uses questionnaire measures to assess my emotional 












I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from University 
College London, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in the research. I give permission for these individuals  
to have access to this data. I understand that such information will be treated as 
strictly confidential. 
 




     




___________________________________         _______________________________        _________________           




___________________________________         _______________________________        _________________ 
  Name of Researcher/PWP  (please print)                    Signature of Researcher/PWP                              Date   214 
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The Attentional Control Scale 
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Items of the Attentional Control Scale 
 
Items are scored on a 4-point scale (1= almost never; 2= sometimes; 3= often; 4= 
always) 
R = reverse-scored item 
 
1.  It’s very hard for me to concentrate on a difficult task when there are noises 
around. (R) 
 
2.  When I need to concentrate and solve a problem, I have trouble focussing my 
attention. (R) 
 
3.  When I am working hard on something, I still get distracted by events around me. 
(R) 
 
4.  My concentration is good even if there is music in the room around me.  
 
5.  When concentrating, I can focus my attention so that I become unaware of what’s 
going on in the room around me.  
 
6.  When I am reading or studying, I am easily distracted if there are people talking in 
the same room.  
 
7.  When trying to focus my attention on something, I have difficulty blocking out 
distracting thoughts.  
 
8.  I have a hard time concentrating when I’m excited about something. (R) 
 
9.  When concentrating I ignore feelings of hunger or thirst.  
 
10. I can quickly switch from one task to another.  
 
11. It takes me a while to get really involved in a new task. (R) 
 
12. It is difficult for me to coordinate my attention between the listening and writing 
required when taking notes during lectures. (R) 
 
13. I can become interested in a new topic very quickly when I need to.  
 
14. It is easy for me to read or write while I’m also talking on the phone.  
 
15. I have trouble carrying on two conversations at once. (R) 
 
16. I have a hard time coming up with new ideas quickly. (R) 
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17. After being interrupted or distracted I can easily shift my attention back to what I 
was doing before.  
 
18. When a distracting thought comes to mind, it is easy for me to shift my attention 
away from it.  
 
19. It is easy for me to alternate between two different tasks. 
 
20. It is hard for me to break from one way of thinking about something and look at it 
from another point of view. (R) 